<![CDATA[MAP - Market Access Podcast]]>4ae14519-4fe6-5e0c-91f7-86a1d634d688Wed, 01 Apr 2026 07:00:33 +0000Captivate.fmDr. Stefan Walzerhttps://artwork.captivate.fm/e04e9c74-007f-4925-92ef-6c7762c2eeaf/8lRQw8zPTfVU-5hmlvy31S61.pngMAP - Market Access PodcastDr. Stefan WalzerDr. Stefan WalzerMarket Access (or alternatively reimbursement) in health care is THE key competence in order to be commercially successful with a new drug, medical device or digital health application. However, given the fact that market access is a complex field involving various disciplines and is an ever-changing field, it is difficult to be up to speed with the different evolvements across the world. MAP is THE bi-weekly Market Access Podcast provided by MArS Market Access & Pricing Strategy, which is your health care consultancy in the German-speaking markets and allows you to keep up to date with market access , reimbursement and pricing issues in the D-A-CH countries and around the world. With MAP you will get a summary of core market access systems and processes as well as latest changes in regulations including statements and opinions of core decision makers and stakeholders from various countries. The CEO and founder of MArS is also the driver behind MAP: Dr. Stefan Walzer works in the field of payer strategy, pricing, health economics and reimbursement since 2004 and is the founder and CEO of MArS Market Access & Pricing Strategy GmbH based in Germany. MArS makes it as easy as possible for you to get your Pharmaceutical, MedTech or digital health product to the market and of course get the price it deserves. Stefan previously worked as a payer consultant for various global pharmaceutical and medical device / diagnostic companies, successfully launching their products across the world. He was the Global Payer Strategy Leader for various products and compounds at F. Hoffmann – La Roche AG, where he successfully developed early payer strategies as well as launching and maintaining the reimbursement process for top brands and early compounds. Stefan is capable in translating the clinical and economic evidence into successful reimbursement submissions and pricing negotiations especially in Austria, Germany and Switzerland. Additionally he teaches market access, pricing and negotiations at the State University of Baden-Wuerttemberg and the University of Applied Sciences Weingarten-Ravensburg (both Germany). Besides other roles and responsibilities. Stefan was the head of the committee “Inpatient care” of the German Health Economic Association (DGGÖ). Furthermore he is also a member of the Austrian Health Economic Association (ATHEA) and the Swiss Health Economic Association (SGGÖ). Additionally, he is a member of the Access Advisory Committee of the Global Pneumonia Prevention Coalition. Stefan received a Master of Science in Economics from the University of Tuebingen (Germany), a PhD in Health Economics from the University of Zurich (Switzerland) and a post-graduate diploma in Clinical Trials from the London School of Hygiene and Tropical Medicine (UK). He is co-author of more than 40 peer-reviewed scientific articles and more than 300 scientific abstracts.https://marketaccess-pricingstrategy.de/falseepisodicnopodcastHow Can Political Leadership Turn Health into an Economic Priority, Hatice Küçük Benton?How Can Political Leadership Turn Health into an Economic Priority, Hatice Küçük Benton?In this episode of the MAP – Market Access Podcast, Dr. Stefan Walzer speaks with Hatice Küçük Beton, Executive Director of the G20 Health and Development Partnership, about how to make global health truly investable – and keep it on the political agenda once the immediate crisis fades. They explore why high-level leadership, from Angela Merkel’s role during Germany’s G20 presidency to Japan’s joint health–finance initiative, was crucial in moving health from a “social cost” to a strategic economic and security issue. Hatice explains how bringing health and finance ministers to the same table – and getting them to speak the same financial language – has begun to reshape thinking around budgets, risk and long‑term system resilience.

The conversation then dives into what a practical health investment framework could look like, with clear positive qualifiers, benchmarks and disqualifiers to guide capital into high-impact areas without overburdening investors with new bureaucracy. Hatice and Stefan discuss why health must be de‑politicised and reframed as a pillar of economic resilience, geopolitical security and human wellbeing – not a “nice to have” public service – and why returns on health investments should not be taboo. If you work in market access, health economics, policy, pharma, medtech or healthcare investment, this episode offers concrete ideas on how smarter, market‑driven health investment can shape global and national health systems by 2030.

Stay connected by subscribing on your favorite podcast platform or listening directly on our website: MAP Podcasts —and if you enjoyed the episode, don’t forget to rate it and the podcast!

MAP is the first and only bi-weekly market access podcast provided by MArS—and the global #1 podcast in the field of health economics. For more information about MArS Market Access and Pricing Strategy, visit: https://marketaccess4-0.com/

#MarketAccess #GlobalHealth #G20 #HealthEconomics #HealthInvestment #HealthFinancing #HealthPolicy #HealthcareFinance #G20Health #ImpactInvesting #marketaccess #marketaccesspodcast

]]>In this episode of the MAP – Market Access Podcast, Dr. Stefan Walzer speaks with Hatice Küçük Beton, Executive Director of the G20 Health and Development Partnership, about how to make global health truly investable – and keep it on the political agenda once the immediate crisis fades. They explore why high-level leadership, from Angela Merkel’s role during Germany’s G20 presidency to Japan’s joint health–finance initiative, was crucial in moving health from a “social cost” to a strategic economic and security issue. Hatice explains how bringing health and finance ministers to the same table – and getting them to speak the same financial language – has begun to reshape thinking around budgets, risk and long‑term system resilience.

The conversation then dives into what a practical health investment framework could look like, with clear positive qualifiers, benchmarks and disqualifiers to guide capital into high-impact areas without overburdening investors with new bureaucracy. Hatice and Stefan discuss why health must be de‑politicised and reframed as a pillar of economic resilience, geopolitical security and human wellbeing – not a “nice to have” public service – and why returns on health investments should not be taboo. If you work in market access, health economics, policy, pharma, medtech or healthcare investment, this episode offers concrete ideas on how smarter, market‑driven health investment can shape global and national health systems by 2030.

Stay connected by subscribing on your favorite podcast platform or listening directly on our website: MAP Podcasts —and if you enjoyed the episode, don’t forget to rate it and the podcast!

MAP is the first and only bi-weekly market access podcast provided by MArS—and the global #1 podcast in the field of health economics. For more information about MArS Market Access and Pricing Strategy, visit: https://marketaccess4-0.com/

#MarketAccess #GlobalHealth #G20 #HealthEconomics #HealthInvestment #HealthFinancing #HealthPolicy #HealthcareFinance #G20Health #ImpactInvesting #marketaccess #marketaccesspodcast

]]>c8087b10-96fe-48fc-aa96-6984fd452272Wed, 01 Apr 2026 09:00:00 +020040:32falsefull11081081Is Europe Still More Attractive Than the US, China, India or MENA for Medtech Investment, Bernard Bichsel?Is Europe Still More Attractive Than the US, China, India or MENA for Medtech Investment, Bernard Bichsel?In the latest Market Access Podcast episode, host Stefan Walzer sits down with Bernard “Bernie” Bichsel – one of Europe’s most experienced voices in medtech regulation and former Head of the Medical Devices Division at Swissmedic – to unpack how regulation and market access truly fit together. They discuss why medical device regulation in Europe is still young compared to pharma, why the MDR/IVDR “notified body bottleneck” is largely yesterday’s problem, and how smart startups build regulatory timelines, costs, and clinical evidence into their plans from day one.

They then zoom out to Omnibus, the AI Act, and geopolitics, and what all of this means for the attractiveness of Europe vs. the US, China, India, and the rapidly growing Arabic region as medtech markets. Despite the challenges, Europe still offers world‑class innovation, strong universities, and a powerful SME ecosystem – and remains a key region for medtech investment. If you’re a medtech founder, regulatory lead, or market access professional, this episode will help you rethink when and how you integrate regulation and reimbursement into your strategy.

Stay connected by subscribing on your favorite podcast platform or listening directly on our website: MAP Podcasts —and if you enjoyed the episode, don’t forget to rate it and the podcast!

MAP is the first and only bi-weekly market access podcast provided by MArS—and the global #1 podcast in the field of health economics. For more information about MArS Market Access and Pricing Strategy, visit: https://marketaccess4-0.com/

#MarketAccess #MedTech #MDR #IVDR #RegulatoryAffairs #HealthEconomics #medtech #medtechregulation #Reimbursement #Startups #EUHealthcare #marketaccess #marketaccesspodcast

]]>In the latest Market Access Podcast episode, host Stefan Walzer sits down with Bernard “Bernie” Bichsel – one of Europe’s most experienced voices in medtech regulation and former Head of the Medical Devices Division at Swissmedic – to unpack how regulation and market access truly fit together. They discuss why medical device regulation in Europe is still young compared to pharma, why the MDR/IVDR “notified body bottleneck” is largely yesterday’s problem, and how smart startups build regulatory timelines, costs, and clinical evidence into their plans from day one.

They then zoom out to Omnibus, the AI Act, and geopolitics, and what all of this means for the attractiveness of Europe vs. the US, China, India, and the rapidly growing Arabic region as medtech markets. Despite the challenges, Europe still offers world‑class innovation, strong universities, and a powerful SME ecosystem – and remains a key region for medtech investment. If you’re a medtech founder, regulatory lead, or market access professional, this episode will help you rethink when and how you integrate regulation and reimbursement into your strategy.

Stay connected by subscribing on your favorite podcast platform or listening directly on our website: MAP Podcasts —and if you enjoyed the episode, don’t forget to rate it and the podcast!

MAP is the first and only bi-weekly market access podcast provided by MArS—and the global #1 podcast in the field of health economics. For more information about MArS Market Access and Pricing Strategy, visit: https://marketaccess4-0.com/

#MarketAccess #MedTech #MDR #IVDR #RegulatoryAffairs #HealthEconomics #medtech #medtechregulation #Reimbursement #Startups #EUHealthcare #marketaccess #marketaccesspodcast

]]>1e9a1565-cf57-47b7-969f-95ccc9e9806dSun, 15 Mar 2026 09:00:00 +020034:42falsefull11071071From Necessary Tasks to New Insights: How Can AI Act as a Sparring Partner in Market Access, Helmut Butscher?From Necessary Tasks to New Insights: How Can AI Act as a Sparring Partner in Market Access, Helmut Butscher?In this episode, Stefan Walzer talks with experienced Market Access manager Helmut Butscher about concrete AI applications across the full Market Access value chain. They explore how AI accelerates systematic literature reviews, unlocks real‑world evidence from complex data sources, supports HTA dossier preparation, and enables smarter decisions on pricing, reimbursement and global launch sequencing. They also address the limits and risks of AI in a highly regulated setting – from opaque HTA and payer decisions to regulatory uncertainty around AI‑generated evidence and the ethical tension between efficiency and fairness in health technology assessment.

Stefan and Helmut then look ahead to the evolving role of the Market Access manager – not as someone replaced by algorithms, but as a central orchestrator who uses AI as a powerful sparring partner to make better, faster and more transparent decisions. Whether you work in Market Access, HEOR, pricing, strategy or related fields, this episode offers a clear, practice‑oriented view on how to start using AI meaningfully in your daily work – and where it pays to remain cautious.

Stay connected by subscribing on your favorite podcast platform or listening directly on our website: MAP Podcasts —and if you enjoyed the episode, don’t forget to rate it and the podcast!

MAP is the first and only bi-weekly market access podcast provided by MArS—and the global #1 podcast in the field of health economics. For more information about MArS Market Access and Pricing Strategy, visit: https://marketaccess4-0.com/

#MarketAccess #OrphanDrugs #RareDisease #DrugPricing #HealthEconomics #CostEffectiveness #BudgetImpact #RealWorldEvidence #InnovativeContracting #GeneTherapy #HealthcarePolicy #Payers #MAPPodcast #marketaccess #marketaccesspodcast

]]>In this episode, Stefan Walzer talks with experienced Market Access manager Helmut Butscher about concrete AI applications across the full Market Access value chain. They explore how AI accelerates systematic literature reviews, unlocks real‑world evidence from complex data sources, supports HTA dossier preparation, and enables smarter decisions on pricing, reimbursement and global launch sequencing. They also address the limits and risks of AI in a highly regulated setting – from opaque HTA and payer decisions to regulatory uncertainty around AI‑generated evidence and the ethical tension between efficiency and fairness in health technology assessment.

Stefan and Helmut then look ahead to the evolving role of the Market Access manager – not as someone replaced by algorithms, but as a central orchestrator who uses AI as a powerful sparring partner to make better, faster and more transparent decisions. Whether you work in Market Access, HEOR, pricing, strategy or related fields, this episode offers a clear, practice‑oriented view on how to start using AI meaningfully in your daily work – and where it pays to remain cautious.

Stay connected by subscribing on your favorite podcast platform or listening directly on our website: MAP Podcasts —and if you enjoyed the episode, don’t forget to rate it and the podcast!

MAP is the first and only bi-weekly market access podcast provided by MArS—and the global #1 podcast in the field of health economics. For more information about MArS Market Access and Pricing Strategy, visit: https://marketaccess4-0.com/

#MarketAccess #OrphanDrugs #RareDisease #DrugPricing #HealthEconomics #CostEffectiveness #BudgetImpact #RealWorldEvidence #InnovativeContracting #GeneTherapy #HealthcarePolicy #Payers #MAPPodcast #marketaccess #marketaccesspodcast

]]>8f6f732c-4f6f-4a4d-92d6-ab8f11cb833aSun, 01 Mar 2026 09:00:00 +020039:40falsefull11061061Can Innovative Contracting Turn High‑Cost Therapies into Sustainable Deals, Omar Ali?Can Innovative Contracting Turn High‑Cost Therapies into Sustainable Deals, Omar Ali?In this thought‑provoking Market Access Podcast episode, host Stefan Walzer sits down with Omar Ali – Head of Payers at Vipora, former NICE advisor, and one of the sharpest minds in drug pricing and innovative contracting to unpack where drug pricing and reimbursement are really heading.

They explore why cost‑effectiveness thresholds are making market access tougher than ever, how uncertainty around CAR‑T, gene therapies and orphan drugs fuels the “orphan bubble”, how innovative contracting and pay‑for‑performance can (sometimes) rescue multi‑million‑euro therapies and why the US is doing HTA at the end, not the beginning – with CMS negotiations, MFN and tariffs reshaping global pricing strategies.

If you work in Market Access, pricing, Health Economics and Outcomes Research (HEOR) or policy, this conversation will resonate with the pressures you feel every day.

Stay connected by subscribing on your favorite podcast platform or listening directly on our website: MAP Podcasts —and if you enjoyed the episode, don’t forget to rate it and the podcast!

MAP is the first and only bi-weekly market access podcast provided by MArS—and the global #1 podcast in the field of health economics. For more information about MArS Market Access and Pricing Strategy, visit: https://marketaccess4-0.com/

#MarketAccess #OrphanDrugs #RareDisease #DrugPricing #HealthEconomics #CostEffectiveness #BudgetImpact #RealWorldEvidence #InnovativeContracting #GeneTherapy #HealthcarePolicy #Payers #MAPPodcast #marketaccess #marketaccesspodcast

]]>In this thought‑provoking Market Access Podcast episode, host Stefan Walzer sits down with Omar Ali – Head of Payers at Vipora, former NICE advisor, and one of the sharpest minds in drug pricing and innovative contracting to unpack where drug pricing and reimbursement are really heading.

They explore why cost‑effectiveness thresholds are making market access tougher than ever, how uncertainty around CAR‑T, gene therapies and orphan drugs fuels the “orphan bubble”, how innovative contracting and pay‑for‑performance can (sometimes) rescue multi‑million‑euro therapies and why the US is doing HTA at the end, not the beginning – with CMS negotiations, MFN and tariffs reshaping global pricing strategies.

If you work in Market Access, pricing, Health Economics and Outcomes Research (HEOR) or policy, this conversation will resonate with the pressures you feel every day.

Stay connected by subscribing on your favorite podcast platform or listening directly on our website: MAP Podcasts —and if you enjoyed the episode, don’t forget to rate it and the podcast!

MAP is the first and only bi-weekly market access podcast provided by MArS—and the global #1 podcast in the field of health economics. For more information about MArS Market Access and Pricing Strategy, visit: https://marketaccess4-0.com/

#MarketAccess #OrphanDrugs #RareDisease #DrugPricing #HealthEconomics #CostEffectiveness #BudgetImpact #RealWorldEvidence #InnovativeContracting #GeneTherapy #HealthcarePolicy #Payers #MAPPodcast #marketaccess #marketaccesspodcast

]]>a3147f7d-352c-445e-bd4d-0bf688413325Sun, 15 Feb 2026 09:00:00 +020052:58falsefull11051051What Makes Australia’s HTA Approach to Equity and Health Productivity Unique, Zanfina Ademi?What Makes Australia’s HTA Approach to Equity and Health Productivity Unique, Zanfina Ademi?In this Market Access Podcast episode, Dr. Stefan Walzer sits down with Prof. Zanfania Ademi, a health economist at Monash University, to explore how Australia’s healthcare system is tackling key issues in market access and health technology assessment. Discover how Australia blends international approaches and new methods being developed by Zanfina and her team like distributional cost-effectiveness and productivity-adjusted life years to advance equity and value in healthcare. Tune in for fresh insights on health as an investment, not just a cost, and what’s next for decision-makers.

Key takeaways from the episode include the shift from qualitative to quantitative measures of equity in HTA, and the use of complex disease models and real-world evidence to drive smarter prevention strategies. The discussion also covers the growing recognition of both paid and unpaid work in productivity metrics, along with lessons from Switzerland on disinvestment, transparency, and the challenges of implementing new value measures in healthcare. Perfect for professionals in market access, health economics, and policy.

Stay connected by subscribing on your favorite podcast platform or listening directly on our website: MAP Podcasts —and if you enjoyed the episode, don’t forget to rate it and the podcast!

MAP is the first and only bi-weekly market access podcast provided by MArS—and the global #1 podcast in the field of health economics. For more information about MArS Market Access and Pricing Strategy, visit: https://marketaccess4-0.com/

#MarketAccess #HTA #Reimbursement #HealthEquity #Productivity #HealthcareInnovation #Australia #HealthEconomics #Prevention #MAPPodcast #marketaccess #marketaccesspodcast

]]>In this Market Access Podcast episode, Dr. Stefan Walzer sits down with Prof. Zanfania Ademi, a health economist at Monash University, to explore how Australia’s healthcare system is tackling key issues in market access and health technology assessment. Discover how Australia blends international approaches and new methods being developed by Zanfina and her team like distributional cost-effectiveness and productivity-adjusted life years to advance equity and value in healthcare. Tune in for fresh insights on health as an investment, not just a cost, and what’s next for decision-makers.

Key takeaways from the episode include the shift from qualitative to quantitative measures of equity in HTA, and the use of complex disease models and real-world evidence to drive smarter prevention strategies. The discussion also covers the growing recognition of both paid and unpaid work in productivity metrics, along with lessons from Switzerland on disinvestment, transparency, and the challenges of implementing new value measures in healthcare. Perfect for professionals in market access, health economics, and policy.

Stay connected by subscribing on your favorite podcast platform or listening directly on our website: MAP Podcasts —and if you enjoyed the episode, don’t forget to rate it and the podcast!

MAP is the first and only bi-weekly market access podcast provided by MArS—and the global #1 podcast in the field of health economics. For more information about MArS Market Access and Pricing Strategy, visit: https://marketaccess4-0.com/

#MarketAccess #HTA #Reimbursement #HealthEquity #Productivity #HealthcareInnovation #Australia #HealthEconomics #Prevention #MAPPodcast #marketaccess #marketaccesspodcast

]]>5d035418-fa9c-4ba9-a6b5-f8276f57b2c4Sun, 01 Feb 2026 09:00:00 +020042:42falsefull11041041No Decisions for Us, Without Us: Why Patient Advocacy Matters in Market Access, Erica Bersin?No Decisions for Us, Without Us: Why Patient Advocacy Matters in Market Access, Erica Bersin?In this episode of the Market Access Podcast, Erica Bersin—founder of ERO Health Communications—joins Dr. Stefan Walzer to discuss the changing role of patient involvement in healthcare. Drawing on her experience in both Europe and the U.S., Erica explains how single-payer systems make patient engagement easier, while the U.S. faces more challenges but also unique advocacy opportunities. She highlights the work of organizations like PCORI and the need for better data transparency.

The episode features real-world examples from HIV/AIDS and breast cancer advocacy, as well as pharma’s efforts to involve patients in clinical trials. Erica’s personal story with multiple sclerosis underscores why every patient’s voice matters. Tune in for a hopeful look at how patients can help shape future healthcare decisions. 

Stay connected by subscribing on your favorite podcast platform or listening directly on our website: MAP Podcasts. If you enjoyed the episode, don’t forget to rate it and the podcast!

MAP is the first and only bi-weekly market access podcast provided by MArS—and the global #1 podcast in the field of health economics. For more information about MArS Market Access and Pricing Strategy, visit: https://marketaccess4-0.com/

#MarketAccess #PatientEngagement #PatientAdvocacy #MedicalAdvocacy #HealthEconomics #Pharma #HealthcareInnovation #HealthcareDecisions #MAPPodcast #marketaccess #marketaccesspodcast

]]>In this episode of the Market Access Podcast, Erica Bersin—founder of ERO Health Communications—joins Dr. Stefan Walzer to discuss the changing role of patient involvement in healthcare. Drawing on her experience in both Europe and the U.S., Erica explains how single-payer systems make patient engagement easier, while the U.S. faces more challenges but also unique advocacy opportunities. She highlights the work of organizations like PCORI and the need for better data transparency.

The episode features real-world examples from HIV/AIDS and breast cancer advocacy, as well as pharma’s efforts to involve patients in clinical trials. Erica’s personal story with multiple sclerosis underscores why every patient’s voice matters. Tune in for a hopeful look at how patients can help shape future healthcare decisions. 

Stay connected by subscribing on your favorite podcast platform or listening directly on our website: MAP Podcasts. If you enjoyed the episode, don’t forget to rate it and the podcast!

MAP is the first and only bi-weekly market access podcast provided by MArS—and the global #1 podcast in the field of health economics. For more information about MArS Market Access and Pricing Strategy, visit: https://marketaccess4-0.com/

#MarketAccess #PatientEngagement #PatientAdvocacy #MedicalAdvocacy #HealthEconomics #Pharma #HealthcareInnovation #HealthcareDecisions #MAPPodcast #marketaccess #marketaccesspodcast

]]>85dfbdcf-6c16-4f74-8e84-dff0ceb0cb5aThu, 15 Jan 2026 09:00:00 +020034:48falsefull11031031Can VR and AR Finally Break Through the Barriers in Medical Innovation, Günther Illert?Can VR and AR Finally Break Through the Barriers in Medical Innovation, Günther Illert?In this episode of the Market Access Podcast, Dr. Stefan Walzer sits down with strategy consultant and XR advocate Günther Illert to explore how virtual, augmented, and extended reality are reshaping healthcare—from patient training and pain therapy to surgical planning and medtech education.

Learn how cross-sector collaboration and early adoption—especially outside traditional reimbursement systems—can unlock the full potential of immersive technology in medicine. A must-listen for innovators, health tech professionals, and digital health strategists.

Stay connected by subscribing on your favorite podcast platform or listening directly on our website: MAP Podcasts —and if you enjoyed the episode, don’t forget to rate it and the podcast!

MAP is the first and only bi-weekly market access podcast provided by MArS — and the global #1 podcast in the field of health economics. For more information about MArS Market Access and Pricing Strategy, visit: https://marketaccess4-0.com/

#MarketAccess #DigitalHealth #HealthcareInnovation #MedTech #VirtualReality #TrainingInHealthcare #HealthTech #XR #AugmentedReality #MAPPodcast #marketaccess #marketaccesspodcast

]]>In this episode of the Market Access Podcast, Dr. Stefan Walzer sits down with strategy consultant and XR advocate Günther Illert to explore how virtual, augmented, and extended reality are reshaping healthcare—from patient training and pain therapy to surgical planning and medtech education.

Learn how cross-sector collaboration and early adoption—especially outside traditional reimbursement systems—can unlock the full potential of immersive technology in medicine. A must-listen for innovators, health tech professionals, and digital health strategists.

Stay connected by subscribing on your favorite podcast platform or listening directly on our website: MAP Podcasts —and if you enjoyed the episode, don’t forget to rate it and the podcast!

MAP is the first and only bi-weekly market access podcast provided by MArS — and the global #1 podcast in the field of health economics. For more information about MArS Market Access and Pricing Strategy, visit: https://marketaccess4-0.com/

#MarketAccess #DigitalHealth #HealthcareInnovation #MedTech #VirtualReality #TrainingInHealthcare #HealthTech #XR #AugmentedReality #MAPPodcast #marketaccess #marketaccesspodcast

]]>bbd3f4e4-f4e4-446b-90da-790a8f59167aMon, 15 Dec 2025 09:00:00 +020035:02falsefull11021021Why Should Pharma and MedTech Innovators Look at New Zealand, Julius Ohrnberger?Why Should Pharma and MedTech Innovators Look at New Zealand, Julius Ohrnberger?Tune in to this new episode of MAP to explore New Zealand’s unique healthcare and reimbursement landscape with Dr. Stefan Walzer and health economist Dr. Julius Ohnberger. Learn how PHARMAC combines HTA and payer roles, why equity and Māori health outcomes are central to market access and what global pharma can gain from launching in Aotearoa. 

Key insights include why New Zealand’s HTA model stands out as a global unicorn, how to navigate cultural and equity requirements in submissions, the importance of local evidence and stakeholder engagement, the impact of budget constraints and the shift toward real‑world data and outcome‑based reimbursement, and why the country may be the ideal testbed for innovations in AI, screening, and chronic care. Essential for professionals in pricing, market access, and global health policy.

Stay connected by subscribing on your favorite podcast platform or listening directly on our website: MAP Podcasts —and if you enjoyed the episode, don’t forget to rate it and the podcast!"

MAP is the first and only bi-weekly market access podcast provided by MArS — and the global #1 podcast in the field of health economics. For more information about MArS Market Access and Pricing Strategy, visit: https://marketaccess4-0.com/

#MarketAccess #HealthEconomics #Pharma #Reimbursement #NewZealand #DigitalHealth #HTA #Pharmac #HealthcareInnovation #EquityInHealthcare #MAPPodcast #marketaccess #marketaccesspodcast

]]>Tune in to this new episode of MAP to explore New Zealand’s unique healthcare and reimbursement landscape with Dr. Stefan Walzer and health economist Dr. Julius Ohnberger. Learn how PHARMAC combines HTA and payer roles, why equity and Māori health outcomes are central to market access and what global pharma can gain from launching in Aotearoa. 

Key insights include why New Zealand’s HTA model stands out as a global unicorn, how to navigate cultural and equity requirements in submissions, the importance of local evidence and stakeholder engagement, the impact of budget constraints and the shift toward real‑world data and outcome‑based reimbursement, and why the country may be the ideal testbed for innovations in AI, screening, and chronic care. Essential for professionals in pricing, market access, and global health policy.

Stay connected by subscribing on your favorite podcast platform or listening directly on our website: MAP Podcasts —and if you enjoyed the episode, don’t forget to rate it and the podcast!"

MAP is the first and only bi-weekly market access podcast provided by MArS — and the global #1 podcast in the field of health economics. For more information about MArS Market Access and Pricing Strategy, visit: https://marketaccess4-0.com/

#MarketAccess #HealthEconomics #Pharma #Reimbursement #NewZealand #DigitalHealth #HTA #Pharmac #HealthcareInnovation #EquityInHealthcare #MAPPodcast #marketaccess #marketaccesspodcast

]]>af56c3fa-8478-42a0-bdac-d465e7228b1dMon, 01 Dec 2025 09:00:00 +020038:02falsefull11011011Are We Ready for a Cultural Shift Toward AI in Pharma, Elizabeth Shanahan?Are We Ready for a Cultural Shift Toward AI in Pharma, Elizabeth Shanahan?In this brand new episode of MAP - the Market Access Podcast, Dr. Stefan Walzer sits down with Elizabeth Shanahan, AI Strategy Lead at Sanofi, for a refreshingly honest conversation on the real-world implementation of artificial intelligence in pricing, evidence generation, and HTA processes.

From streamlining evidence generation to enhancing pricing strategies and dossier creation, they explore how AI tools are driving efficiency and strategic thinking. Learn how cultural change, human-in-the-loop systems, and transparency with payers are key to success in the digital health era. Whether you're exploring AI for the first time or scaling adoption across teams, this episode offers strategic insight, hard-won lessons, and a clear-eyed look at the future of pharma.

Stay connected by subscribing on your favorite podcast platform or listening directly on our website: MAP Podcasts — and if you enjoyed the episode, don’t forget to rate it and the podcast!

MAP is the first and only bi-weekly market access podcast provided by MArS — and the global #1 podcast in the field of health economics. For more information about MArS Market Access and Pricing Strategy, visit: https://marketaccess4-0.com/

#MarketAccess #HealthEconomics #ArtificialIntelligence #PharmaInnovation #HTA #DigitalHealth #AIinPharma #MAPPodcast  #marketaccess #marketaccesspodcast

]]>In this brand new episode of MAP - the Market Access Podcast, Dr. Stefan Walzer sits down with Elizabeth Shanahan, AI Strategy Lead at Sanofi, for a refreshingly honest conversation on the real-world implementation of artificial intelligence in pricing, evidence generation, and HTA processes.

From streamlining evidence generation to enhancing pricing strategies and dossier creation, they explore how AI tools are driving efficiency and strategic thinking. Learn how cultural change, human-in-the-loop systems, and transparency with payers are key to success in the digital health era. Whether you're exploring AI for the first time or scaling adoption across teams, this episode offers strategic insight, hard-won lessons, and a clear-eyed look at the future of pharma.

Stay connected by subscribing on your favorite podcast platform or listening directly on our website: MAP Podcasts — and if you enjoyed the episode, don’t forget to rate it and the podcast!

MAP is the first and only bi-weekly market access podcast provided by MArS — and the global #1 podcast in the field of health economics. For more information about MArS Market Access and Pricing Strategy, visit: https://marketaccess4-0.com/

#MarketAccess #HealthEconomics #ArtificialIntelligence #PharmaInnovation #HTA #DigitalHealth #AIinPharma #MAPPodcast  #marketaccess #marketaccesspodcast

]]>354ec022-55f7-4e8a-99c8-fe4204740d24Sat, 15 Nov 2025 09:00:00 +020037:13falsefull11001001What Can Europe and the U.S. Learn from Each Other on Market Access, Anne Loos?What Can Europe and the U.S. Learn from Each Other on Market Access, Anne Loos?Tune in to this new episode of MAP, the Market Access Podcast, where Dr. Stefan Walzer is joined by Anne Loos from Wickenstones, to explore the evolving landscape of U.S. market access and reimbursement.

The U.S. reimbursement landscape is changing — driven by AI, global influences with the European JCA and political programs such as the Inflation Reduction Act. As fragmentation and rising complexity are pushing pharma to rethink strategy and timelines - this is a must-listen for professionals in pricing, HEOR, and market access.

Stay connected by subscribing on your favorite podcast platform or listening directly on our website: MAP Podcasts —and if you enjoyed the episode, don’t forget to rate it and the podcast!

MAP is the first and only bi-weekly market access podcast provided by MArS — and the global #1 podcast in the field of health economics. For more information about MArS Market Access and Pricing Strategy, visit: https://marketaccess4-0.com/

#MarketAccess #ArtificialIntelligence #Reimbursement #PharmaAI #HealthcareStrategy #HTA #USHealthcare #MAPPodcast #marketaccess #marketaccesspodcast

]]>Tune in to this new episode of MAP, the Market Access Podcast, where Dr. Stefan Walzer is joined by Anne Loos from Wickenstones, to explore the evolving landscape of U.S. market access and reimbursement.

The U.S. reimbursement landscape is changing — driven by AI, global influences with the European JCA and political programs such as the Inflation Reduction Act. As fragmentation and rising complexity are pushing pharma to rethink strategy and timelines - this is a must-listen for professionals in pricing, HEOR, and market access.

Stay connected by subscribing on your favorite podcast platform or listening directly on our website: MAP Podcasts —and if you enjoyed the episode, don’t forget to rate it and the podcast!

MAP is the first and only bi-weekly market access podcast provided by MArS — and the global #1 podcast in the field of health economics. For more information about MArS Market Access and Pricing Strategy, visit: https://marketaccess4-0.com/

#MarketAccess #ArtificialIntelligence #Reimbursement #PharmaAI #HealthcareStrategy #HTA #USHealthcare #MAPPodcast #marketaccess #marketaccesspodcast

]]>4ccfa223-e328-4b7b-96f7-5929860dee39Sat, 01 Nov 2025 09:00:00 +020027:04falsefull199991Will AI and Living Reviews Define the Next Era of Health Policy, Anna Forsythe?Will AI and Living Reviews Define the Next Era of Health Policy, Anna Forsythe?Join this episode of MAP – The Market Access Podcast as Dr. Stefan Walzer sits down with Anna Forsythe, founder of OncoScope-AI, to explore how Living Systematic Literature Reviews (Living SLRs) are redefining evidence generation in oncology and beyond - highlighting the power of real-time updates, advanced automation, and the essential role of human insight.

Traditional SLRs are static snapshots, while Living SLRs are real-time, dynamic, and AI-powered—delivering continuously updated insights crucial for life-or-death decisions and payer evaluations. Join this discussion as they explore the myth of AI chatbots as true decision support tools, the need for actionable data over summaries, and the future of evidence synthesis, clinical decision-making, and smarter market access.

Stay updated for upcoming webinars through LinkedIn, and take the chance to stay connected through subscribing with your favorite podcasting platform or directly listen on our website: MAP Podcasts 

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: https://marketaccess4-0.com/

#MarketAccess #HealthEconomics #AIinHealthcare #SLR #Oncology #HTA #MAPPodcast #marketaccess #marketaccesspodcast

]]>Join this episode of MAP – The Market Access Podcast as Dr. Stefan Walzer sits down with Anna Forsythe, founder of OncoScope-AI, to explore how Living Systematic Literature Reviews (Living SLRs) are redefining evidence generation in oncology and beyond - highlighting the power of real-time updates, advanced automation, and the essential role of human insight.

Traditional SLRs are static snapshots, while Living SLRs are real-time, dynamic, and AI-powered—delivering continuously updated insights crucial for life-or-death decisions and payer evaluations. Join this discussion as they explore the myth of AI chatbots as true decision support tools, the need for actionable data over summaries, and the future of evidence synthesis, clinical decision-making, and smarter market access.

Stay updated for upcoming webinars through LinkedIn, and take the chance to stay connected through subscribing with your favorite podcasting platform or directly listen on our website: MAP Podcasts 

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: https://marketaccess4-0.com/

#MarketAccess #HealthEconomics #AIinHealthcare #SLR #Oncology #HTA #MAPPodcast #marketaccess #marketaccesspodcast

]]>3935a615-afa9-4789-a4a1-c1ca59192d48Wed, 15 Oct 2025 09:00:00 +020029:16falsefull198981Are We Undervaluing the Economic Power of Health, Dr. Malina Müller?Are We Undervaluing the Economic Power of Health, Dr. Malina Müller?In the latest MAP Podcast, our host Dr. Stefan Walzer is joined by Dr. Malina Müller from the WifOR Institute to rethink how we value health. From real-world ROI data to policy shifts and long-term strategies, they explore why investing in health pays off—not just in lives saved, but in economic growth, workforce productivity, and resilient societies.

Listen now to discover how viewing healthcare as an investment—not just a cost—can transform market access and what it means for pricing, innovation, and the future of care. If you work in pharma, policy, or health economics—this one’s for you!

Stay updated for upcoming webinars through LinkedIn, and take the chance to stay connected through subscribing with your favorite podcasting platform or directly listen on our website: MAP Podcasts 

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: https://marketaccess4-0.com/

#MarketAccess #HealthEconomics #ValueBasedHealthcare #HealthInvestment #Pharma #HTA #MAPPodcast #marketaccess #marketaccesspodcast

]]>In the latest MAP Podcast, our host Dr. Stefan Walzer is joined by Dr. Malina Müller from the WifOR Institute to rethink how we value health. From real-world ROI data to policy shifts and long-term strategies, they explore why investing in health pays off—not just in lives saved, but in economic growth, workforce productivity, and resilient societies.

Listen now to discover how viewing healthcare as an investment—not just a cost—can transform market access and what it means for pricing, innovation, and the future of care. If you work in pharma, policy, or health economics—this one’s for you!

Stay updated for upcoming webinars through LinkedIn, and take the chance to stay connected through subscribing with your favorite podcasting platform or directly listen on our website: MAP Podcasts 

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: https://marketaccess4-0.com/

#MarketAccess #HealthEconomics #ValueBasedHealthcare #HealthInvestment #Pharma #HTA #MAPPodcast #marketaccess #marketaccesspodcast

]]>cf6b2af0-b38e-4bb0-8208-b7ca6812108cWed, 01 Oct 2025 09:00:00 +020038:02falsefull197971How Should Pharma Respond to the New Reality of Market Access in Germany, Prof. Dr. Thomas Hammerschmidt?How Should Pharma Respond to the New Reality of Market Access in Germany, Prof. Dr. Thomas Hammerschmidt?In this episode of MAP - the Market Access Podcast, Dr. Stefan Walzer sits down with expert Prof. Dr. Thomas Hammerschmidt, to dive deep into Germany’s evolving AMNOG framework and what it really means for pharmaceutical pricing. 

This insightful conversation explores key changes in Germany’s pharma landscape, including the shift from negotiation-based pricing to benefit-linked guardrails, the 5% clinical trial rule, and their impact on innovation and reimbursement strategy. A must-listen for pharma professionals, health economists, and market access leaders!

Stay updated for upcoming webinars through LinkedIn, and take the chance to stay connected through subscribing with your favorite podcasting platform or directly listen on our website: MAP Podcasts 

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: https://marketaccess4-0.com/

#MarketAccess #HealthEconomics #PharmaPricing #AMNOG #Reimbursement #Germany #HTA #PharmaStrategy #marketaccess #marketaccesspodcast

]]>In this episode of MAP - the Market Access Podcast, Dr. Stefan Walzer sits down with expert Prof. Dr. Thomas Hammerschmidt, to dive deep into Germany’s evolving AMNOG framework and what it really means for pharmaceutical pricing. 

This insightful conversation explores key changes in Germany’s pharma landscape, including the shift from negotiation-based pricing to benefit-linked guardrails, the 5% clinical trial rule, and their impact on innovation and reimbursement strategy. A must-listen for pharma professionals, health economists, and market access leaders!

Stay updated for upcoming webinars through LinkedIn, and take the chance to stay connected through subscribing with your favorite podcasting platform or directly listen on our website: MAP Podcasts 

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: https://marketaccess4-0.com/

#MarketAccess #HealthEconomics #PharmaPricing #AMNOG #Reimbursement #Germany #HTA #PharmaStrategy #marketaccess #marketaccesspodcast

]]>bbb0638e-3a8c-4a22-b16f-4549f2f3ea50Mon, 15 Sep 2025 09:00:00 +020034:19falsefull196961Do Swiss Reimbursement Reforms Open Doors—or Raise New Barriers, Petra Erni?Do Swiss Reimbursement Reforms Open Doors—or Raise New Barriers, Petra Erni?Tune in to this episode of MAP – The Market Access Podcast, to hear from Dr. Stefan Walzer as he speaks with Swiss reimbursement expert Petra Erni, who brings a rare perspective from both the industry and payer sides.

Together they explore the evolving Swiss drug reimbursement landscape, discussing the rise of cost consequence models, the growing role of health economic evidence, early access pathways, and strategic pricing challenges in Switzerland. Essential listening for pharma, market access, and health policy professionals—especially those eyeing the Swiss market.

Stay updated for upcoming webinars through LinkedIn, and take the chance to stay connected through subscribing with your favorite podcasting platform or directly listen on our website: MAP Podcasts 

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: https://marketaccess4-0.com/

#MarketAccess #PharmaPricing #Switzerland #HealthEconomics #Reimbursement #HTA #DrugPricing #HealthcareStrategy #marketaccess #marketaccesspodcast

]]>Tune in to this episode of MAP – The Market Access Podcast, to hear from Dr. Stefan Walzer as he speaks with Swiss reimbursement expert Petra Erni, who brings a rare perspective from both the industry and payer sides.

Together they explore the evolving Swiss drug reimbursement landscape, discussing the rise of cost consequence models, the growing role of health economic evidence, early access pathways, and strategic pricing challenges in Switzerland. Essential listening for pharma, market access, and health policy professionals—especially those eyeing the Swiss market.

Stay updated for upcoming webinars through LinkedIn, and take the chance to stay connected through subscribing with your favorite podcasting platform or directly listen on our website: MAP Podcasts 

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: https://marketaccess4-0.com/

#MarketAccess #PharmaPricing #Switzerland #HealthEconomics #Reimbursement #HTA #DrugPricing #HealthcareStrategy #marketaccess #marketaccesspodcast

]]>f76df06f-7bc5-4b03-a159-433c9b250c39Mon, 01 Sep 2025 09:00:00 +020029:13falsefull195951The Startup Guide to Navigating Healthcare Reimbursement, Featuring Ron de Graaff (Repost)The Startup Guide to Navigating Healthcare Reimbursement, Featuring Ron de Graaff (Repost)This is a repost of a popular episode of MAP - Market Access Podcast, from December 1st 2023.

We are thrilled to announce our latest podcast episode, featuring a riveting conversation between our CEO Dr. Stefan Walzer and the esteemed healthcare reimbursement expert, Ron de Graaff. 

Ron, with his deep-rooted experience starting from 1978, shares his invaluable insights on the evolution of healthcare reimbursement, a journey from simpler times to today's intricate landscape involving multiple stakeholders like health insurance companies.

🔍 Key Highlights:

- Ron's path from founding his company in 1985, which has since assisted over 900 entities, including governments, in understanding medical technology markets.

- Challenges faced by startups in healthcare, often led by technical experts who struggle with the language and complexities of reimbursement processes.

- The criticality of startups understanding both the payer perspectives and the changing requirements of reimbursement systems across Europe.

- Ron's advice to startups: comprehensively understand the reimbursement system of your target market and assess if your product is likely to be reimbursable.

This episode is a must-listen for anyone in the healthcare industry, particularly startups navigating the daunting world of reimbursement. Expect to gain a thorough understanding of how to strategically plan for reimbursement, the importance of being updated with current regulations, and how to choose the right market for your product.

Stay updated for upcoming webinars through LinkedIn, and take the chance to stay connected through subscribing with your favorite podcasting platform or directly listen on our website: MAP Podcasts 

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: https://marketaccess4-0.com/

#MarketAccess #HealthcareReimbursement #StartupChallenges #MedicalTechnology #Podcast #HealthcareInnovation #marketaccess #marketaccesspodcast

]]>This is a repost of a popular episode of MAP - Market Access Podcast, from December 1st 2023.

We are thrilled to announce our latest podcast episode, featuring a riveting conversation between our CEO Dr. Stefan Walzer and the esteemed healthcare reimbursement expert, Ron de Graaff. 

Ron, with his deep-rooted experience starting from 1978, shares his invaluable insights on the evolution of healthcare reimbursement, a journey from simpler times to today's intricate landscape involving multiple stakeholders like health insurance companies.

🔍 Key Highlights:

- Ron's path from founding his company in 1985, which has since assisted over 900 entities, including governments, in understanding medical technology markets.

- Challenges faced by startups in healthcare, often led by technical experts who struggle with the language and complexities of reimbursement processes.

- The criticality of startups understanding both the payer perspectives and the changing requirements of reimbursement systems across Europe.

- Ron's advice to startups: comprehensively understand the reimbursement system of your target market and assess if your product is likely to be reimbursable.

This episode is a must-listen for anyone in the healthcare industry, particularly startups navigating the daunting world of reimbursement. Expect to gain a thorough understanding of how to strategically plan for reimbursement, the importance of being updated with current regulations, and how to choose the right market for your product.

Stay updated for upcoming webinars through LinkedIn, and take the chance to stay connected through subscribing with your favorite podcasting platform or directly listen on our website: MAP Podcasts 

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: https://marketaccess4-0.com/

#MarketAccess #HealthcareReimbursement #StartupChallenges #MedicalTechnology #Podcast #HealthcareInnovation #marketaccess #marketaccesspodcast

]]>8b1a4d69-f664-4fbd-966b-5413d7b1b5b4Fri, 15 Aug 2025 09:00:00 +020033:56falsefull194941Europe vs. US: Who Leads the Future of Market Access, Dr. Doug Niven?Europe vs. US: Who Leads the Future of Market Access, Dr. Doug Niven?In this thought-provoking episode of MAP, the Market Access Podcast, Dr. Stefan Walzer sits down with strategic Market Access consultant Dr. Doug Niven to explore one of the most pressing questions in pharma today - can Europe maintain its leadership in Market Access, or is it falling behind? 

From joint HTA (JCA), pricing reforms, and AI-driven tools to global value frameworks and real-world data, this episode unpacks key trends shaping pharma, biotech, and healthcare access in 2025 and beyond. If you're in health economics, pricing & reimbursement, or regulatory strategy, this is a must-listen.

Stay updated for upcoming webinars through LinkedIn, and take the chance to stay connected through subscribing with your favorite podcasting platform or directly listen on our website: MAP Podcasts 

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: https://marketaccess4-0.com/

#MarketAccess #HealthEconomics #PharmaStrategy #PricingAndReimbursement #HTA #marketaccess #marketaccesspodcast

]]>In this thought-provoking episode of MAP, the Market Access Podcast, Dr. Stefan Walzer sits down with strategic Market Access consultant Dr. Doug Niven to explore one of the most pressing questions in pharma today - can Europe maintain its leadership in Market Access, or is it falling behind? 

From joint HTA (JCA), pricing reforms, and AI-driven tools to global value frameworks and real-world data, this episode unpacks key trends shaping pharma, biotech, and healthcare access in 2025 and beyond. If you're in health economics, pricing & reimbursement, or regulatory strategy, this is a must-listen.

Stay updated for upcoming webinars through LinkedIn, and take the chance to stay connected through subscribing with your favorite podcasting platform or directly listen on our website: MAP Podcasts 

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: https://marketaccess4-0.com/

#MarketAccess #HealthEconomics #PharmaStrategy #PricingAndReimbursement #HTA #marketaccess #marketaccesspodcast

]]>fc9b23ef-321a-43c5-a235-f4c6bbef0b61Fri, 01 Aug 2025 09:00:00 +020043:30falsefull193931What Does It Really Take to Master AMNOG in Today’s Market Access Landscape, Anja Pownell?What Does It Really Take to Master AMNOG in Today’s Market Access Landscape, Anja Pownell?Tune in to this new episode of the Market Access Podcast, where our host Dr. Stefan Walzer is joined by AMNOG expert Anja Pownell to bust some of the most persistent misconceptions about German market access—and share actionable survival tips for navigating the GBA process.

Learn how to strategically prepare for AMNOG submissions, navigate price negotiations, and leverage AI tools to streamline dossier writing and literature reviews. A must-listen for anyone involved in pharmaceutical pricing, reimbursement, and European market access strategy.

Stay updated for upcoming webinars through LinkedIn, and take the chance to stay connected through subscribing with your favorite podcasting platform or directly listen on our website: MAP Podcasts 

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: https://marketaccess4-0.com/

#MarketAccess #HealthEconomics #HealthcareInnovation #PharmaStrategy #AMNOG #PharmaInnovation  #GBA #Reimbursement #marketaccess #marketaccesspodcast

]]>Tune in to this new episode of the Market Access Podcast, where our host Dr. Stefan Walzer is joined by AMNOG expert Anja Pownell to bust some of the most persistent misconceptions about German market access—and share actionable survival tips for navigating the GBA process.

Learn how to strategically prepare for AMNOG submissions, navigate price negotiations, and leverage AI tools to streamline dossier writing and literature reviews. A must-listen for anyone involved in pharmaceutical pricing, reimbursement, and European market access strategy.

Stay updated for upcoming webinars through LinkedIn, and take the chance to stay connected through subscribing with your favorite podcasting platform or directly listen on our website: MAP Podcasts 

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: https://marketaccess4-0.com/

#MarketAccess #HealthEconomics #HealthcareInnovation #PharmaStrategy #AMNOG #PharmaInnovation  #GBA #Reimbursement #marketaccess #marketaccesspodcast

]]>5531a3b0-8620-4d80-abea-e42dfb5939eeTue, 15 Jul 2025 09:00:00 +020025:49falsefull192921Is Cross-Functional Alignment the Secret to Successful Market Access, Kasem Akhras?Is Cross-Functional Alignment the Secret to Successful Market Access, Kasem Akhras?In this episode of the Market Access Podcast, Dr. Stefan Walzer sits down with Kasem Akhras, veteran access strategist and author of Frontiers in Market Access, to unpack what it really takes to bring innovative therapies to patients across emerging markets. From the rising demand for innovative therapies to the tightening grip of healthcare budgets, this episode explores the real challenges and opportunities in market access today.

Discover why pricing strategies must be tailored to each market, how cross-functional collaboration and early planning are key to success, and how digital health and AI are reshaping the future of market access. A must-listen for anyone navigating the complexities of global market access.

Stay updated for upcoming webinars through LinkedIn, and take the chance to stay connected through subscribing with your favorite podcasting platform or directly listen on our website: MAP Podcasts 

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: https://marketaccess4-0.com/

#MarketAccess #HealthEconomics #EmergingMarkets #PricingStrategy #PharmaInnovation #DigitalHealth #AIinPharma #marketaccess #marketaccesspodcast

]]>In this episode of the Market Access Podcast, Dr. Stefan Walzer sits down with Kasem Akhras, veteran access strategist and author of Frontiers in Market Access, to unpack what it really takes to bring innovative therapies to patients across emerging markets. From the rising demand for innovative therapies to the tightening grip of healthcare budgets, this episode explores the real challenges and opportunities in market access today.

Discover why pricing strategies must be tailored to each market, how cross-functional collaboration and early planning are key to success, and how digital health and AI are reshaping the future of market access. A must-listen for anyone navigating the complexities of global market access.

Stay updated for upcoming webinars through LinkedIn, and take the chance to stay connected through subscribing with your favorite podcasting platform or directly listen on our website: MAP Podcasts 

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: https://marketaccess4-0.com/

#MarketAccess #HealthEconomics #EmergingMarkets #PricingStrategy #PharmaInnovation #DigitalHealth #AIinPharma #marketaccess #marketaccesspodcast

]]>61a7fa99-62ad-4c15-a8b8-316ba9140afdTue, 01 Jul 2025 09:00:00 +020038:29falsefull191911How Do You Unlock the Power of Statistics in Market Access, Necdet Gunsoy?How Do You Unlock the Power of Statistics in Market Access, Necdet Gunsoy?Tune in to the latest episode of the Market Access Podcast, where Dr. Stefan Walzer welcomes statistician and Evimed founder Necdet Gunsoy to explore the critical role of statistics in health economics, HTA, and payer strategy. Learn how better collaboration between statisticians and market access teams can drive evidence-based decision-making, improve communication, and support strategic planning—plus the impact of AI on future workflows.

This conversation spans key topics—from real-world evidence and health technology assessment (HTA) to internal cross-functional alignment and strategic planning in market access. Whether you're a health economist, market access leader, or data expert, this is a must-listen to improve cross-functional impact and efficiency.

Stay updated for upcoming webinars through LinkedIn, and take the chance to stay connected through subscribing with your favorite podcasting platform or directly listen on our website: MAP Podcasts 

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: https://marketaccess4-0.com/

#MarketAccess #HealthEconomics #HTA #Pharma #PayerStrategy #marketaccess #marketaccesspodcast

]]>Tune in to the latest episode of the Market Access Podcast, where Dr. Stefan Walzer welcomes statistician and Evimed founder Necdet Gunsoy to explore the critical role of statistics in health economics, HTA, and payer strategy. Learn how better collaboration between statisticians and market access teams can drive evidence-based decision-making, improve communication, and support strategic planning—plus the impact of AI on future workflows.

This conversation spans key topics—from real-world evidence and health technology assessment (HTA) to internal cross-functional alignment and strategic planning in market access. Whether you're a health economist, market access leader, or data expert, this is a must-listen to improve cross-functional impact and efficiency.

Stay updated for upcoming webinars through LinkedIn, and take the chance to stay connected through subscribing with your favorite podcasting platform or directly listen on our website: MAP Podcasts 

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: https://marketaccess4-0.com/

#MarketAccess #HealthEconomics #HTA #Pharma #PayerStrategy #marketaccess #marketaccesspodcast

]]>757740e6-4eba-4e8f-80cd-b9e09d7ca60bSun, 15 Jun 2025 09:00:00 +020036:03falsefull190901How will AI shape the future of Market Access and Systematic Reviews, Jeffrey Johnson and Kevin Kallmes? (Repost)How will AI shape the future of Market Access and Systematic Reviews, Jeffrey Johnson and Kevin Kallmes? (Repost)This is a repost of a popular episode of MAP - Market Access Podcast, from July 15th 2024.

Unlock the Future of Market Access with AI and Systematic Literature Reviews! Join Dr. Stefan Walzer in the latest episode of the Market Access Podcast as he delves into the transformative power of AI in systematic literature searches. Featuring Jeffrey Johnson and Kevin Kallmes from Nested Knowledge, this episode explores how their innovative platform revolutionizes literature reviews, making them faster, more efficient, and more enjoyable.

This episode is for anyone who wants to learn more about the integration of AI in market access, reimbursement planning, and dossier creation. Tune in to find out how AI is not only saving time but also enhancing the quality of research and market access strategies. Don’t miss this insightful discussion on the future of AI in healthcare!

Stay updated for upcoming webinars through LinkedIn, and take the chance to stay connected through subscribing with your favorite podcasting platform or directly listen on our website: MAP Podcasts 

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: https://marketaccess4-0.com/

#MarketAccess #AI #SystematicReview #HealthcareInnovation #Pharma #marketaccess #marketaccesspodcast

]]>This is a repost of a popular episode of MAP - Market Access Podcast, from July 15th 2024.

Unlock the Future of Market Access with AI and Systematic Literature Reviews! Join Dr. Stefan Walzer in the latest episode of the Market Access Podcast as he delves into the transformative power of AI in systematic literature searches. Featuring Jeffrey Johnson and Kevin Kallmes from Nested Knowledge, this episode explores how their innovative platform revolutionizes literature reviews, making them faster, more efficient, and more enjoyable.

This episode is for anyone who wants to learn more about the integration of AI in market access, reimbursement planning, and dossier creation. Tune in to find out how AI is not only saving time but also enhancing the quality of research and market access strategies. Don’t miss this insightful discussion on the future of AI in healthcare!

Stay updated for upcoming webinars through LinkedIn, and take the chance to stay connected through subscribing with your favorite podcasting platform or directly listen on our website: MAP Podcasts 

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: https://marketaccess4-0.com/

#MarketAccess #AI #SystematicReview #HealthcareInnovation #Pharma #marketaccess #marketaccesspodcast

]]>b7a4bcb6-a010-4d64-ae4e-d4d9cf646fa8Sun, 01 Jun 2025 09:00:00 +020034:09falsefull189891How Can Market Access Professionals Plan for Long-Term Success, Adrian Kielhorn?How Can Market Access Professionals Plan for Long-Term Success, Adrian Kielhorn?What does it take to succeed in Market Access? In this brand new episode of MAP, the Market Access podcast, Dr. Stefan Walzer sits down with industry veteran Adrian Kielhorn, co-author of The Market Access Guide. Together, they unpack the evolving role of market access professionals, the power of strategic thinking, mastering negotiations, and why patient centricity is key to success.

Learn how to develop a strong value story, navigate pricing and reimbursement, and stay ahead in the dynamic pharmaceutical and healthcare landscape. Whether you’re a seasoned professional or just starting out, this episode is packed with insights, strategy, and a touch of humor to help you navigate the ever-changing market access landscape. Tune in now for expert insights on the future of market access & health economics!

Want to get ahold of The Market Access Guide? Get your copy here or download the Kindle version now!

Stay updated for upcoming webinars through LinkedIn, and take the chance to stay connected through subscribing with your favorite podcasting platform or directly listen on our website: MAP Podcasts 

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: https://marketaccess4-0.com/

#MarketAccess #Pharma #HealthEconomics #PatientCentricity #NegotiationSkills #PricingStrategy #PharmaceuticalIndustry #HealthcareInnovation #marketaccess #marketaccesspodcast

]]>What does it take to succeed in Market Access? In this brand new episode of MAP, the Market Access podcast, Dr. Stefan Walzer sits down with industry veteran Adrian Kielhorn, co-author of The Market Access Guide. Together, they unpack the evolving role of market access professionals, the power of strategic thinking, mastering negotiations, and why patient centricity is key to success.

Learn how to develop a strong value story, navigate pricing and reimbursement, and stay ahead in the dynamic pharmaceutical and healthcare landscape. Whether you’re a seasoned professional or just starting out, this episode is packed with insights, strategy, and a touch of humor to help you navigate the ever-changing market access landscape. Tune in now for expert insights on the future of market access & health economics!

Want to get ahold of The Market Access Guide? Get your copy here or download the Kindle version now!

Stay updated for upcoming webinars through LinkedIn, and take the chance to stay connected through subscribing with your favorite podcasting platform or directly listen on our website: MAP Podcasts 

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: https://marketaccess4-0.com/

#MarketAccess #Pharma #HealthEconomics #PatientCentricity #NegotiationSkills #PricingStrategy #PharmaceuticalIndustry #HealthcareInnovation #marketaccess #marketaccesspodcast

]]>b2eb5d3f-6b10-49b8-93b0-552a6a3e5d83Thu, 15 May 2025 09:00:00 +020038:13falsefull188881What Are the Biggest Challenges & Opportunities of JCA, Dr. Nick Leach?What Are the Biggest Challenges & Opportunities of JCA, Dr. Nick Leach?In this brand new episode of MAP, the Market Access Podcast, our host Dr. Stefan Walzer is joined by Dr. Nick Leach, Market Access expert and managing director at Red Thread, to break down the Joint Clinical Assessment (JCA) process, its impact on pharma, biotech, and medical device companies, and how early advice can shape market access and reimbursement strategies in Europe.

Tune in to learn about JCA’s mandatory requirements, challenges, opportunities, and future developments as companies prepare for the evolving EU market access framework. JCA is changing the market access landscape in Europe - don’t miss out on this insightful discussion!

Stay updated for upcoming webinars through LinkedIn, and take the chance to stay connected through subscribing with your favorite podcasting platform or directly listen on our website: MAP Podcasts 

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: https://marketaccess4-0.com/

#MarketAccess #JCA #Pharma #HealthEconomics #HTA #Reimbursement #Biotech #marketaccess #marketaccesspodcast

]]>In this brand new episode of MAP, the Market Access Podcast, our host Dr. Stefan Walzer is joined by Dr. Nick Leach, Market Access expert and managing director at Red Thread, to break down the Joint Clinical Assessment (JCA) process, its impact on pharma, biotech, and medical device companies, and how early advice can shape market access and reimbursement strategies in Europe.

Tune in to learn about JCA’s mandatory requirements, challenges, opportunities, and future developments as companies prepare for the evolving EU market access framework. JCA is changing the market access landscape in Europe - don’t miss out on this insightful discussion!

Stay updated for upcoming webinars through LinkedIn, and take the chance to stay connected through subscribing with your favorite podcasting platform or directly listen on our website: MAP Podcasts 

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: https://marketaccess4-0.com/

#MarketAccess #JCA #Pharma #HealthEconomics #HTA #Reimbursement #Biotech #marketaccess #marketaccesspodcast

]]>5e93d520-7881-4aac-b39b-2d9a9bdcd463Thu, 01 May 2025 09:00:00 +020035:42falsefull187871Are We Overlooking the Real Benefits of Medical Innovation, Dr. Ahmed Seddik?Are We Overlooking the Real Benefits of Medical Innovation, Dr. Ahmed Seddik?Join the latest episode of the Market Access Podcast, where our host Dr. Stefan Walzer and expert Dr. Ahmed Seddik dissect the complexities of the societal impact of medical innovation. Dr. Ahmed Seddik shares important insights from his journey starting as a dentist in Egypt to his PhD research in health economics and social impact, focusing on how the access to innovation transforms communities and economies.

Explore how medical innovation shapes healthcare systems and economies, and take part in the discussion of how health economics, cost-effectiveness, and societal impact influence reimbursement decisions. Listen now to learn more about how different countries integrate social value into healthcare policies and what the future holds for market access and innovation adoption.

Curious to explore this topic further? You can find Ahmed Seddik’s thesis here: The social impact of medical innovations

Stay updated for upcoming webinars through LinkedIn, and take the chance to stay connected through subscribing with your favorite podcasting platform or directly listen on our website: MAP Podcasts 

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: https://marketaccess4-0.com/

#MarketAccess #HealthEconomics #MedicalInnovation #SocialImpact #HealthcarePolicy #marketaccess #marketaccesspodcast

]]>Join the latest episode of the Market Access Podcast, where our host Dr. Stefan Walzer and expert Dr. Ahmed Seddik dissect the complexities of the societal impact of medical innovation. Dr. Ahmed Seddik shares important insights from his journey starting as a dentist in Egypt to his PhD research in health economics and social impact, focusing on how the access to innovation transforms communities and economies.

Explore how medical innovation shapes healthcare systems and economies, and take part in the discussion of how health economics, cost-effectiveness, and societal impact influence reimbursement decisions. Listen now to learn more about how different countries integrate social value into healthcare policies and what the future holds for market access and innovation adoption.

Curious to explore this topic further? You can find Ahmed Seddik’s thesis here: The social impact of medical innovations

Stay updated for upcoming webinars through LinkedIn, and take the chance to stay connected through subscribing with your favorite podcasting platform or directly listen on our website: MAP Podcasts 

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: https://marketaccess4-0.com/

#MarketAccess #HealthEconomics #MedicalInnovation #SocialImpact #HealthcarePolicy #marketaccess #marketaccesspodcast

]]>5363c230-ff38-4b97-b33a-5686ce801878Tue, 15 Apr 2025 09:00:00 +020033:42falsefull186861What Are the Biggest Challenges in Implementing AI in Pharma, Jan Kroschinski?What Are the Biggest Challenges in Implementing AI in Pharma, Jan Kroschinski?How can AI revolutionize Market Access, and what does it take to drive successful change in pharma? Tune into the latest episode of MAP, the Market Access Podcast, where our host Dr. Stefan Walzer and Jan Kroschinski, an expert in digital transformation, will delve into change management and AI adoption in pharma.

Follow along as they explore how AI can streamline processes like dossier writing and HTA submissions, while tackling resistance to change. Discover strategies for effective AI adoption, leadership engagement, and risk vs. opportunity - how to shift from fear-based thinking to opportunity-driven AI adoption. Get ahead of the AI curve with this insightful discussion!

Stay updated for upcoming webinars through LinkedIn, and take the chance to stay connected through subscribing with your favorite podcasting platform or directly listen on our website: MAP Podcasts 

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: https://marketaccess4-0.com/

#MarketAccess #AI #DigitalTransformation #ChangeManagement #Pharma #HealthTech #marketaccess #marketaccesspodcast

]]>How can AI revolutionize Market Access, and what does it take to drive successful change in pharma? Tune into the latest episode of MAP, the Market Access Podcast, where our host Dr. Stefan Walzer and Jan Kroschinski, an expert in digital transformation, will delve into change management and AI adoption in pharma.

Follow along as they explore how AI can streamline processes like dossier writing and HTA submissions, while tackling resistance to change. Discover strategies for effective AI adoption, leadership engagement, and risk vs. opportunity - how to shift from fear-based thinking to opportunity-driven AI adoption. Get ahead of the AI curve with this insightful discussion!

Stay updated for upcoming webinars through LinkedIn, and take the chance to stay connected through subscribing with your favorite podcasting platform or directly listen on our website: MAP Podcasts 

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: https://marketaccess4-0.com/

#MarketAccess #AI #DigitalTransformation #ChangeManagement #Pharma #HealthTech #marketaccess #marketaccesspodcast

]]>5bec444a-e0a2-40c3-b528-1f890be05b07Tue, 01 Apr 2025 09:00:00 +020043:38falsefull185851How Can Startups Leverage Market Access to Attract Investors, Johan Olsson?How Can Startups Leverage Market Access to Attract Investors, Johan Olsson?In the latest episode of MAP, the Market Access Podcast, our host Dr. Stefan Walzer sits down with Johan Olsson, a seasoned life sciences investor, to uncover the critical role of market access and reimbursement in early-stage healthcare investments.

They explore how early market access planning impacts healthcare startups, investment decisions, and commercialization success. Discover why pricing, reimbursement, and payer strategies are key to securing funding, mitigating risk, and maximizing valuation. An understanding of the market access landscape can make or break a healthcare startup’s valuation, funding potential, and commercial viability. Tune in now to learn how to navigate market access for healthcare investments!

Stay updated for upcoming webinars through LinkedIn, and take the chance to stay connected through subscribing with your favorite podcasting platform or directly listen on our website: MAP Podcasts 

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: https://marketaccess4-0.com/

#MarketAccess #HealthcareInvestments #BiotechStartups #ReimbursementStrategies #Commercialization #AIHealthcare #marketaccess #marketaccesspodcast

]]>In the latest episode of MAP, the Market Access Podcast, our host Dr. Stefan Walzer sits down with Johan Olsson, a seasoned life sciences investor, to uncover the critical role of market access and reimbursement in early-stage healthcare investments.

They explore how early market access planning impacts healthcare startups, investment decisions, and commercialization success. Discover why pricing, reimbursement, and payer strategies are key to securing funding, mitigating risk, and maximizing valuation. An understanding of the market access landscape can make or break a healthcare startup’s valuation, funding potential, and commercial viability. Tune in now to learn how to navigate market access for healthcare investments!

Stay updated for upcoming webinars through LinkedIn, and take the chance to stay connected through subscribing with your favorite podcasting platform or directly listen on our website: MAP Podcasts 

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: https://marketaccess4-0.com/

#MarketAccess #HealthcareInvestments #BiotechStartups #ReimbursementStrategies #Commercialization #AIHealthcare #marketaccess #marketaccesspodcast

]]>6c198086-0b00-4696-8bac-8e5901d09d89Sat, 15 Mar 2025 09:00:00 +020033:03falsefull184841How Are Data Privacy Laws Delaying Patient Access to New Treatments, Douglas Drake and Adam Skali?How Are Data Privacy Laws Delaying Patient Access to New Treatments, Douglas Drake and Adam Skali?In this episode of MAP, Dr. Stefan Walzer, together with experts Douglas Drake and Adam Skali, unpacks the complexities of how GDPR regulations affect real-world evidence, cross-border studies, and market access in Europe. The discussion highlights data privacy challenges, delays in commercialization, and the future of healthcare data regulation.

Learn more about how data privacy laws create barriers for cross-border studies, delaying access to life-saving treatments, and how companies can navigate these hurdles and optimize market entry strategies. Can Europe find a balance between data privacy and innovation? Tune in to explore the challenges, solutions, and what’s next for healthcare in the EU.

Stay updated for upcoming webinars through LinkedIn, and take the chance to stay connected through subscribing with your favorite podcasting platform or directly listen on our website: MAP Podcasts 

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: https://marketaccess4-0.com/

#GDPR, #MarketAccess, #Real-WorldEvidence, #HealthcareData, #Pharma, #MedTech, #Cross-BorderStudies #marketaccess #marketaccesspodcast

]]>In this episode of MAP, Dr. Stefan Walzer, together with experts Douglas Drake and Adam Skali, unpacks the complexities of how GDPR regulations affect real-world evidence, cross-border studies, and market access in Europe. The discussion highlights data privacy challenges, delays in commercialization, and the future of healthcare data regulation.

Learn more about how data privacy laws create barriers for cross-border studies, delaying access to life-saving treatments, and how companies can navigate these hurdles and optimize market entry strategies. Can Europe find a balance between data privacy and innovation? Tune in to explore the challenges, solutions, and what’s next for healthcare in the EU.

Stay updated for upcoming webinars through LinkedIn, and take the chance to stay connected through subscribing with your favorite podcasting platform or directly listen on our website: MAP Podcasts 

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: https://marketaccess4-0.com/

#GDPR, #MarketAccess, #Real-WorldEvidence, #HealthcareData, #Pharma, #MedTech, #Cross-BorderStudies #marketaccess #marketaccesspodcast

]]>44b12ba0-39f7-426b-86ba-921e9ec11e8fSat, 01 Mar 2025 09:00:00 +020034:58falsefull183831How Can Innovation Planning Transform Market Access Success, Dr. Kasia Hein-Peters?How Can Innovation Planning Transform Market Access Success, Dr. Kasia Hein-Peters?Tune in to the latest episode of MAP, the Market Access Podcast, where Dr. Stefan Walzer sits down with Amazon bestselling author Dr. Kasia Hein-Peters to explore the power of structured innovation planning.

Get a deeper understanding of how healthcare companies better can balance short-term commercialization with long-term innovation, as well as what roles of AI, digital twins and scenario-based planning play in shaping market access. 

Hear the expert insights on commercialization, reimbursement, and future-proofing market access strategies. From Horizon 1 (current business) to Horizon 3 (future disruptions), this episode unpacks the key strategies to ensure market access success in an evolving healthcare landscape.

Get the book: Innovation Planner 2025 by Dr Kasia Hein-Peters

Stay updated for upcoming webinars through LinkedIn, and take the chance to stay connected through subscribing with your favorite podcasting platform or directly listen on our website: MAP Podcasts 

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: https://marketaccess4-0.com/

#MarketAccess #HealthcareInnovation #AI #DigitalHealth #InnovationManagement #Pharma #MedTech #marketaccess #marketaccesspodcast

]]>Tune in to the latest episode of MAP, the Market Access Podcast, where Dr. Stefan Walzer sits down with Amazon bestselling author Dr. Kasia Hein-Peters to explore the power of structured innovation planning.

Get a deeper understanding of how healthcare companies better can balance short-term commercialization with long-term innovation, as well as what roles of AI, digital twins and scenario-based planning play in shaping market access. 

Hear the expert insights on commercialization, reimbursement, and future-proofing market access strategies. From Horizon 1 (current business) to Horizon 3 (future disruptions), this episode unpacks the key strategies to ensure market access success in an evolving healthcare landscape.

Get the book: Innovation Planner 2025 by Dr Kasia Hein-Peters

Stay updated for upcoming webinars through LinkedIn, and take the chance to stay connected through subscribing with your favorite podcasting platform or directly listen on our website: MAP Podcasts 

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: https://marketaccess4-0.com/

#MarketAccess #HealthcareInnovation #AI #DigitalHealth #InnovationManagement #Pharma #MedTech #marketaccess #marketaccesspodcast

]]>65ca9363-0a5d-4701-99d9-041f11a04f36Sat, 15 Feb 2025 09:00:00 +020033:27falsefull183831How does early Market Access bridge the gap between innovation and commercial success, Catherine Bacon?How does early Market Access bridge the gap between innovation and commercial success, Catherine Bacon?Discover the newest episode of MAP, the Market Access Podcast, your go-to podcast for all things Market Access. In todays episode our host Dr. Stefan Walzer dives deep into early market access in commercialization planning, bridging the gap between innovation and market success. Joined by Catherine Bacon, founder of Fingerpost Consulting, the conversation unpacks the critical steps early-stage healthcare companies must take to ensure patient access, maximize funding, and achieve commercial success.

Explore the importance of early market access in commercialization planning. Learn how to align clinical trials, evidence generation, and payer requirements to ensure patient access and commercial success. Whether you’re aiming for a successful exit or launching your own product, this episode is packed with actionable advice to secure your path to market success by 2030 and beyond.

Tune in to the full episode and explore how Market Access 4.0 is transforming healthcare commercialization!

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: MAP Podcasts

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: https://marketacces4-0.de

www.marketaccess4-0.com/

#MarketAccess #HealthcareInnovation #PharmaFuture #marketaccess #marketaccesspodcast

]]>Discover the newest episode of MAP, the Market Access Podcast, your go-to podcast for all things Market Access. In todays episode our host Dr. Stefan Walzer dives deep into early market access in commercialization planning, bridging the gap between innovation and market success. Joined by Catherine Bacon, founder of Fingerpost Consulting, the conversation unpacks the critical steps early-stage healthcare companies must take to ensure patient access, maximize funding, and achieve commercial success.

Explore the importance of early market access in commercialization planning. Learn how to align clinical trials, evidence generation, and payer requirements to ensure patient access and commercial success. Whether you’re aiming for a successful exit or launching your own product, this episode is packed with actionable advice to secure your path to market success by 2030 and beyond.

Tune in to the full episode and explore how Market Access 4.0 is transforming healthcare commercialization!

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: MAP Podcasts

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: https://marketacces4-0.de

www.marketaccess4-0.com/

#MarketAccess #HealthcareInnovation #PharmaFuture #marketaccess #marketaccesspodcast

]]>02c89c80-da6e-4057-9f79-b35a7e0430d0Sat, 01 Feb 2025 09:00:00 +020031:42falsefull181811A Flourishing Career in Pharmaceutical Market Access: Which Skills Are Essential, Dipti Tankala? (Repost)A Flourishing Career in Pharmaceutical Market Access: Which Skills Are Essential, Dipti Tankala? (Repost)This is a repost of a popular episode of MAP - Market Access Podcast, from March 15th 2024.

Explore the inspiring journey of Dipti Tankala in this podcast episode as she delves into market access within the pharmaceutical industry. From facing challenges in community pharmacy to leading in oncology market access, Dipti shares valuable insights on making impactful career transitions. Market Access veteran Dr. Stefan Walzer and Dipti Tankala also talk about the significance of networking, mentorship, and the essential skills for success. This episode is a must-listen for professionals looking to navigate the complex world of market access and leverage opportunities in the pharmaceutical field. Tune in to unlock your career potential with expert advice from a seasoned market access professional.

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: MAP Podcasts

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: https://marketacces4-0.de

www.marketaccess4-0.com/

#Medtech #MarketAccess #Canada #HealthcareSystem #marketaccess #marketaccesspodcast #medtech

]]>This is a repost of a popular episode of MAP - Market Access Podcast, from March 15th 2024.

Explore the inspiring journey of Dipti Tankala in this podcast episode as she delves into market access within the pharmaceutical industry. From facing challenges in community pharmacy to leading in oncology market access, Dipti shares valuable insights on making impactful career transitions. Market Access veteran Dr. Stefan Walzer and Dipti Tankala also talk about the significance of networking, mentorship, and the essential skills for success. This episode is a must-listen for professionals looking to navigate the complex world of market access and leverage opportunities in the pharmaceutical field. Tune in to unlock your career potential with expert advice from a seasoned market access professional.

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: MAP Podcasts

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: https://marketacces4-0.de

www.marketaccess4-0.com/

#Medtech #MarketAccess #Canada #HealthcareSystem #marketaccess #marketaccesspodcast #medtech

]]>6977f001-f09c-4bf0-8124-f9978b4a9c2cWed, 15 Jan 2025 09:00:00 +020032:05falsefull180801What happens, when negotiations fail, Prof. Dr. Jürgen Wasem? (Repost)What happens, when negotiations fail, Prof. Dr. Jürgen Wasem? (Repost)This is a repost of a popular episode of MAP - Market Access Podcast, from December 15th 2021.

Who could be better to tell us the real insights, how the arbitration board works than Prof. Dr. Juergen Wasem, the former head of the AMNOG arbitration board and the current head of the DiGA arbitration board.

In this wide ranging conversation Dr. Stefan Walzer confronted Prof. Wasem with in-depth issues to take the arbitration board as well into strategic considerations.

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: MAP Podcasts

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: https://marketacces4-0.de

www.marketaccess4-0.com/

#MarketAccess #marketaccess #marketaccesspodcast

]]>This is a repost of a popular episode of MAP - Market Access Podcast, from December 15th 2021.

Who could be better to tell us the real insights, how the arbitration board works than Prof. Dr. Juergen Wasem, the former head of the AMNOG arbitration board and the current head of the DiGA arbitration board.

In this wide ranging conversation Dr. Stefan Walzer confronted Prof. Wasem with in-depth issues to take the arbitration board as well into strategic considerations.

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: MAP Podcasts

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: https://marketacces4-0.de

www.marketaccess4-0.com/

#MarketAccess #marketaccess #marketaccesspodcast

]]>83cbd0ac-77f2-411d-9a34-fd4ace34e0bdSun, 15 Dec 2024 09:00:00 +020038:56falsefull179791How can people get equal access to pharmaceuticals, Dr. Nina Lathia? (Repost)How can people get equal access to pharmaceuticals, Dr. Nina Lathia? (Repost)This is a repost of a popular episode of MAP - Market Access Podcast, from April 15th 2023.

All patients within all populations should have access to high quality medications that improve their health outcomes regardless of race, ethnicity, socio-economic status or any other individual factors, wrote Dr. Utibe R. Essien in an Jama article 2021. But how does reality look like? Equality in access starts with the generalizability of RCT data and the inclusion and exclusion criteria for these studies. But it does not stop there. How do regulators, payers and physicians work against inequality? The market access veteran Dr. Stefan Walzer and the Canadian health economist Dr. Nina Lathia have discussed these pharmacoequity issues from a global perspective. What does this mean for drug development? What does this mean for clinical trials?

Let’s not leave these questions with politicians alone. The voice from all stakeholders is needed and wanted. 

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: MAP Podcasts

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: https://marketacces4-0.de

www.marketaccess4-0.com/

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #Canada #pharmacoequity #pharma #healthcare 

]]>This is a repost of a popular episode of MAP - Market Access Podcast, from April 15th 2023.

All patients within all populations should have access to high quality medications that improve their health outcomes regardless of race, ethnicity, socio-economic status or any other individual factors, wrote Dr. Utibe R. Essien in an Jama article 2021. But how does reality look like? Equality in access starts with the generalizability of RCT data and the inclusion and exclusion criteria for these studies. But it does not stop there. How do regulators, payers and physicians work against inequality? The market access veteran Dr. Stefan Walzer and the Canadian health economist Dr. Nina Lathia have discussed these pharmacoequity issues from a global perspective. What does this mean for drug development? What does this mean for clinical trials?

Let’s not leave these questions with politicians alone. The voice from all stakeholders is needed and wanted. 

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: MAP Podcasts

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: https://marketacces4-0.de

www.marketaccess4-0.com/

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #Canada #pharmacoequity #pharma #healthcare 

]]>e882f346-5869-48a0-9e1e-4f09abbacab3Sun, 01 Dec 2024 09:00:00 +020030:27falsefull178781How might digitization change health care in Germany by 2035, Julian Molitor? (Repost)How might digitization change health care in Germany by 2035, Julian Molitor? (Repost)This is a repost of a popular episode of MAP - Market Access Podcast, from October 1st 2022.

Digital health could improve the efficiency, care and way patients are treated in all health care systems in the next years. Germany has started by implementing digital health applications (“DIGAs”) and is currently on its way to improve the digital infrastructure in hospitals. Anyway, some core questions remain such as reimbursement for high risk medical devices, e.g. artificial intelligence (AI), interoperability.

Dr. Stefan Walzer and Julian Molitor are discussing the current state as well as future opportunities with digital tools across the health care system. If you need to know where the German adoption is with respect to digitization you should not miss this podcast episode. 

Stay updated for upcoming webinars through LinkedIn, and take the chance to stay connected through subscribing with your favorite podcasting platform or directly listen on our website: MAP Podcasts 

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: https://marketaccess4-0.com/

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #digitalisation #germany

]]>This is a repost of a popular episode of MAP - Market Access Podcast, from October 1st 2022.

Digital health could improve the efficiency, care and way patients are treated in all health care systems in the next years. Germany has started by implementing digital health applications (“DIGAs”) and is currently on its way to improve the digital infrastructure in hospitals. Anyway, some core questions remain such as reimbursement for high risk medical devices, e.g. artificial intelligence (AI), interoperability.

Dr. Stefan Walzer and Julian Molitor are discussing the current state as well as future opportunities with digital tools across the health care system. If you need to know where the German adoption is with respect to digitization you should not miss this podcast episode. 

Stay updated for upcoming webinars through LinkedIn, and take the chance to stay connected through subscribing with your favorite podcasting platform or directly listen on our website: MAP Podcasts 

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: https://marketaccess4-0.com/

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #digitalisation #germany

]]>88c20f11-acf5-4445-b26f-09e667b2f274Fri, 15 Nov 2024 09:00:00 +020031:22falsefull177771How to optimize commercialisation of innovative life science products, Dr. Kasia Hein-Peters? (Repost)How to optimize commercialisation of innovative life science products, Dr. Kasia Hein-Peters? (Repost)This is a repost of a popular episode of MAP, Market Access Podcast, from 15th of July 2023.

Even though there are great accelerators and a lot of innovative product ideas, only very few products actually make it to the market and are commercially successful. What is the reason behind that and even more important how could this situation be improved?

In this podcast episode, Dr. Stefan Walzer and Dr. Kasia Hein-Peters are discussing the necessity for an overarching business and company strategy approach. In health care this is sometimes referred to a lifecycle approach, the invented approach by Dr. Kasia Hein-Peters is called DIVE. Within these approaches, all stakeholders would always need to be captured and dealt with - clinical development, regulatory and payers.

Stay updated for upcoming webinars through LinkedIn, and take the chance to stay connected through subscribing with your favorite podcasting platform or directly listen on our website: MAP Podcasts 

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: https://marketaccess4-0.com/

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #innovation #pricing #drugs #medtech #livescience #strategy

]]>This is a repost of a popular episode of MAP, Market Access Podcast, from 15th of July 2023.

Even though there are great accelerators and a lot of innovative product ideas, only very few products actually make it to the market and are commercially successful. What is the reason behind that and even more important how could this situation be improved?

In this podcast episode, Dr. Stefan Walzer and Dr. Kasia Hein-Peters are discussing the necessity for an overarching business and company strategy approach. In health care this is sometimes referred to a lifecycle approach, the invented approach by Dr. Kasia Hein-Peters is called DIVE. Within these approaches, all stakeholders would always need to be captured and dealt with - clinical development, regulatory and payers.

Stay updated for upcoming webinars through LinkedIn, and take the chance to stay connected through subscribing with your favorite podcasting platform or directly listen on our website: MAP Podcasts 

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: https://marketaccess4-0.com/

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #innovation #pricing #drugs #medtech #livescience #strategy

]]>04a27887-c346-46dd-b2cb-f05727dbad39Fri, 01 Nov 2024 09:00:00 +020031:30falsefull176761What does environmental sustainability mean for Market Access, Gerdi Strydom?What does environmental sustainability mean for Market Access, Gerdi Strydom?Join us on the latest episode of MAP - the Market Access Podcast - where our host Dr. Stefan Walzer, together with special guest Gerdi Strydom, Managing Director at Valid Insight, explore the integration of ESG (Environmental, Social, and Governance) into Health Technology Assessments (HTAs).

In this episode, they unpack how healthcare's carbon footprint and environmental impact are influencing policy, payor decisions, and industry strategies. Discover how leaders are addressing these challenges, the steps being taken in regions like the Nordics and the UK, and what the future holds for low-carbon pharmaceuticals.

This episode is for anyone who wants to get a better understanding of the growing role of environmental factors in HTAs as well as how global collaboration can drive sustainability in healthcare. Stay ahead of the trends in market access, and join the conversation around sustainability’s role in healthcare. Tune in now!

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: MAP Podcasts

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: https://marketacces4-0.de

www.marketaccess4-0.com/

#MarketAccess #HealthcareInnovation #Sustainability #HTA #Pharma #ESG #marketaccess #marketaccesspodcast

]]>Join us on the latest episode of MAP - the Market Access Podcast - where our host Dr. Stefan Walzer, together with special guest Gerdi Strydom, Managing Director at Valid Insight, explore the integration of ESG (Environmental, Social, and Governance) into Health Technology Assessments (HTAs).

In this episode, they unpack how healthcare's carbon footprint and environmental impact are influencing policy, payor decisions, and industry strategies. Discover how leaders are addressing these challenges, the steps being taken in regions like the Nordics and the UK, and what the future holds for low-carbon pharmaceuticals.

This episode is for anyone who wants to get a better understanding of the growing role of environmental factors in HTAs as well as how global collaboration can drive sustainability in healthcare. Stay ahead of the trends in market access, and join the conversation around sustainability’s role in healthcare. Tune in now!

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: MAP Podcasts

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: https://marketacces4-0.de

www.marketaccess4-0.com/

#MarketAccess #HealthcareInnovation #Sustainability #HTA #Pharma #ESG #marketaccess #marketaccesspodcast

]]>b1a8b82b-ba91-456b-85c1-a0b08705415eTue, 15 Oct 2024 09:00:00 +020034:07falsefull175751What are the main obstacles in oncology market access, Ed Schoonveld? (Repost)What are the main obstacles in oncology market access, Ed Schoonveld? (Repost)This is a repost of a popular MAP, Market Access Podcast, from 1st of January 2023. 

Companies launching oncology drugs sometimes struggle with existing reimbursement pathways and negotiations with payers, mainly in Europe, but also in other parts of the world. Evidence generation is the start of every drug development, but especially in oncology the design is important – not only that payers want to get a proof of a longer survival, but they also have further needs in their internal assessment. Enjoy the insights shared by the oncology market access veterans Dr. Stefan Walzer and Ed Schoonveld. 

Stay updated for upcoming webinars through LinkedIn, and take the chance to stay connected through subscribing with your favorite podcasting platform or directly listen on our website: MAP Podcasts 

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: https://marketaccess4-0.com/ 

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #germany #Europe #oncology 

]]>This is a repost of a popular MAP, Market Access Podcast, from 1st of January 2023. 

Companies launching oncology drugs sometimes struggle with existing reimbursement pathways and negotiations with payers, mainly in Europe, but also in other parts of the world. Evidence generation is the start of every drug development, but especially in oncology the design is important – not only that payers want to get a proof of a longer survival, but they also have further needs in their internal assessment. Enjoy the insights shared by the oncology market access veterans Dr. Stefan Walzer and Ed Schoonveld. 

Stay updated for upcoming webinars through LinkedIn, and take the chance to stay connected through subscribing with your favorite podcasting platform or directly listen on our website: MAP Podcasts 

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: https://marketaccess4-0.com/ 

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #germany #Europe #oncology 

]]>7a728ccc-c42d-42bb-b185-5d2a412aaaf8Tue, 01 Oct 2024 09:00:00 +020038:30falsefull174741Is there a place for Real World Evidence in HTA, Dr. Karen Facey? (Repost)Is there a place for Real World Evidence in HTA, Dr. Karen Facey? (Repost)This is a repost of a popular MAP, Market Access Podcast, from January 2023. 

A strong evidence package is important as a solid base for health technology assessments and the following price negotiations with health care payers. It is widely agreed, that randomized controlled trials are the gold standard in HTA, but there are also strong advocates of real-world evidence as a complementary way to measure the effectiveness of treatments. 

One of these advocates is Dr. Karen Facey and so Dr. Stefan Walzer brought her on the podcast and asked all the tough questions about real world evidence and the reality with payers around the world. Are there opportunities in such RWE data or is that a dead-end? 

 

Take the chance to stay connected and subscribe with your favourite podcasting platform or directly listen on our website: MAP Podcasts

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: https://marketacces4-0.de

www.marketaccess4-0.com/

 

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #hta #pharma #healthcare #realworldevidence #rwe 

]]>This is a repost of a popular MAP, Market Access Podcast, from January 2023. 

A strong evidence package is important as a solid base for health technology assessments and the following price negotiations with health care payers. It is widely agreed, that randomized controlled trials are the gold standard in HTA, but there are also strong advocates of real-world evidence as a complementary way to measure the effectiveness of treatments. 

One of these advocates is Dr. Karen Facey and so Dr. Stefan Walzer brought her on the podcast and asked all the tough questions about real world evidence and the reality with payers around the world. Are there opportunities in such RWE data or is that a dead-end? 

 

Take the chance to stay connected and subscribe with your favourite podcasting platform or directly listen on our website: MAP Podcasts

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: https://marketacces4-0.de

www.marketaccess4-0.com/

 

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #hta #pharma #healthcare #realworldevidence #rwe 

]]>f5a94c66-0383-479a-9699-d0262d914b01Sun, 15 Sep 2024 09:00:00 +020033:29falsefull173731How should market access and medical affairs work together, Dr. Mike Rosenblatt? (Repost)How should market access and medical affairs work together, Dr. Mike Rosenblatt? (Repost)In this repost of MAP, the Market Access Podcast, from 15th of September 2023, you’ll hear from Dr Stefan Walzer and Dr Mike Rosenblatt as they’re discussing the age we are currently in of massive medical innovation, including a lot of new modalities especially in the area of ATMPs, and this insightful conversation highlights some core questions:

- What are the differences between Clinical Development and Medical Affairs?

- When should a company start telling their medical story about a new product?

- What are the differences between drugs and vaccinations from a medical affairs’ perspective?

- ... and how should market access and medical affairs ideally work together?

Tune in to listen to the Market Access veteran Dr. Stefan Walzer and Dr. Mike Rosenblatt, one of the pioneers in Medical Affairs, Commercialisation and Market Access, as they continued their conversation from Boston, May 2023, through this epic podcast episode.

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: MAP Podcasts

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: https://marketacces4-0.de

www.marketaccess4-0.com/

#Medtech #MarketAccess #US #HealthcareSystem #marketaccess #marketaccesspodcast #pricing #medtech #pharmaceuticals #innovation #vaccination

]]>In this repost of MAP, the Market Access Podcast, from 15th of September 2023, you’ll hear from Dr Stefan Walzer and Dr Mike Rosenblatt as they’re discussing the age we are currently in of massive medical innovation, including a lot of new modalities especially in the area of ATMPs, and this insightful conversation highlights some core questions:

- What are the differences between Clinical Development and Medical Affairs?

- When should a company start telling their medical story about a new product?

- What are the differences between drugs and vaccinations from a medical affairs’ perspective?

- ... and how should market access and medical affairs ideally work together?

Tune in to listen to the Market Access veteran Dr. Stefan Walzer and Dr. Mike Rosenblatt, one of the pioneers in Medical Affairs, Commercialisation and Market Access, as they continued their conversation from Boston, May 2023, through this epic podcast episode.

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: MAP Podcasts

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: https://marketacces4-0.de

www.marketaccess4-0.com/

#Medtech #MarketAccess #US #HealthcareSystem #marketaccess #marketaccesspodcast #pricing #medtech #pharmaceuticals #innovation #vaccination

]]>ec611276-3051-409e-b68b-86beabe59c83Sun, 01 Sep 2024 09:00:00 +020030:51falsefull172721Summer Special - Webinar: How AI can revolutionize dossier writing, with special guest Aleksey ZavgorodniySummer Special - Webinar: How AI can revolutionize dossier writing, with special guest Aleksey ZavgorodniyTune in to the latest episode of MAP, the Market Access Podcast, hosted by Dr Stefan Walzer. In this summer special you will hear some profound insights from the recent MArS Webinar about the new platform DO-Bo - the first and only AI bot for creating reimbursement dossiers globally. Alongside Dr. Stefan Walzer you will also hear from Aleksey Zavgorodniy from Ukraine as they dive deep into how large language models are revolutionizing healthcare dossier writing.

The journey to create DO-Bo highlighted unique challenges and innovative solutions. Integrating expert knowledge with AI, maintaining data security, and optimizing data processing were key to DO-Bo's success. Explore how DO-Bo can save time and enhance quality in your market access strategies. Interested in transforming your dossier writing process? Request a live demo today and witness firsthand how DO-Bo is redefining healthcare dossier creation.

Stay updated about upcoming webinars through LinkedIn, and take the chance to stay connected through subscribing with your favorite podcasting platform or directly listen on our website: MAP Podcasts 

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: https://marketaccess4-0.com/

#Medtech #MarketAccess #DO-Bo #HealthcareSystem #dossierwriting #marketaccess #marketaccesspodcast #dossier #webinar

]]>Tune in to the latest episode of MAP, the Market Access Podcast, hosted by Dr Stefan Walzer. In this summer special you will hear some profound insights from the recent MArS Webinar about the new platform DO-Bo - the first and only AI bot for creating reimbursement dossiers globally. Alongside Dr. Stefan Walzer you will also hear from Aleksey Zavgorodniy from Ukraine as they dive deep into how large language models are revolutionizing healthcare dossier writing.

The journey to create DO-Bo highlighted unique challenges and innovative solutions. Integrating expert knowledge with AI, maintaining data security, and optimizing data processing were key to DO-Bo's success. Explore how DO-Bo can save time and enhance quality in your market access strategies. Interested in transforming your dossier writing process? Request a live demo today and witness firsthand how DO-Bo is redefining healthcare dossier creation.

Stay updated about upcoming webinars through LinkedIn, and take the chance to stay connected through subscribing with your favorite podcasting platform or directly listen on our website: MAP Podcasts 

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: https://marketaccess4-0.com/

#Medtech #MarketAccess #DO-Bo #HealthcareSystem #dossierwriting #marketaccess #marketaccesspodcast #dossier #webinar

]]>28fccb0a-b90f-44fa-ae56-09babb134f20Thu, 15 Aug 2024 09:00:00 +020034:49falsefull171711What are the latest trends in Turkish Healthcare Market Access, Oznur Seyhun?What are the latest trends in Turkish Healthcare Market Access, Oznur Seyhun?Join us on the latest episode of MAP - the Market Access Podcast - hosted by Dr. Stefan Walzer, as we delve into the dynamic world of market access in Turkey. This episode features Oznur Seyhun, from Market Access Today, who brings expertise from over 20 years of experience in pharmaceutical chemistry, economics, and global management.

Explore the latest trends in healthcare market access in Turkey, and discover how they are adapting to economic challenges like inflation and currency fluctuations. Learn about the introduction of Multi-Criteria Decision Analysis (MCDA) in reimbursement submissions, the rise of digital health solutions, and patient support programs.

This episode is for anyone looking to deepen their understanding of why Turkey remains an attractive market for pharmaceutical companies despite economic pressures, with insights into local manufacturing incentives and the evolving private sector.

Tune in to gain a comprehensive understanding of the current landscape and future prospects of market access in Turkey. Don’t miss out on this insightful discussion!

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: MAP Podcasts

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: www.marketaccess4-0.com/

#MarketAccess #HealthcareInnovation #DigitalHealth #Turkey #HealthcareSystem #marketaccess #marketaccesspodcast #medtech

]]>Join us on the latest episode of MAP - the Market Access Podcast - hosted by Dr. Stefan Walzer, as we delve into the dynamic world of market access in Turkey. This episode features Oznur Seyhun, from Market Access Today, who brings expertise from over 20 years of experience in pharmaceutical chemistry, economics, and global management.

Explore the latest trends in healthcare market access in Turkey, and discover how they are adapting to economic challenges like inflation and currency fluctuations. Learn about the introduction of Multi-Criteria Decision Analysis (MCDA) in reimbursement submissions, the rise of digital health solutions, and patient support programs.

This episode is for anyone looking to deepen their understanding of why Turkey remains an attractive market for pharmaceutical companies despite economic pressures, with insights into local manufacturing incentives and the evolving private sector.

Tune in to gain a comprehensive understanding of the current landscape and future prospects of market access in Turkey. Don’t miss out on this insightful discussion!

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: MAP Podcasts

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: www.marketaccess4-0.com/

#MarketAccess #HealthcareInnovation #DigitalHealth #Turkey #HealthcareSystem #marketaccess #marketaccesspodcast #medtech

]]>6d087705-f5fc-4327-a204-ce6c3aad29fbThu, 01 Aug 2024 09:00:00 +020034:26falsefull170701How will AI shape the future of Market Access and Systematic Reviews, Jeffrey Johnson and Kevin Kallmes?How will AI shape the future of Market Access and Systematic Reviews, Jeffrey Johnson and Kevin Kallmes?Unlock the Future of Market Access with AI and Systematic Literature Reviews! Join Dr. Stefan Walzer in the latest episode of the Market Access Podcast as he delves into the transformative power of AI in systematic literature searches. Featuring Jeffrey Johnson and Kevin Kallmes from Nested Knowledge, this episode explores how their innovative platform revolutionizes literature reviews, making them faster, more efficient, and more enjoyable.

This episode is for anyone who wants to learn more about the integration of AI in market access, reimbursement planning, and dossier creation. Tune in to find out how AI is not only saving time but also enhancing the quality of research and market access strategies. Don’t miss this insightful discussion on the future of AI in healthcare!

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: MAP Podcasts

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: www.marketaccess4-0.com/

#MarketAccess #AI #SystematicReview #HealthcareInnovation #Pharma #marketaccess #marketaccesspodcast

]]>Unlock the Future of Market Access with AI and Systematic Literature Reviews! Join Dr. Stefan Walzer in the latest episode of the Market Access Podcast as he delves into the transformative power of AI in systematic literature searches. Featuring Jeffrey Johnson and Kevin Kallmes from Nested Knowledge, this episode explores how their innovative platform revolutionizes literature reviews, making them faster, more efficient, and more enjoyable.

This episode is for anyone who wants to learn more about the integration of AI in market access, reimbursement planning, and dossier creation. Tune in to find out how AI is not only saving time but also enhancing the quality of research and market access strategies. Don’t miss this insightful discussion on the future of AI in healthcare!

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: MAP Podcasts

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: www.marketaccess4-0.com/

#MarketAccess #AI #SystematicReview #HealthcareInnovation #Pharma #marketaccess #marketaccesspodcast

]]>59c43982-f139-4db3-8a23-3755d19713dfMon, 15 Jul 2024 09:00:00 +020034:09falsefull169691How can Virtual Reality become a game-changer in Healthcare Training, Rodrigo Silva?How can Virtual Reality become a game-changer in Healthcare Training, Rodrigo Silva?Tune in to the new episode of the Market Access Podcast (MAP), where Dr. Stefan Walzer, a pioneer in Market Access 4.0, explores groundbreaking solutions and innovative technologies shaping the future of healthcare reimbursement. Discover how AI-based platforms like Q-Bo and Wafle are revolutionizing health care trainings with all stakeholders.

Special guest Rodrigo Silva shares his insights on the transformative power of virtual reality in healthcare, from enhancing nurse training to potential applications in the pharmaceutical industry. Discover how these technologies are revolutionizing market access and how digital health platforms can address critical healthcare challenges like nursing shortages.

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: MAP Podcasts

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: www.marketaccess4-0.com

#MarketAccess #AI #VirtualReality #HealthcareInnovation #Pharma #marketaccess #marketaccesspodcast #FutureOfHealthcare"

]]>Tune in to the new episode of the Market Access Podcast (MAP), where Dr. Stefan Walzer, a pioneer in Market Access 4.0, explores groundbreaking solutions and innovative technologies shaping the future of healthcare reimbursement. Discover how AI-based platforms like Q-Bo and Wafle are revolutionizing health care trainings with all stakeholders.

Special guest Rodrigo Silva shares his insights on the transformative power of virtual reality in healthcare, from enhancing nurse training to potential applications in the pharmaceutical industry. Discover how these technologies are revolutionizing market access and how digital health platforms can address critical healthcare challenges like nursing shortages.

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: MAP Podcasts

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: www.marketaccess4-0.com

#MarketAccess #AI #VirtualReality #HealthcareInnovation #Pharma #marketaccess #marketaccesspodcast #FutureOfHealthcare"

]]>17c380c8-6ecb-46a6-bb51-7c8205a6ff61Mon, 01 Jul 2024 09:00:00 +020035:54falsefull168681How Can AI Unlock the Potential of Market Access, Sandip Shah?How Can AI Unlock the Potential of Market Access, Sandip Shah?In the latest episode of MAP - the Market Access Podcast, Dr. Stefan Walzer discusses the transformative power of AI with industry veteran Sandip Shah. With over three decades in healthcare, Sandip shares his journey from sales rep to running Market Access Solutions, emphasizing on how AI is reshaping the landscape. 

Discover how AI is revolutionizing market research, streamlining dossier preparation, and reshaping pricing strategies. This episode is for anyone who wants to dive deep into how the potential of AI in enhancing market research through emotion recognition and data analysis can significantly impact payer research and training for sales reps. Imagine having comprehensive dossiers at your fingertips in the future, reducing preparation time from months to seconds.

Listen now to explore how AI is set to redefine market access, driving efficiency and innovation in ways we've only begun to imagine. Stay ahead of the curve and join the conversation on how AI will shape our industry's future!

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: MAP Podcasts

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

#MarketAccess #AI #HealthcareInnovation #HealthcareSystem #marketaccess #marketaccesspodcast 

]]>In the latest episode of MAP - the Market Access Podcast, Dr. Stefan Walzer discusses the transformative power of AI with industry veteran Sandip Shah. With over three decades in healthcare, Sandip shares his journey from sales rep to running Market Access Solutions, emphasizing on how AI is reshaping the landscape. 

Discover how AI is revolutionizing market research, streamlining dossier preparation, and reshaping pricing strategies. This episode is for anyone who wants to dive deep into how the potential of AI in enhancing market research through emotion recognition and data analysis can significantly impact payer research and training for sales reps. Imagine having comprehensive dossiers at your fingertips in the future, reducing preparation time from months to seconds.

Listen now to explore how AI is set to redefine market access, driving efficiency and innovation in ways we've only begun to imagine. Stay ahead of the curve and join the conversation on how AI will shape our industry's future!

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: MAP Podcasts

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

#MarketAccess #AI #HealthcareInnovation #HealthcareSystem #marketaccess #marketaccesspodcast 

]]>c00fbcbf-9540-4aa3-a3ec-9fec90cf50fcSat, 15 Jun 2024 09:00:00 +020038:36falsefull167671What Does the Future Hold for AI in Healthcare, Aleksey Zavgorodniy?What Does the Future Hold for AI in Healthcare, Aleksey Zavgorodniy?What will the future of AI in healthcare look like? Join us in the latest episode of MAP, the Market Access Podcast, featuring Alexey Zavgorodniy from Unicsoft, and explore the transformative world of artificial intelligence. With extensive experience in AI and large language models, Alexey shares invaluable insights into how AI is reshaping healthcare, pharmaceuticals, and beyond.

In this episode you will learn how AI mirrors the industrial revolution and how that results in both unique opportunities and challenges. Aleksey also illustrates some real-world applications of AI in market access, from predictive analytics in drug pricing to automated literature reviews and more. 

The discussion also goes further into the importance of privacy and ethical considerations that follows AI use, and why it is necessary to ensure data security while maximizing the benefits of technology

Whether you're an industry professional or a tech enthusiast, this episode offers a comprehensive overview of AI's current applications and its potential to drive future innovations in healthcare.

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: MAP Podcasts

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

#ArtificialIntelligence #AIInsights #HealthcareInnovation #Medtech #MarketAccess #HealthcareSystem #MedicalTechnology #marketaccess #marketaccesspodcast #medtech

]]>What will the future of AI in healthcare look like? Join us in the latest episode of MAP, the Market Access Podcast, featuring Alexey Zavgorodniy from Unicsoft, and explore the transformative world of artificial intelligence. With extensive experience in AI and large language models, Alexey shares invaluable insights into how AI is reshaping healthcare, pharmaceuticals, and beyond.

In this episode you will learn how AI mirrors the industrial revolution and how that results in both unique opportunities and challenges. Aleksey also illustrates some real-world applications of AI in market access, from predictive analytics in drug pricing to automated literature reviews and more. 

The discussion also goes further into the importance of privacy and ethical considerations that follows AI use, and why it is necessary to ensure data security while maximizing the benefits of technology

Whether you're an industry professional or a tech enthusiast, this episode offers a comprehensive overview of AI's current applications and its potential to drive future innovations in healthcare.

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: MAP Podcasts

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

#ArtificialIntelligence #AIInsights #HealthcareInnovation #Medtech #MarketAccess #HealthcareSystem #MedicalTechnology #marketaccess #marketaccesspodcast #medtech

]]>5510ac2f-39c7-426f-94ac-239ea5a5add9Sat, 01 Jun 2024 09:00:00 +020034:28falsefull166661How to Decode Market Access in Canada: Are There Essential Tips for Success, Tara Cowling and Jody Filkowski?How to Decode Market Access in Canada: Are There Essential Tips for Success, Tara Cowling and Jody Filkowski?In the newest episode of MAP - the Market Access podcast, experts Tara Cowling and Jody Filkowski unpacks the complexities and nuances of Canada's market access for pharmaceuticals and medical devices. From regulatory hurdles to intricate reimbursement pathways, they shed light on what it takes to successfully navigate this diverse and challenging landscape.

Whether you're dealing with drugs or medical devices, understanding the distinct processes in Canada, including the differences between provinces and the role of private versus public payers, is crucial. This episode offers a deep dive into the practical strategies and real-world challenges faced by industry professionals working within the Canadian healthcare system. They also share insights about the emerging role of digital health in Canada, and the potential changes with the introduction of the Canadian Drug Agency.

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: MAP Podcasts

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

#Medtech #MarketAccess #Canada #Healthcare #marketaccess #marketaccesspodcast #medtech #pharmaceuticals #medicaldevices #digitalhealth

]]>In the newest episode of MAP - the Market Access podcast, experts Tara Cowling and Jody Filkowski unpacks the complexities and nuances of Canada's market access for pharmaceuticals and medical devices. From regulatory hurdles to intricate reimbursement pathways, they shed light on what it takes to successfully navigate this diverse and challenging landscape.

Whether you're dealing with drugs or medical devices, understanding the distinct processes in Canada, including the differences between provinces and the role of private versus public payers, is crucial. This episode offers a deep dive into the practical strategies and real-world challenges faced by industry professionals working within the Canadian healthcare system. They also share insights about the emerging role of digital health in Canada, and the potential changes with the introduction of the Canadian Drug Agency.

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: MAP Podcasts

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

#Medtech #MarketAccess #Canada #Healthcare #marketaccess #marketaccesspodcast #medtech #pharmaceuticals #medicaldevices #digitalhealth

]]>70e5f9d6-822b-4dfe-b2e1-9ebc8b9ee3b3Wed, 15 May 2024 09:00:00 +020044:38falsefull165651How has virtual become reality in market access, Glib Kutepov?How has virtual become reality in market access, Glib Kutepov?What role will AI & VR transformations play in the future? Tune in to this fascinating episode of the Market Access Podcast to hear as our special guest, Glib Kutepov, CEO and founder of Modulate, shares his expertise. 

Glib uncovers the potential of generative AI and neural networks in revolutionizing market access strategies and highlights the challenges and solutions around data privacy as well as the integration of private layers to protect sensitive information. He also touches on the role of VR in empathizing with patients' experiences, adding a deeply human element to the data-driven world of market access. This episode will not only provide a deeper understanding for the technology, but also tools of practical ways to implement it.

AI and VR could change the data driven health care in the future, as it can benefit the strategic work as well as assist in ensuring a better understanding for the patients’ experiences. Whether you're a healthcare professional, market access manager, or tech enthusiast, this conversation offers a glimpse into a future where technology enhances our approach to healthcare on multiple levels.

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: MAP Podcasts

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

#HealthcareInnovation #MarketAccess #marketaccesspodcast #ArtificialIntelligence #VirtualReality #FutureOfHealthcare #marketaccess

]]>What role will AI & VR transformations play in the future? Tune in to this fascinating episode of the Market Access Podcast to hear as our special guest, Glib Kutepov, CEO and founder of Modulate, shares his expertise. 

Glib uncovers the potential of generative AI and neural networks in revolutionizing market access strategies and highlights the challenges and solutions around data privacy as well as the integration of private layers to protect sensitive information. He also touches on the role of VR in empathizing with patients' experiences, adding a deeply human element to the data-driven world of market access. This episode will not only provide a deeper understanding for the technology, but also tools of practical ways to implement it.

AI and VR could change the data driven health care in the future, as it can benefit the strategic work as well as assist in ensuring a better understanding for the patients’ experiences. Whether you're a healthcare professional, market access manager, or tech enthusiast, this conversation offers a glimpse into a future where technology enhances our approach to healthcare on multiple levels.

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: MAP Podcasts

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

#HealthcareInnovation #MarketAccess #marketaccesspodcast #ArtificialIntelligence #VirtualReality #FutureOfHealthcare #marketaccess

]]>c0aa90b1-5d45-48f6-9fd6-fb6025dac7a3Wed, 01 May 2024 09:00:00 +020031:08falsefull164641What Makes Italy's Healthcare System So Complex, Giacomo Matteo Bruno?What Makes Italy's Healthcare System So Complex, Giacomo Matteo Bruno?Tune into a brand new episode of the Market Access Podcast to listen to an intriguing conversation about the Italian healthcare system with Giacomo Matteo Bruno and Dr Stefan Walzer. Together they explore the balance between innovation, sustainability, and patient access in the heart of Europe. Discover the evolution, challenges, and future of healthcare in Italy, from the foundational principles laid down in 1978 to the dynamic, ever-evolving landscape of today.

Giacomo shares his insights on how to navigate the crucial role of health economics in drug pathways as well as giving a birds-eye perspective over the healthcare system in Italy today and the challenges that comes with an aging population and rising chronic diseases. Giacomo presents a vision for embracing innovation while maintaining the system’s integrity. 

If you are searching for deeper knowledge about the Italian healthcare system and learn about strategies on how to enter the Italian market, this episode is for you. Learn about the regional nuances that make Italy unique, the steps for drug reimbursement, and the importance of targeted therapies in personalized medicine. Giacomo also sheds light on the pioneering electronic dossier system introduced by IFA, streamlining the approval process and setting a new standard in healthcare innovation.

Whether you're a healthcare professional, a pharmaceutical company, or just intrigued by the global healthcare landscape, this conversation offers valuable lessons and strategies for success in one of the world's most revered healthcare systems. 

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: MAP Podcasts

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

#HealthcareInnovation #MarketAccess #Italy #ItalianHealthcare #PharmaceuticalIndustry #marketaccesspodcast #marketaccess

]]>Tune into a brand new episode of the Market Access Podcast to listen to an intriguing conversation about the Italian healthcare system with Giacomo Matteo Bruno and Dr Stefan Walzer. Together they explore the balance between innovation, sustainability, and patient access in the heart of Europe. Discover the evolution, challenges, and future of healthcare in Italy, from the foundational principles laid down in 1978 to the dynamic, ever-evolving landscape of today.

Giacomo shares his insights on how to navigate the crucial role of health economics in drug pathways as well as giving a birds-eye perspective over the healthcare system in Italy today and the challenges that comes with an aging population and rising chronic diseases. Giacomo presents a vision for embracing innovation while maintaining the system’s integrity. 

If you are searching for deeper knowledge about the Italian healthcare system and learn about strategies on how to enter the Italian market, this episode is for you. Learn about the regional nuances that make Italy unique, the steps for drug reimbursement, and the importance of targeted therapies in personalized medicine. Giacomo also sheds light on the pioneering electronic dossier system introduced by IFA, streamlining the approval process and setting a new standard in healthcare innovation.

Whether you're a healthcare professional, a pharmaceutical company, or just intrigued by the global healthcare landscape, this conversation offers valuable lessons and strategies for success in one of the world's most revered healthcare systems. 

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: MAP Podcasts

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

#HealthcareInnovation #MarketAccess #Italy #ItalianHealthcare #PharmaceuticalIndustry #marketaccesspodcast #marketaccess

]]>c2893982-8554-4a3c-80aa-95f8f7e2f6d6Tue, 16 Apr 2024 08:15:00 +020031:28falsefull163631Is Healthcare Just a Business in the US, Aymeric Chaupin?Is Healthcare Just a Business in the US, Aymeric Chaupin?In this captivating episode of MAP, the Market Access Podcast, we welcome Aymeric Chaupin, a seasoned expert in pricing and market access. Aymeric's unique perspective, shaped by his deep understanding of both the American and European healthcare systems, sheds light on the complexities of healthcare reimbursement pathways in the US and their impact on the delivery of health services.

Join us as Aymeric unveils the challenges and opportunities within the US healthcare market. He emphasizes the importance of coding and understanding reimbursement pathways for effective market access and explores the broader implications for patient care and the healthcare system as a whole.

This episode is a treasure trove of insights for startups and companies looking to navigate the US healthcare landscape. Aymeric shares practical advice on entering the market, from partnering with pharmaceutical giants to engaging with the FDA early in the clinical trial process. He stresses the necessity of having a clear strategy and representation in the US to negotiate coverage and formulary placement, ensuring commercial success in this pivotal market.

Despite the hurdles, the US remains a key player in the global pharmaceutical and medical device industry, accounting for a significant portion of global revenue.

Tune in for an enlightening discussion that navigates the intricacies of the US healthcare system, providing valuable lessons and strategies for companies aspiring to make their mark in this challenging yet rewarding market.

#HealthcareInnovation #MarketAccess #US #USHealthcareSystem #PharmaceuticalIndustry #MedicalDevices #HealthcareReform #marketaccess #marketaccesspodcast

]]>In this captivating episode of MAP, the Market Access Podcast, we welcome Aymeric Chaupin, a seasoned expert in pricing and market access. Aymeric's unique perspective, shaped by his deep understanding of both the American and European healthcare systems, sheds light on the complexities of healthcare reimbursement pathways in the US and their impact on the delivery of health services.

Join us as Aymeric unveils the challenges and opportunities within the US healthcare market. He emphasizes the importance of coding and understanding reimbursement pathways for effective market access and explores the broader implications for patient care and the healthcare system as a whole.

This episode is a treasure trove of insights for startups and companies looking to navigate the US healthcare landscape. Aymeric shares practical advice on entering the market, from partnering with pharmaceutical giants to engaging with the FDA early in the clinical trial process. He stresses the necessity of having a clear strategy and representation in the US to negotiate coverage and formulary placement, ensuring commercial success in this pivotal market.

Despite the hurdles, the US remains a key player in the global pharmaceutical and medical device industry, accounting for a significant portion of global revenue.

Tune in for an enlightening discussion that navigates the intricacies of the US healthcare system, providing valuable lessons and strategies for companies aspiring to make their mark in this challenging yet rewarding market.

#HealthcareInnovation #MarketAccess #US #USHealthcareSystem #PharmaceuticalIndustry #MedicalDevices #HealthcareReform #marketaccess #marketaccesspodcast

]]>e49ae649-031d-4855-bf24-77de83b7bffcMon, 01 Apr 2024 09:00:00 +020033:06falsefull162621A Flourishing Career in Pharmaceutical Market Access: Which Skills Are Essential, Dipti Tankala?A Flourishing Career in Pharmaceutical Market Access: Which Skills Are Essential, Dipti Tankala?Explore the inspiring journey of Dipti Tankala in this podcast episode as she delves into market access within the pharmaceutical industry. From facing challenges in community pharmacy to leading in oncology market access, Dipti shares valuable insights on making impactful career transitions. Market Access veteran Dr. Stefan Walzer and Dipti Tankala also talk about the significance of networking, mentorship, and the essential skills for success. This episode is a must-listen for professionals looking to navigate the complex world of market access and leverage opportunities in the pharmaceutical field. Tune in to unlock your career potential with expert advice from a seasoned market access professional. 
Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: MAP Podcasts
MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de
#Medtech #MarketAccess #Canada #HealthcareSystem #marketaccess #marketaccesspodcast #medtech
]]>Explore the inspiring journey of Dipti Tankala in this podcast episode as she delves into market access within the pharmaceutical industry. From facing challenges in community pharmacy to leading in oncology market access, Dipti shares valuable insights on making impactful career transitions. Market Access veteran Dr. Stefan Walzer and Dipti Tankala also talk about the significance of networking, mentorship, and the essential skills for success. This episode is a must-listen for professionals looking to navigate the complex world of market access and leverage opportunities in the pharmaceutical field. Tune in to unlock your career potential with expert advice from a seasoned market access professional. 
Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: MAP Podcasts
MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de
#Medtech #MarketAccess #Canada #HealthcareSystem #marketaccess #marketaccesspodcast #medtech
]]>4b271521-68b5-4822-a844-e4613a22ca6cFri, 15 Mar 2024 12:15:00 +020032:02falsefull161611Mastering US Market Access: What are proven Strategies for Success, Paul-Lukas Hoffschmidt?Mastering US Market Access: What are proven Strategies for Success, Paul-Lukas Hoffschmidt?In this essential episode of the Market Access Podcast, we're diving deep into the critical aspects of commercializing healthcare innovations in the US market. Whether you're in medtech, pharma, biotech, or health tech, understanding the US healthcare landscape is key to your product's success. Join us as Dr. Stefan Walzer and Paul-Lukas Hoffschmidt, CEO of Alpha Sophia (www.alphasophia.com), share their wealth of knowledge on effective strategies for navigating this complex terrain.

Key Topics Covered:

  • Understanding US Market Access: An overview of the unique challenges and opportunities in the US healthcare system for new entrants.
  • Role of Healthcare Professionals: Insight into how healthcare professionals influence market access and product uptake.
  • Data-Driven Strategies: The importance of leveraging data in targeting and positioning your product effectively.
  • Commercialization Pathways: Expert advice on navigating regulatory, reimbursement, and distribution challenges.
  • Case Studies: Real-world examples of successful market entry and the lessons learned.
  • Future Trends: Predictions on how the US market access landscape may evolve and what it means for healthcare innovators.

Why You Should Listen:

  • Gain Expert Insights: Learn from leading experts with firsthand experience in the US healthcare market.
  • Strategic Advice: Receive actionable advice on overcoming the hurdles to market entry and expansion.
  • Stay Ahead: Understand the latest trends and how they impact market access strategies.

This episode is indispensable for CEOs, entrepreneurs, market access professionals, and anyone involved in the commercialization of healthcare innovations looking to penetrate or expand their presence in the US market.

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: MAP Podcasts

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

#Medtech #MarketAccess #US #HealthcareSystem #MarketAccessPodcast

]]>In this essential episode of the Market Access Podcast, we're diving deep into the critical aspects of commercializing healthcare innovations in the US market. Whether you're in medtech, pharma, biotech, or health tech, understanding the US healthcare landscape is key to your product's success. Join us as Dr. Stefan Walzer and Paul-Lukas Hoffschmidt, CEO of Alpha Sophia (www.alphasophia.com), share their wealth of knowledge on effective strategies for navigating this complex terrain.

Key Topics Covered:

  • Understanding US Market Access: An overview of the unique challenges and opportunities in the US healthcare system for new entrants.
  • Role of Healthcare Professionals: Insight into how healthcare professionals influence market access and product uptake.
  • Data-Driven Strategies: The importance of leveraging data in targeting and positioning your product effectively.
  • Commercialization Pathways: Expert advice on navigating regulatory, reimbursement, and distribution challenges.
  • Case Studies: Real-world examples of successful market entry and the lessons learned.
  • Future Trends: Predictions on how the US market access landscape may evolve and what it means for healthcare innovators.

Why You Should Listen:

  • Gain Expert Insights: Learn from leading experts with firsthand experience in the US healthcare market.
  • Strategic Advice: Receive actionable advice on overcoming the hurdles to market entry and expansion.
  • Stay Ahead: Understand the latest trends and how they impact market access strategies.

This episode is indispensable for CEOs, entrepreneurs, market access professionals, and anyone involved in the commercialization of healthcare innovations looking to penetrate or expand their presence in the US market.

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: MAP Podcasts

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

#Medtech #MarketAccess #US #HealthcareSystem #MarketAccessPodcast

]]>34fc8b32-2d79-45f7-9bba-1905b85725fbFri, 01 Mar 2024 13:30:00 +020033:08falsefull160601Beyond the CE Mark: How can we achieve Medtech Reimbursement in France, Dr. Benoit Salaun?Beyond the CE Mark: How can we achieve Medtech Reimbursement in France, Dr. Benoit Salaun?Join us for a fascinating dive into the complexities of French market access with our latest episode of the Map Podcast. Dr. Stefan Walzer, health economist and founder of Mars Market Access & Pricing Strategy, engages with Dr. Benoit Salaun, a seasoned expert in French healthcare reimbursement.

They unravel:

  • The nuances of the French healthcare system
  • The essentials of medical device reimbursement
  • The importance of demonstrating efficacy, safety, and affordability
  • The role of clinical evidence and the adaptability of international data to French contexts
  • The strategic considerations for medtech companies entering the French market

Whether you’re a healthcare professional, a medtech innovator, or a market access strategist, this episode is packed with insights on how to ensure your medical device not only enters the French market but also achieves the price it deserves.

Tune in to gain expert knowledge on creating a successful roadmap for market access in France, and discover if the "French way" aligns with your company's goals.

🎧 Listen now and elevate your market access strategy! 

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: MAP Podcasts

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

#Medtech #MarketAccess #HealthcareInnovation #FrenchHealthcareSystem #marketaccess #marketaccesspodcast

]]>Join us for a fascinating dive into the complexities of French market access with our latest episode of the Map Podcast. Dr. Stefan Walzer, health economist and founder of Mars Market Access & Pricing Strategy, engages with Dr. Benoit Salaun, a seasoned expert in French healthcare reimbursement.

They unravel:

  • The nuances of the French healthcare system
  • The essentials of medical device reimbursement
  • The importance of demonstrating efficacy, safety, and affordability
  • The role of clinical evidence and the adaptability of international data to French contexts
  • The strategic considerations for medtech companies entering the French market

Whether you’re a healthcare professional, a medtech innovator, or a market access strategist, this episode is packed with insights on how to ensure your medical device not only enters the French market but also achieves the price it deserves.

Tune in to gain expert knowledge on creating a successful roadmap for market access in France, and discover if the "French way" aligns with your company's goals.

🎧 Listen now and elevate your market access strategy! 

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: MAP Podcasts

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

#Medtech #MarketAccess #HealthcareInnovation #FrenchHealthcareSystem #marketaccess #marketaccesspodcast

]]>9c83c4e2-0c79-4614-a71d-a47cc7cb708fThu, 15 Feb 2024 16:00:00 +020034:25falsefull159591Remo Christen – Early paid access in Switzerland – Switzerland, wonderland? (Repost)Remo Christen – Early paid access in Switzerland – Switzerland, wonderland? (Repost)In this Podcast episode, Dr. Stefan Walzer is discussing the specifics of the Swiss market access & reimbursement including the famous article 71, which allows an early paid access.

Who else could better speak about the Swiss system with him than Remo Christen? Remo is working since > 20 years in the Swiss market access environment in a leading role at Roche’s Swiss affiliate.

In this episode, listeners will learn the specifics of the Swiss culture, the reimbursement process also in comparison to the German AMNOG and why Switzerland is attractive for drug launches.

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: MAP Podcasts

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

]]>In this Podcast episode, Dr. Stefan Walzer is discussing the specifics of the Swiss market access & reimbursement including the famous article 71, which allows an early paid access.

Who else could better speak about the Swiss system with him than Remo Christen? Remo is working since > 20 years in the Swiss market access environment in a leading role at Roche’s Swiss affiliate.

In this episode, listeners will learn the specifics of the Swiss culture, the reimbursement process also in comparison to the German AMNOG and why Switzerland is attractive for drug launches.

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: MAP Podcasts

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

]]>0be970ca-110b-4151-be3c-2c267a4ad833Thu, 01 Feb 2024 09:00:00 +020034:11falsefull158581How can we overcome the complexity of market access for medical devices in Spain, Sergio Gil?How can we overcome the complexity of market access for medical devices in Spain, Sergio Gil?Are you intrigued by the pulsing heart of Spain’s healthcare sector, or are you considering navigating the vibrant market of medical devices in Spain? Dive into our latest Market Access podcast episode where we unravel the complexities and dynamism of Spain’s medical landscape. 🇪🇸

Join us as Sergio Gil, a seasoned veteran with over three decades in the medical device industry, shares his invaluable insights. From understanding Spain's unique regional healthcare powers to decoding the reimbursement conundrums, Sergio illuminates the path to successful market entry and what makes Spain not just culturally, but commercially captivating.

Here’s a sneak peek at what you’ll discover:

🔹 The striking differences between the pharmaceutical and medical device sectors in Spain.

🔹 An insider’s guide to Spain’s decentralized healthcare approach and how it impacts market access.

🔹 Key strategies for companies aiming to penetrate the Spanish market – straight from the expert.

🔹 The burgeoning world of digital health in Spain and the emerging trends to watch out for.

Whether you're a startup eyeing Spain for your next big launch or a seasoned player looking to deepen your market footprint, this episode is packed with strategic gold.

✏️ Take the chance to stay connected and subscribe with your favorite podcast platform: map-market-access.captivate.fm

MAP is the first and only bi-weekly #marketaccess podcast provided by MArS. For more information about MArS Market Access & Pricing Strategy GmbH visit: marketaccess-pricingstrategy.de

#MedicalDevices #Healthcare #MarketAccess #Spain #Podcast #DigitalHealth #Innovation #BusinessStrategy

]]>Are you intrigued by the pulsing heart of Spain’s healthcare sector, or are you considering navigating the vibrant market of medical devices in Spain? Dive into our latest Market Access podcast episode where we unravel the complexities and dynamism of Spain’s medical landscape. 🇪🇸

Join us as Sergio Gil, a seasoned veteran with over three decades in the medical device industry, shares his invaluable insights. From understanding Spain's unique regional healthcare powers to decoding the reimbursement conundrums, Sergio illuminates the path to successful market entry and what makes Spain not just culturally, but commercially captivating.

Here’s a sneak peek at what you’ll discover:

🔹 The striking differences between the pharmaceutical and medical device sectors in Spain.

🔹 An insider’s guide to Spain’s decentralized healthcare approach and how it impacts market access.

🔹 Key strategies for companies aiming to penetrate the Spanish market – straight from the expert.

🔹 The burgeoning world of digital health in Spain and the emerging trends to watch out for.

Whether you're a startup eyeing Spain for your next big launch or a seasoned player looking to deepen your market footprint, this episode is packed with strategic gold.

✏️ Take the chance to stay connected and subscribe with your favorite podcast platform: map-market-access.captivate.fm

MAP is the first and only bi-weekly #marketaccess podcast provided by MArS. For more information about MArS Market Access & Pricing Strategy GmbH visit: marketaccess-pricingstrategy.de

#MedicalDevices #Healthcare #MarketAccess #Spain #Podcast #DigitalHealth #Innovation #BusinessStrategy

]]>70966269-dcf9-4d2d-85f1-00dfc0fa7941Mon, 15 Jan 2024 09:00:00 +020033:15falsefull157571What is the secret of the cost-efficient healthcare system in Israel, Mirel Stelian? (Repost)What is the secret of the cost-efficient healthcare system in Israel, Mirel Stelian? (Repost)We are looking at Israel a lot recently, but did you know how innovative this rather small country is in terms of healthcare?

Israel spends only 7.6% of the GDP on healthcare – significantly less than most other Western OECD countries. At the same time, Israel has a higher life expectancy and lower infant mortality. So, better results for less money?! How does Israel do this?

Dr. Stefan Walzer and Mirel Stelian are discussing in depth, how the application and reimbursement process works and what options are available for companies who want to enter the Israeli market. If you want to understand the Israeli health care market and specifically the reimbursement process in Israel, you should not miss this episode. 

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: MAP Podcasts

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

 

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #europe #israel

]]>We are looking at Israel a lot recently, but did you know how innovative this rather small country is in terms of healthcare?

Israel spends only 7.6% of the GDP on healthcare – significantly less than most other Western OECD countries. At the same time, Israel has a higher life expectancy and lower infant mortality. So, better results for less money?! How does Israel do this?

Dr. Stefan Walzer and Mirel Stelian are discussing in depth, how the application and reimbursement process works and what options are available for companies who want to enter the Israeli market. If you want to understand the Israeli health care market and specifically the reimbursement process in Israel, you should not miss this episode. 

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: MAP Podcasts

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

 

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #europe #israel

]]>0ed91543-f509-4fca-96d0-e866cde8251aFri, 15 Dec 2023 09:00:00 +020033:41falsefull156561The Startup Guide to Navigating Healthcare Reimbursement, Featuring Ron de GraaffThe Startup Guide to Navigating Healthcare Reimbursement, Featuring Ron de GraaffWe are thrilled to announce our latest podcast episode, featuring a riveting conversation between our CEO Dr. Stefan Walzer and the esteemed healthcare reimbursement expert, Ron de Graaff. 

Ron, with his deep-rooted experience starting from 1978, shares his invaluable insights on the evolution of healthcare reimbursement, a journey from simpler times to today's intricate landscape involving multiple stakeholders like health insurance companies.

🔍 Key Highlights:

- Ron's path from founding his company in 1985, which has since assisted over 900 entities, including governments, in understanding medical technology markets.

- Challenges faced by startups in healthcare, often led by technical experts who struggle with the language and complexities of reimbursement processes.

- The criticality of startups understanding both the payer perspectives and the changing requirements of reimbursement systems across Europe.

- Ron's advice to startups: comprehensively understand the reimbursement system of your target market and assess if your product is likely to be reimbursable.

This episode is a must-listen for anyone in the healthcare industry, particularly startups navigating the daunting world of reimbursement. Expect to gain a thorough understanding of how to strategically plan for reimbursement, the importance of being updated with current regulations, and how to choose the right market for your product.

🌟 Tune in for a blend of expert insights, practical advice, and a glimpse into the future of healthcare reimbursement strategies. For more information on early reimbursement planning utilizing artificial intelligence, visit max-insights.com.

✏️ Take the chance to stay connected and subscribe with your favorite podcast platform: https://lnkd.in/dyTZ3yQb

MAP is the first and only bi-weekly #marketaccess podcast provided by MArS. For more information about MArS Market Access & Pricing Strategy GmbH visit: marketaccess-pricingstrategy.de

#HealthcareReimbursement #StartupChallenges #MedicalTechnology #Podcast #HealthcareInnovation“

]]>We are thrilled to announce our latest podcast episode, featuring a riveting conversation between our CEO Dr. Stefan Walzer and the esteemed healthcare reimbursement expert, Ron de Graaff. 

Ron, with his deep-rooted experience starting from 1978, shares his invaluable insights on the evolution of healthcare reimbursement, a journey from simpler times to today's intricate landscape involving multiple stakeholders like health insurance companies.

🔍 Key Highlights:

- Ron's path from founding his company in 1985, which has since assisted over 900 entities, including governments, in understanding medical technology markets.

- Challenges faced by startups in healthcare, often led by technical experts who struggle with the language and complexities of reimbursement processes.

- The criticality of startups understanding both the payer perspectives and the changing requirements of reimbursement systems across Europe.

- Ron's advice to startups: comprehensively understand the reimbursement system of your target market and assess if your product is likely to be reimbursable.

This episode is a must-listen for anyone in the healthcare industry, particularly startups navigating the daunting world of reimbursement. Expect to gain a thorough understanding of how to strategically plan for reimbursement, the importance of being updated with current regulations, and how to choose the right market for your product.

🌟 Tune in for a blend of expert insights, practical advice, and a glimpse into the future of healthcare reimbursement strategies. For more information on early reimbursement planning utilizing artificial intelligence, visit max-insights.com.

✏️ Take the chance to stay connected and subscribe with your favorite podcast platform: https://lnkd.in/dyTZ3yQb

MAP is the first and only bi-weekly #marketaccess podcast provided by MArS. For more information about MArS Market Access & Pricing Strategy GmbH visit: marketaccess-pricingstrategy.de

#HealthcareReimbursement #StartupChallenges #MedicalTechnology #Podcast #HealthcareInnovation“

]]>63696772-94b5-4fda-87b6-8aab9b9b88ceFri, 01 Dec 2023 09:00:00 +020033:53falsefull155551Navigating the Healthcare Startup Galaxy - key insights with Dr. Thomas Kerscher and Mark Anken.Navigating the Healthcare Startup Galaxy - key insights with Dr. Thomas Kerscher and Mark Anken.🎧 Excited to share our CEO, Dr. Stefan Walzer's newest Market Access podcast episode that's nothing short of a masterclass for healthcare startups venturing into the European market!

In this engaging episode, Dr. Walzer sits down with Dr. Thomas Kerscher and Mark Anken, both titans in the healthcare and pharmaceutical sectors with over two decades of experience. Currently at the helm of advantage, they're shaping the future of startups in this complex field. 🌍

Key Highlights:

1️⃣ Tailored Strategies: The critical need for startups to tailor their strategies based on product type and the unique healthcare landscapes of European countries.

2️⃣ Realistic Approach: The importance of balancing optimism with realism, especially when pitching to well-informed investors.

3️⃣ Scaling Up: The power of starting small, akin to Airbnb's model, then scaling up based on market feedback and minimal business model alterations.

4️⃣ Innovation vs. Reimbursement: Understanding the delicate balance between being innovative and navigating the reimbursement strategies crucial for startup viability.


💡 The duo shares invaluable insights on the significance of understanding your target customer, the nuances of entering varied European markets, and the complexities startups face in aligning their business models with healthcare policies. They stress the importance of innovation, not just for product differentiation, but as a tool to address cost pressures in healthcare systems.


📈 For those in healthcare startups, this episode is a goldmine of advice on developing effective business plans, understanding investor expectations, and the imperative of global market awareness.


Join us in exploring these vital topics, and gain a wealth of knowledge to propel your healthcare startup to new heights. Don't miss out on this incredible episode for a roadmap to success in the challenging yet rewarding realm of healthcare entrepreneurship.


#HealthcareStartups #MarketAccess #Podcast #Innovation #BusinessStrategy #HealthcareInvestment #EuropeanMarket #DrStefanWalzer


👉 Tune in to the full episode for a deep dive into these groundbreaking insights! 🎙️👇

]]>🎧 Excited to share our CEO, Dr. Stefan Walzer's newest Market Access podcast episode that's nothing short of a masterclass for healthcare startups venturing into the European market!

In this engaging episode, Dr. Walzer sits down with Dr. Thomas Kerscher and Mark Anken, both titans in the healthcare and pharmaceutical sectors with over two decades of experience. Currently at the helm of advantage, they're shaping the future of startups in this complex field. 🌍

Key Highlights:

1️⃣ Tailored Strategies: The critical need for startups to tailor their strategies based on product type and the unique healthcare landscapes of European countries.

2️⃣ Realistic Approach: The importance of balancing optimism with realism, especially when pitching to well-informed investors.

3️⃣ Scaling Up: The power of starting small, akin to Airbnb's model, then scaling up based on market feedback and minimal business model alterations.

4️⃣ Innovation vs. Reimbursement: Understanding the delicate balance between being innovative and navigating the reimbursement strategies crucial for startup viability.


💡 The duo shares invaluable insights on the significance of understanding your target customer, the nuances of entering varied European markets, and the complexities startups face in aligning their business models with healthcare policies. They stress the importance of innovation, not just for product differentiation, but as a tool to address cost pressures in healthcare systems.


📈 For those in healthcare startups, this episode is a goldmine of advice on developing effective business plans, understanding investor expectations, and the imperative of global market awareness.


Join us in exploring these vital topics, and gain a wealth of knowledge to propel your healthcare startup to new heights. Don't miss out on this incredible episode for a roadmap to success in the challenging yet rewarding realm of healthcare entrepreneurship.


#HealthcareStartups #MarketAccess #Podcast #Innovation #BusinessStrategy #HealthcareInvestment #EuropeanMarket #DrStefanWalzer


👉 Tune in to the full episode for a deep dive into these groundbreaking insights! 🎙️👇

]]>a6d3d485-cee6-4e5a-bc3a-57259b69eceeWed, 15 Nov 2023 09:00:00 +020034:06falsefull154541How to navigate complexities, Aurelie Moser: Market Access in Digital Health vs. Drugs?How to navigate complexities, Aurelie Moser: Market Access in Digital Health vs. Drugs?🎙️ Exciting Podcast Episode Is Here! 🎙️

In this episode of our podcast series, I'm excited to share that Stefan Walzer, a seasoned reimbursement expert, hosts the incredibly talented Amelie Moser, a business consultant with two decades of unparalleled expertise in market access!

🎯 What's Happening?

Immerse yourself in the fascinating world of digital health and see how it sharply contrasts with traditional drug landscapes.

Grasp the challenges of moving global product strategies into local implementations, all through the lens of Aurelies experience.

Navigate the crucial role of ecosystem mapping, and learn why it's important to engage all stakeholders.

💡 Key Takeaways:

Experience the dynamic nature of strategy adaptation — it's an evolving process, not just a set document!

Join in on an enlightening discussion about the mindset shift crucial for companies making the leap from global to local viewpoints.

Gain perspective on balancing qualitative vs. quantitative data for local market achievement.

Uncover the unexplored complexities of digital health solutions and the challenges they pose.

✨ Special Mention: Dive deep with Aurelie as she discusses her founding venture, BAMBOOSTER, and how she plays a crucial role in connecting top pharma giants with startups in the digital health and AI sectors.

If the evolving landscape of healthcare piques your curiosity as much as it does mine, you won't want to miss this episode. Listen now for this enlightening conversation! 🚀

🔗 Find the 3C Business Model Canvas here.


✏️ Take the chance to stay connected and subscribe with your favorite podcast platform: https://lnkd.in/dyTZ3yQb


MAP is the first and only bi-weekly #marketaccess podcast provided by MArS. For more information about MArS Market Access & Pricing Strategy GmbH visit: https://lnkd.in/db8aQWf

#DigitalHealth #MarketAccess #Podcast #HealthcareInnovation #LocalVsGlobal #StrategiesForSuccess

]]>🎙️ Exciting Podcast Episode Is Here! 🎙️

In this episode of our podcast series, I'm excited to share that Stefan Walzer, a seasoned reimbursement expert, hosts the incredibly talented Amelie Moser, a business consultant with two decades of unparalleled expertise in market access!

🎯 What's Happening?

Immerse yourself in the fascinating world of digital health and see how it sharply contrasts with traditional drug landscapes.

Grasp the challenges of moving global product strategies into local implementations, all through the lens of Aurelies experience.

Navigate the crucial role of ecosystem mapping, and learn why it's important to engage all stakeholders.

💡 Key Takeaways:

Experience the dynamic nature of strategy adaptation — it's an evolving process, not just a set document!

Join in on an enlightening discussion about the mindset shift crucial for companies making the leap from global to local viewpoints.

Gain perspective on balancing qualitative vs. quantitative data for local market achievement.

Uncover the unexplored complexities of digital health solutions and the challenges they pose.

✨ Special Mention: Dive deep with Aurelie as she discusses her founding venture, BAMBOOSTER, and how she plays a crucial role in connecting top pharma giants with startups in the digital health and AI sectors.

If the evolving landscape of healthcare piques your curiosity as much as it does mine, you won't want to miss this episode. Listen now for this enlightening conversation! 🚀

🔗 Find the 3C Business Model Canvas here.


✏️ Take the chance to stay connected and subscribe with your favorite podcast platform: https://lnkd.in/dyTZ3yQb


MAP is the first and only bi-weekly #marketaccess podcast provided by MArS. For more information about MArS Market Access & Pricing Strategy GmbH visit: https://lnkd.in/db8aQWf

#DigitalHealth #MarketAccess #Podcast #HealthcareInnovation #LocalVsGlobal #StrategiesForSuccess

]]>c0a1b3d6-7114-486d-955b-ce7d637299a9Wed, 01 Nov 2023 09:00:00 +020032:00falsefull153531AMNOG 2.0 - significant changes for the industry since January 2023, correct - Dr. Flume?AMNOG 2.0 - significant changes for the industry since January 2023, correct - Dr. Flume?Join us in the latest episode where pharmacist and head of a regional physicians association, Matthias Flume, engages in a thought-provoking discussion with host Stefan Walzer, exploring the intricate tapestry of reforms enveloped within the AMNOG (Arzneimittelmarktneuordnungsgesetz) 2.0, especially scrutinizing those unveiled in 2023!

🚀 Dive Deep into the Core of Pharmaceutical Reforms!

Matthias unearths various pivotal changes, including the mandated discounts for products with no additional benefit rating and the perceptible adjustments in the orphan drug area, dissecting the threshold reduction for annual sales in the full regular benefit assessment. 🚀


🌎 Explore the Global Impact!

Navigate through their insightful discussion on how these reforms potentially sculpt Germany’s presence on the global stage, especially in the orphan drugs market, and assess Germany's unique positioning in evaluating them! 🌎


💡 Illuminating the Opaqueness of Drug Pricing!

Embark on a journey through the complexities and pragmatic implications of drug pricing, dissecting the nuances of arbitration boards, pricing mechanisms, and the often intricate physician prescription behaviors amidst the recent reforms. 💡


🤔 Facing the Challenges Head-On!

Explore the potential disconnect between pricing strategies and actual prescription practices, as our experts shed light on the vital need for enhancing transparency and communication with physicians regarding pricing negotiations and adjustments. 🤔


👥 Join Matthias and Stefan as they scrutinize the germane issues of drug pricing, contemplate future adjustments within the system, and ponder upon the possible shifts influenced by the upcoming national elections and continual changes within the healthcare landscape! 👥


🎧 Tune in to immerse yourself in a conversation that not only explores the multidimensional aspects of the healthcare and pharmaceutical reimbursement system but also poses potent questions regarding its future amidst regulatory and structural shifts! 🎧


A journey through the dynamics of pharmaceutical pricing and reforms awaits you, amplifying both economic and patient care perspectives amidst the shifting tides of the healthcare system in Germany! Don’t miss it! 🚀🚀

]]>Join us in the latest episode where pharmacist and head of a regional physicians association, Matthias Flume, engages in a thought-provoking discussion with host Stefan Walzer, exploring the intricate tapestry of reforms enveloped within the AMNOG (Arzneimittelmarktneuordnungsgesetz) 2.0, especially scrutinizing those unveiled in 2023!

🚀 Dive Deep into the Core of Pharmaceutical Reforms!

Matthias unearths various pivotal changes, including the mandated discounts for products with no additional benefit rating and the perceptible adjustments in the orphan drug area, dissecting the threshold reduction for annual sales in the full regular benefit assessment. 🚀


🌎 Explore the Global Impact!

Navigate through their insightful discussion on how these reforms potentially sculpt Germany’s presence on the global stage, especially in the orphan drugs market, and assess Germany's unique positioning in evaluating them! 🌎


💡 Illuminating the Opaqueness of Drug Pricing!

Embark on a journey through the complexities and pragmatic implications of drug pricing, dissecting the nuances of arbitration boards, pricing mechanisms, and the often intricate physician prescription behaviors amidst the recent reforms. 💡


🤔 Facing the Challenges Head-On!

Explore the potential disconnect between pricing strategies and actual prescription practices, as our experts shed light on the vital need for enhancing transparency and communication with physicians regarding pricing negotiations and adjustments. 🤔


👥 Join Matthias and Stefan as they scrutinize the germane issues of drug pricing, contemplate future adjustments within the system, and ponder upon the possible shifts influenced by the upcoming national elections and continual changes within the healthcare landscape! 👥


🎧 Tune in to immerse yourself in a conversation that not only explores the multidimensional aspects of the healthcare and pharmaceutical reimbursement system but also poses potent questions regarding its future amidst regulatory and structural shifts! 🎧


A journey through the dynamics of pharmaceutical pricing and reforms awaits you, amplifying both economic and patient care perspectives amidst the shifting tides of the healthcare system in Germany! Don’t miss it! 🚀🚀

]]>da10ff92-543f-4ba6-9b3b-544f5c5e221eSun, 15 Oct 2023 09:00:00 +020031:00falsefull152521Inside the Swiss decision-makers - how does the system for drugs really work, Dr. Heiner Sandmeier?Inside the Swiss decision-makers - how does the system for drugs really work, Dr. Heiner Sandmeier?Listen to this podcast on your favourite podcast player: https://lnkd.in/eGemZRTi

 

Switzerland is seen as a small but still attractive market for pharmaceuticals, even though that the Swiss decision-makers are considered as tough and sometimes even difficult. A core issue might especially be, that the assessment and negotiations primarily happen intransparently „behind the doors“. 

Dr. Heiner Sandmeier has been part of the drug evaluation committee advising the Swiss decision makers for over a century and opens his insights and secrets to all listeners. 

Some of the topics Dr. Sandmeier and reimbursement veteran Dr. Stefan Walzer discuss are as follows: 

  • What are the main drivers for a positive decision in Switzerland?
  • Who is involved in the decision process?
  • What are the challenges as well as possible solutions for the main issues?
  • What are the differences to other countries in Europe?

And last but not least: Why should you still consider to enter the Swiss market with an innovative pharmaceutical product?

✏️ Take the chance to stay connected and subscribe with your favorite podcast platform: https://lnkd.in/dyTZ3yQb


MAP is the first and only bi-weekly #marketaccess podcast provided by MArS. For more information about MArS Market Access & Pricing Strategy GmbH visit: https://lnkd.in/db8aQWf


#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #pricingstrategy #negotiations #pricing #pharmaceuticals #switzerland #innovation #reimbursement

]]>Listen to this podcast on your favourite podcast player: https://lnkd.in/eGemZRTi

 

Switzerland is seen as a small but still attractive market for pharmaceuticals, even though that the Swiss decision-makers are considered as tough and sometimes even difficult. A core issue might especially be, that the assessment and negotiations primarily happen intransparently „behind the doors“. 

Dr. Heiner Sandmeier has been part of the drug evaluation committee advising the Swiss decision makers for over a century and opens his insights and secrets to all listeners. 

Some of the topics Dr. Sandmeier and reimbursement veteran Dr. Stefan Walzer discuss are as follows: 

  • What are the main drivers for a positive decision in Switzerland?
  • Who is involved in the decision process?
  • What are the challenges as well as possible solutions for the main issues?
  • What are the differences to other countries in Europe?

And last but not least: Why should you still consider to enter the Swiss market with an innovative pharmaceutical product?

✏️ Take the chance to stay connected and subscribe with your favorite podcast platform: https://lnkd.in/dyTZ3yQb


MAP is the first and only bi-weekly #marketaccess podcast provided by MArS. For more information about MArS Market Access & Pricing Strategy GmbH visit: https://lnkd.in/db8aQWf


#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #pricingstrategy #negotiations #pricing #pharmaceuticals #switzerland #innovation #reimbursement

]]>dde5ae3c-b5ce-4142-808d-3e0f5d6ae8caSun, 01 Oct 2023 09:00:00 +020036:26falsefull151511How should market access and medical affairs work together, Dr. Mike Rosenblatt?How should market access and medical affairs work together, Dr. Mike Rosenblatt?Listen to this podcast on your favourite podcast player: https://lnkd.in/eGemZRTi

We are living in an age of massive medical innovation including a lot of new modalities especially in the area of ATMPs, but also beyond. Within this area, but obviously also beyond, there are core questions in the area of tensions such as the followings:

- What are the differences between Clinical Development and Medical Affairs?

- When should a company start telling their medical story about a new product?

- What are the differences between drugs and vaccinations from a medical affairs’ perspective?

- And how should market access and medical affairs ideally work together?

Market access veteran Dr. Stefan Walzer and Dr. Mike Rosenblatt, one of the pioneers in Medical Affairs, Commercialisation and Market Access continued their come together in Boston in May 2023 in this epic podcast episode. 

Don’t miss this amazing conversation. 

 

✏️ Take the chance to stay connected and subscribe with your favorite podcast platform: https://lnkd.in/dyTZ3yQb

MAP is the first and only bi-weekly #marketaccesspodcast provided by MArS. For more information about MArS Market Access & Pricing Strategy GmbH visit: https://lnkd.in/db8aQWf

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #medicalaffairs #pricingstrategy #negotiations

#pricing #medtech #pharmaceuticals #usa #innovation #vaccination 

]]>Listen to this podcast on your favourite podcast player: https://lnkd.in/eGemZRTi

We are living in an age of massive medical innovation including a lot of new modalities especially in the area of ATMPs, but also beyond. Within this area, but obviously also beyond, there are core questions in the area of tensions such as the followings:

- What are the differences between Clinical Development and Medical Affairs?

- When should a company start telling their medical story about a new product?

- What are the differences between drugs and vaccinations from a medical affairs’ perspective?

- And how should market access and medical affairs ideally work together?

Market access veteran Dr. Stefan Walzer and Dr. Mike Rosenblatt, one of the pioneers in Medical Affairs, Commercialisation and Market Access continued their come together in Boston in May 2023 in this epic podcast episode. 

Don’t miss this amazing conversation. 

 

✏️ Take the chance to stay connected and subscribe with your favorite podcast platform: https://lnkd.in/dyTZ3yQb

MAP is the first and only bi-weekly #marketaccesspodcast provided by MArS. For more information about MArS Market Access & Pricing Strategy GmbH visit: https://lnkd.in/db8aQWf

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #medicalaffairs #pricingstrategy #negotiations

#pricing #medtech #pharmaceuticals #usa #innovation #vaccination 

]]>57160eab-58f2-4efd-8b24-440e268ab0fcFri, 15 Sep 2023 09:00:00 +020030:49falsefull150501📠 How will Switzerland make the leap from FAX machines to Digital Healthcare, Dr. Peter Indra?📠 How will Switzerland make the leap from FAX machines to Digital Healthcare, Dr. Peter Indra?🎧 Listen to this podcast on your favourite podcast player: https://lnkd.in/eGemZRTi  

🇨🇭Switzerland has one of the highest healthcare spendings per person across the world! At the same time, one could also say that Switzerland has also one of the best healthcare systems... 

💥 … but health care expert Dr. Peter Intra calls it still a developing country in terms of digitalisation! In this MAP podcast episode, health care system veteran Dr. Stefan Walzer and Dr. Peter Indra are discussing the current state of digital health in Switzerland, possible improvements and the inspiring example of Estonia.

What are we talking about, when we address the topic of digitalisation and e-health?

  1. Data + AI, which is dealing with the data
  2. Infrastructure like electronic patient record and vaccination registries
  3. Processes 

Don't miss this inspiring conversation with spill-overs for all countries around the world. 

✏️ Take the chance to stay connected and subscribe with your favorite podcast platform: https://lnkd.in/dyTZ3yQb

MAP is the first and only bi-weekly #marketaccesspodcast provided by MArS. For more information about MArS Market Access & Pricing Strategy GmbH visit: https://lnkd.in/db8aQWf


#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #digitization #digitalhealth #funding #ehealth #healthcare #digitalisation #healthservices #switzerland

]]>🎧 Listen to this podcast on your favourite podcast player: https://lnkd.in/eGemZRTi  

🇨🇭Switzerland has one of the highest healthcare spendings per person across the world! At the same time, one could also say that Switzerland has also one of the best healthcare systems... 

💥 … but health care expert Dr. Peter Intra calls it still a developing country in terms of digitalisation! In this MAP podcast episode, health care system veteran Dr. Stefan Walzer and Dr. Peter Indra are discussing the current state of digital health in Switzerland, possible improvements and the inspiring example of Estonia.

What are we talking about, when we address the topic of digitalisation and e-health?

  1. Data + AI, which is dealing with the data
  2. Infrastructure like electronic patient record and vaccination registries
  3. Processes 

Don't miss this inspiring conversation with spill-overs for all countries around the world. 

✏️ Take the chance to stay connected and subscribe with your favorite podcast platform: https://lnkd.in/dyTZ3yQb

MAP is the first and only bi-weekly #marketaccesspodcast provided by MArS. For more information about MArS Market Access & Pricing Strategy GmbH visit: https://lnkd.in/db8aQWf


#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #digitization #digitalhealth #funding #ehealth #healthcare #digitalisation #healthservices #switzerland

]]>b8b23c42-698b-4a26-8a94-fc621c3b1e33Fri, 01 Sep 2023 09:00:00 +020029:04falsefull149491How does an optimized communication strategy look like, Dr. Arne Näveke?How does an optimized communication strategy look like, Dr. Arne Näveke?Listen to this podcast on your favourite podcast player: https://lnkd.in/eGemZRTi

Companies, including start-ups, are usually focused solely on the development of the product and/or the technical platform in the early days. As understandable and important these aspects are, if they don’t start to think about their public communications strategy from the very beginning, they might be in danger of failing.                                                           

Already in the very early stages of the development of pharmaceuticals or med tech products, companies need to think about the following key points: 

Will patients need and want the new product?

Will physicians prescribe it?

Will payers pay for it?

 

And thus they should come up with a convincing value story towards all stakeholders as only if they could convince all of these, investors will see the potential return of investment! But ultimately, all of that needs to be communicated… The reimbursement veteran Dr. Stefan Walzer these and more aspects around (global and local) communication with the communication expert Dr. Arne Näveke. 


✏️ Take the chance to stay connected and subscribe with your favorite podcast platform: https://lnkd.in/dyTZ3yQb


MAP is the first and only bi-weekly #marketaccesspodcast provided by MArS. For more information about MArS Market Access & Pricing Strategy GmbH visit: https://lnkd.in/db8aQWf


#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #medtech #pharmaceuticals #communications #funding #medicaldevices #germany

]]>Listen to this podcast on your favourite podcast player: https://lnkd.in/eGemZRTi

Companies, including start-ups, are usually focused solely on the development of the product and/or the technical platform in the early days. As understandable and important these aspects are, if they don’t start to think about their public communications strategy from the very beginning, they might be in danger of failing.                                                           

Already in the very early stages of the development of pharmaceuticals or med tech products, companies need to think about the following key points: 

Will patients need and want the new product?

Will physicians prescribe it?

Will payers pay for it?

 

And thus they should come up with a convincing value story towards all stakeholders as only if they could convince all of these, investors will see the potential return of investment! But ultimately, all of that needs to be communicated… The reimbursement veteran Dr. Stefan Walzer these and more aspects around (global and local) communication with the communication expert Dr. Arne Näveke. 


✏️ Take the chance to stay connected and subscribe with your favorite podcast platform: https://lnkd.in/dyTZ3yQb


MAP is the first and only bi-weekly #marketaccesspodcast provided by MArS. For more information about MArS Market Access & Pricing Strategy GmbH visit: https://lnkd.in/db8aQWf


#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #medtech #pharmaceuticals #communications #funding #medicaldevices #germany

]]>7619cb97-e81c-4f3f-aabe-f2825311eb5bTue, 15 Aug 2023 09:00:00 +020032:02falsefull148481How does the German evaluation committee work, Prof. Jürgen Wasem?How does the German evaluation committee work, Prof. Jürgen Wasem?Listen to this podcast on your favourite podcast player: https://lnkd.in/eGemZRTi

 

New methods such as diagnostics need to be assessed and the included in the reimbursement catalogue in the outpatient setting in Germany. However, key question remains which requirements are needed for such an evaluation and who is responsible for it. In some instances the responsible body is a sub-committee of the German federal Committee (G-BA) the so-called evaluation committee. But how does that body come to a conclusion and what do they really assess. How does price setting work in such an environment.

 

The reimbursement veteran Dr. Stefan Walzer discussed all of these questions and many more secrets with the Head of the arbitration board of the before-mentioned evaluation committee, Prof. Jürgen Wasem.

✏️ Take the chance to stay connected and subscribe with your favourite podcast platform: https://lnkd.in/dyTZ3yQb

MAP is the first and only bi-weekly #marketaccesspodcast provided by MArS. For more information about MArS Market Access & Pricing Strategy GmbH visit: https://lnkd.in/db8aQWf


#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations

#pricing #medtech #diagnostics #arbitrationboard #funding #medicaldevices #germany

]]>Listen to this podcast on your favourite podcast player: https://lnkd.in/eGemZRTi

 

New methods such as diagnostics need to be assessed and the included in the reimbursement catalogue in the outpatient setting in Germany. However, key question remains which requirements are needed for such an evaluation and who is responsible for it. In some instances the responsible body is a sub-committee of the German federal Committee (G-BA) the so-called evaluation committee. But how does that body come to a conclusion and what do they really assess. How does price setting work in such an environment.

 

The reimbursement veteran Dr. Stefan Walzer discussed all of these questions and many more secrets with the Head of the arbitration board of the before-mentioned evaluation committee, Prof. Jürgen Wasem.

✏️ Take the chance to stay connected and subscribe with your favourite podcast platform: https://lnkd.in/dyTZ3yQb

MAP is the first and only bi-weekly #marketaccesspodcast provided by MArS. For more information about MArS Market Access & Pricing Strategy GmbH visit: https://lnkd.in/db8aQWf


#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations

#pricing #medtech #diagnostics #arbitrationboard #funding #medicaldevices #germany

]]>e187a645-d640-45f2-a063-6eafc7ee27dfTue, 01 Aug 2023 09:00:00 +020034:26falsefull147471How to optimize commercialisation of innovative life science products, Dr. Kasia Hein-Peters?How to optimize commercialisation of innovative life science products, Dr. Kasia Hein-Peters?Even though there are great accelerators and a lot of innovative product ideas, only very few products actually make it to the market and are commercially successful. What is the reason behind that and even more important how could this situation be improved?

In this podcast episode, Dr. Stefan Walzer and Dr. Kasia Hein-Peters are discussing the necessity for an overarching business and company strategy approach. In health care this is sometimes referred to a lifecycle approach, the invented approach by Dr. Kasia Hein-Peters is called DIVE. Within these approaches, all stakeholders would always need to be captured and dealt with - clinical development, regulatory and payers.

✏️ Take the chance to stay connected and subscribe with your favourite podcast platform: https://lnkd.in/dyTZ3yQb

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #innovation #pricing #drugs #medtech #livescience #strategy

]]>Even though there are great accelerators and a lot of innovative product ideas, only very few products actually make it to the market and are commercially successful. What is the reason behind that and even more important how could this situation be improved?

In this podcast episode, Dr. Stefan Walzer and Dr. Kasia Hein-Peters are discussing the necessity for an overarching business and company strategy approach. In health care this is sometimes referred to a lifecycle approach, the invented approach by Dr. Kasia Hein-Peters is called DIVE. Within these approaches, all stakeholders would always need to be captured and dealt with - clinical development, regulatory and payers.

✏️ Take the chance to stay connected and subscribe with your favourite podcast platform: https://lnkd.in/dyTZ3yQb

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #innovation #pricing #drugs #medtech #livescience #strategy

]]>7c1dd0c0-fcf7-4b4e-a51c-0763cabbfef6Sat, 15 Jul 2023 09:00:00 +020031:28falsefull146461How do I get approved by the US FDA, Dr. Jamie Cross?How do I get approved by the US FDA, Dr. Jamie Cross?In order to commercialize a health care product in the USA, the US FDA would need to approve it. But what is the standard process and how early would a company need to be involved and maybe even get advice? Additionally, the core question remains how could US FDA requirements be aligned with potential payer needs - are there any relationships?

The #marketaccess veterans Dr. Stefan Walzer and Dr. Jamie Cross are discussing the principles as well as some very specific details. 

✏️ Take the chance to stay connected and subscribe with your favorite podcast platform: https://lnkd.in/dyTZ3yQb

MAP is the first and only bi-weekly #marketaccesspodcast provided by MArS. For more information about MArS Market Access & Pricing Strategy GmbH visit: https://lnkd.in/db8aQWf


#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations

#pricing #drugs #medtech #usa #fda

]]>In order to commercialize a health care product in the USA, the US FDA would need to approve it. But what is the standard process and how early would a company need to be involved and maybe even get advice? Additionally, the core question remains how could US FDA requirements be aligned with potential payer needs - are there any relationships?

The #marketaccess veterans Dr. Stefan Walzer and Dr. Jamie Cross are discussing the principles as well as some very specific details. 

✏️ Take the chance to stay connected and subscribe with your favorite podcast platform: https://lnkd.in/dyTZ3yQb

MAP is the first and only bi-weekly #marketaccesspodcast provided by MArS. For more information about MArS Market Access & Pricing Strategy GmbH visit: https://lnkd.in/db8aQWf


#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations

#pricing #drugs #medtech #usa #fda

]]>780943ae-e54d-4f84-bb3e-438013942494Sat, 01 Jul 2023 09:00:00 +020046:14falsefull145451How will the US Inflation Reduction Act change pricing of pharmaceuticals, Anita Burrell?How will the US Inflation Reduction Act change pricing of pharmaceuticals, Anita Burrell?The Inflation Reduction Act in the US will change fundamental how the US pharmaceutical industry works. 

The IRA will negotiate their own prices for Medicare and Medicaid, which will have the result, that they will not pay the same prices in the future anymore.

With Medicare the government directly funds pharmaceuticals for 65+ years old population.

With Medicaid the government fund low income and other vulnerable populations.

Given, that the private insurance sector will follow the lead of government negotiated prices, all prices will decrease.

Revenues in the US will decline, and it will be interesting to see, what that will mean economically and in terms of availability of pharmaceuticals for the US and the global market?


Please enjoy the discussion of market access veterans Dr. Stefan Walzer and Anita Burell MBA on this major change in the major market for pharmaceuticals.


#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations

#pricing #drugs #medtech #usa #inflationreductionact #inflation #ira

]]>The Inflation Reduction Act in the US will change fundamental how the US pharmaceutical industry works. 

The IRA will negotiate their own prices for Medicare and Medicaid, which will have the result, that they will not pay the same prices in the future anymore.

With Medicare the government directly funds pharmaceuticals for 65+ years old population.

With Medicaid the government fund low income and other vulnerable populations.

Given, that the private insurance sector will follow the lead of government negotiated prices, all prices will decrease.

Revenues in the US will decline, and it will be interesting to see, what that will mean economically and in terms of availability of pharmaceuticals for the US and the global market?


Please enjoy the discussion of market access veterans Dr. Stefan Walzer and Anita Burell MBA on this major change in the major market for pharmaceuticals.


#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations

#pricing #drugs #medtech #usa #inflationreductionact #inflation #ira

]]>1dccfa83-6c29-4c0a-beca-7a1cce698553Thu, 15 Jun 2023 09:00:00 +020035:03falsefull144441How does market access work in Japan, Heather Wellam?How does market access work in Japan, Heather Wellam?The market access experts Dr. Stefan Walzer and Heather Wellam are discussing the market access process in Japan, one of the largest health care markets in the world!

In Japan not all products need to go through the full process, so an important question is, what the criteria are and what role does cost-effectiveness play in this market? What are the differences in the process between drugs and medical devices?

On top, the two experts are also discussing the opportunity to apply for price premiums in the reimbursement process. 

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: https://lnkd.in/dZtyKw8B

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de


#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #drugs #medtech #japan

]]>The market access experts Dr. Stefan Walzer and Heather Wellam are discussing the market access process in Japan, one of the largest health care markets in the world!

In Japan not all products need to go through the full process, so an important question is, what the criteria are and what role does cost-effectiveness play in this market? What are the differences in the process between drugs and medical devices?

On top, the two experts are also discussing the opportunity to apply for price premiums in the reimbursement process. 

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: https://lnkd.in/dZtyKw8B

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de


#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #drugs #medtech #japan

]]>07bd810f-fa9a-40d7-b96b-3e276951dfc6Thu, 01 Jun 2023 09:00:00 +020030:36falsefull143431Would AI substitute or (only) support market access managers, Dr. Andree Bates? (Repost)Would AI substitute or (only) support market access managers, Dr. Andree Bates? (Repost)Since the original publication of this podcast, AI has received enormous public attention, and we have also seen an amazing increase in performance. This makes this discussion even more relevant - with this REPOST we want to give you the opportunity to hear it, in case you missed the first publication.

Dr. Stefan Walzer, market access expert, and his guest Dr. Andree Battes, expert in artificial intelligence (AI), are discussing the future of market access within the health care industry. How could AI support market access planning, submissions and negotiations, especially with the ever-increasing data? How could AI be beneficial in defining an optimal price anchor? And finally, would AI substitute the market access manager roles within the industry?

Further reading is available on "How to Embed AI into the Market Access Process“:  https://eularis.com/resources 

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: https://lnkd.in/dZtyKw8B

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de


#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #ai #artificialintelligence

]]>Since the original publication of this podcast, AI has received enormous public attention, and we have also seen an amazing increase in performance. This makes this discussion even more relevant - with this REPOST we want to give you the opportunity to hear it, in case you missed the first publication.

Dr. Stefan Walzer, market access expert, and his guest Dr. Andree Battes, expert in artificial intelligence (AI), are discussing the future of market access within the health care industry. How could AI support market access planning, submissions and negotiations, especially with the ever-increasing data? How could AI be beneficial in defining an optimal price anchor? And finally, would AI substitute the market access manager roles within the industry?

Further reading is available on "How to Embed AI into the Market Access Process“:  https://eularis.com/resources 

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: https://lnkd.in/dZtyKw8B

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de


#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #ai #artificialintelligence

]]>c2db5e54-d255-4f64-9511-5c093e36618bMon, 15 May 2023 09:00:00 +020031:31falsefull142421Is there a place for Real World Evidence in HTA, Dr. Karen Facey?Is there a place for Real World Evidence in HTA, Dr. Karen Facey?A strong evidence package is important as a solid base for health technology assessments and the following price negotiations with health care payers. It is widely agreed, that randomized controlled trials are the gold standard in HTA, but there are also strong advocates of real-world evidence as a complementary way to measure the effectiveness of treatments. 

One of these advocates is Dr. Karen Facey and so Dr. Stefan Walzer brought her on the podcast and asked all the tough questions about real world evidence and the reality with payers around the world. Are there opportunities in such RWE data or is that a dead-end? 

 

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: https://lnkd.in/dZtyKw8B

  

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

 

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #hta #pharma #healthcare #realworldevidence #rwe 

]]>A strong evidence package is important as a solid base for health technology assessments and the following price negotiations with health care payers. It is widely agreed, that randomized controlled trials are the gold standard in HTA, but there are also strong advocates of real-world evidence as a complementary way to measure the effectiveness of treatments. 

One of these advocates is Dr. Karen Facey and so Dr. Stefan Walzer brought her on the podcast and asked all the tough questions about real world evidence and the reality with payers around the world. Are there opportunities in such RWE data or is that a dead-end? 

 

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: https://lnkd.in/dZtyKw8B

  

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

 

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #hta #pharma #healthcare #realworldevidence #rwe 

]]>9659c260-fbbd-4443-afee-26977bdc750aMon, 01 May 2023 09:00:00 +020033:26falsefull141411How can people get equal access to pharmaceuticals, Dr. Nina Lathia?How can people get equal access to pharmaceuticals, Dr. Nina Lathia?All patients within all populations should have access to high quality medications that improve their health outcomes regardless of race, ethnicity, socio-economic status or any other individual factors, wrote Dr. Utibe R. Essien in an Jama article 2021. But how does reality look like? Equality in access starts with the generalizability of RCT data and the inclusion and exclusion criteria for these studies. But it does not stop there. How do regulators, payers and physicians work against inequality? The market access veteran Dr. Stefan Walzer and the Canadian health economist Dr. Nina Lathia have discussed these pharmacoequity issues from a global perspective. What does this mean for drug development? What does this mean for clinical trials?

Let’s not leave these questions with politicians alone. The voice from all stakeholders is needed and wanted. 

 

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: https://lnkd.in/dZtyKw8B

  

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

 

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #Canada #pharmacoequity #pharma #healthcare 

]]>All patients within all populations should have access to high quality medications that improve their health outcomes regardless of race, ethnicity, socio-economic status or any other individual factors, wrote Dr. Utibe R. Essien in an Jama article 2021. But how does reality look like? Equality in access starts with the generalizability of RCT data and the inclusion and exclusion criteria for these studies. But it does not stop there. How do regulators, payers and physicians work against inequality? The market access veteran Dr. Stefan Walzer and the Canadian health economist Dr. Nina Lathia have discussed these pharmacoequity issues from a global perspective. What does this mean for drug development? What does this mean for clinical trials?

Let’s not leave these questions with politicians alone. The voice from all stakeholders is needed and wanted. 

 

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: https://lnkd.in/dZtyKw8B

  

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

 

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #Canada #pharmacoequity #pharma #healthcare 

]]>71e2e7cb-afaa-4e22-a52c-deb21d320dc6Sat, 15 Apr 2023 09:00:00 +020029:50falsefull140401How to be successful in Canadian health care market access & pricing!How to be successful in Canadian health care market access & pricing!Canadian health care reimbursement might be seen as complex and difficult. Well, not totally wrong… The reimbursement veteran Dr. Stefan Walzer discusses with the Canadian experts Louise Perrault and Nicole Tunstall the process for reimbursement and the specifics of Quebec. What are requirements and what might be important early steps to consider in order to plan for success. Additionally, the pricing is being considered, especially the various institutions and the way to get prices negotiated and agreed within the health care system in Canada.

 

 

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: https://lnkd.in/dZtyKw8B

  

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

 

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #Canada #HTA #pharma #healthcare 

]]>Canadian health care reimbursement might be seen as complex and difficult. Well, not totally wrong… The reimbursement veteran Dr. Stefan Walzer discusses with the Canadian experts Louise Perrault and Nicole Tunstall the process for reimbursement and the specifics of Quebec. What are requirements and what might be important early steps to consider in order to plan for success. Additionally, the pricing is being considered, especially the various institutions and the way to get prices negotiated and agreed within the health care system in Canada.

 

 

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: https://lnkd.in/dZtyKw8B

  

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

 

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #Canada #HTA #pharma #healthcare 

]]>16ef42ba-ac3e-42bc-9244-32491d6ba852Sat, 01 Apr 2023 09:00:00 +020045:50falsefull139391How can companies prepare for EU Joint HTA, Priyanka Kiritharan and Chloe Sheppard?How can companies prepare for EU Joint HTA, Priyanka Kiritharan and Chloe Sheppard?EU Joint HTA will become reality for ATMPs and therapies in oncology by the end of 2024. Anyhow, methods and processes are not yet communicated and established as of March 2023. Furthermore, there are no opportunities for early consultation to plan clinical trials and/or EU joint HTA dossiers. The core question still remains for which endpoints and comparators data would need to be submitted and by when? What would happen if the EMA label changes last minute with an impact on joint HTA assessments. Furthermore, nobody yet knows how these results will be implemented by national payers. More established HTA systems such as France and Germany might only adopt (slightly), others might utilize the full report of the EU joint HTA and directly start with the price negotiations.

Many open questions which have been discussed between the reimbursement veteran Dr. Stefan Walzer and his guests on the podcast Priyanka Kiritharan and Chloe Sheppard. 

 

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: https://lnkd.in/dZtyKw8B

  

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

 

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #EU #EU-Joint-HTA #pharma #healthcare 

]]>EU Joint HTA will become reality for ATMPs and therapies in oncology by the end of 2024. Anyhow, methods and processes are not yet communicated and established as of March 2023. Furthermore, there are no opportunities for early consultation to plan clinical trials and/or EU joint HTA dossiers. The core question still remains for which endpoints and comparators data would need to be submitted and by when? What would happen if the EMA label changes last minute with an impact on joint HTA assessments. Furthermore, nobody yet knows how these results will be implemented by national payers. More established HTA systems such as France and Germany might only adopt (slightly), others might utilize the full report of the EU joint HTA and directly start with the price negotiations.

Many open questions which have been discussed between the reimbursement veteran Dr. Stefan Walzer and his guests on the podcast Priyanka Kiritharan and Chloe Sheppard. 

 

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: https://lnkd.in/dZtyKw8B

  

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

 

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #EU #EU-Joint-HTA #pharma #healthcare 

]]>b2bce718-449e-4ee1-9e2a-ac0b196d6cc6Wed, 15 Mar 2023 09:00:00 +020035:04falsefull138381Is quality cancer care in Ukraine still possible, Yevgen Brovko?Is quality cancer care in Ukraine still possible, Yevgen Brovko?Cancer care is a challenge in all countries. Now imagine, how difficult it is to organize and manage cancer care in a war zone!  

In this special MAP Podcast episode the Ukrainian market access expert Yevgen Brovko explains the situation and market access of cancer care before the Russian invasion and the current state in Ukraine. After a more broad overview, he also explains the Ukrainian health care system in general and explicitly in the oncology area, how new treatments are made available and the steps to launch into the Ukrainian market.

Finally, the market access expert Dr. Stefan Walzer puts the current environment into perspective.

 

Due to the difficulty in the energy supply in Ukraine, this episode has not been recorded in a one-to-one conversation but was recorded by Yevgen Brovko and sent for finalization to Dr. Stefan Walzer. україна переможе

 

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: https://lnkd.in/dZtyKw8B

  

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

 

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #Ukraine #pharma #healthcare #standwithukraine

]]>Cancer care is a challenge in all countries. Now imagine, how difficult it is to organize and manage cancer care in a war zone!  

In this special MAP Podcast episode the Ukrainian market access expert Yevgen Brovko explains the situation and market access of cancer care before the Russian invasion and the current state in Ukraine. After a more broad overview, he also explains the Ukrainian health care system in general and explicitly in the oncology area, how new treatments are made available and the steps to launch into the Ukrainian market.

Finally, the market access expert Dr. Stefan Walzer puts the current environment into perspective.

 

Due to the difficulty in the energy supply in Ukraine, this episode has not been recorded in a one-to-one conversation but was recorded by Yevgen Brovko and sent for finalization to Dr. Stefan Walzer. україна переможе

 

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: https://lnkd.in/dZtyKw8B

  

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

 

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #Ukraine #pharma #healthcare #standwithukraine

]]>d17fbb80-b4ee-4942-964a-aadb103b6a6fWed, 01 Mar 2023 09:00:00 +020021:21falsefull137371What are drivers for a positive approval by Health Canada, Fraidianie Sévignè?What are drivers for a positive approval by Health Canada, Fraidianie Sévignè?Regulatory processes might vary across the world, EMA and FDA are mostly known, but what are drivers by Health Canada? What to consider when expanding e.g. from the US into Canada with a medical device? Are there differences between US FDA and Canadian decisions for drugs? And if so, why? The reimbursement veteran Dr. Stefan Walzer and the regulatory expert for Canada, Fraidianie Sévignè, discuss and recommend steps to consider for medical device and pharmaceutical companies.

 

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: https://lnkd.in/dZtyKw8B

  

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy, visit: marketaccess-pricingstrategy.de

 

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #Canada #pharma #healthcare

]]>Regulatory processes might vary across the world, EMA and FDA are mostly known, but what are drivers by Health Canada? What to consider when expanding e.g. from the US into Canada with a medical device? Are there differences between US FDA and Canadian decisions for drugs? And if so, why? The reimbursement veteran Dr. Stefan Walzer and the regulatory expert for Canada, Fraidianie Sévignè, discuss and recommend steps to consider for medical device and pharmaceutical companies.

 

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: https://lnkd.in/dZtyKw8B

  

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy, visit: marketaccess-pricingstrategy.de

 

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #Canada #pharma #healthcare

]]>4fb9a412-d31b-4fc5-b353-43812da1e519Wed, 15 Feb 2023 09:00:00 +020032:34falsefull136361EU joint HTA – decided, but how will it be executed and how should companies prepare, Dr. Elvira Müller?EU joint HTA – decided, but how will it be executed and how should companies prepare, Dr. Elvira Müller?In Europe, there are at least as many reimbursement assessment processes in place as European countries. Some of these are transparent and clearly defined like the German AMNOG process, others are even more complex and sometimes even unclear, dependent also on the product of interest. Anyhow, the European Commission has already decided that a European joint assessment will come into place in 2025 starting with oncology and ATMP products. Anyhow, currently timelines and national processes to implement the outcomes of the European evaluation are still unclear and to be defined. Dr. Stefan Walzer and Dr. Elvira Mueller discuss the current status as well as issues and potential solutions for the new upcoming reimbursement start in Europe.

 

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: https://lnkd.in/dZtyKw8B

  

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

 

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #germany #Europe #JointHTA 

]]>In Europe, there are at least as many reimbursement assessment processes in place as European countries. Some of these are transparent and clearly defined like the German AMNOG process, others are even more complex and sometimes even unclear, dependent also on the product of interest. Anyhow, the European Commission has already decided that a European joint assessment will come into place in 2025 starting with oncology and ATMP products. Anyhow, currently timelines and national processes to implement the outcomes of the European evaluation are still unclear and to be defined. Dr. Stefan Walzer and Dr. Elvira Mueller discuss the current status as well as issues and potential solutions for the new upcoming reimbursement start in Europe.

 

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: https://lnkd.in/dZtyKw8B

  

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

 

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #germany #Europe #JointHTA 

]]>2cfd8d63-7461-40ff-9633-28e0656c25bbWed, 01 Feb 2023 09:00:00 +020033:13falsefull135351The US pricing reform has an impact on Europe as well, correct Dr. Renato Dellamano and Jack Mycka?!The US pricing reform has an impact on Europe as well, correct Dr. Renato Dellamano and Jack Mycka?!It seems to be a given, that prices in the US are higher than in the rest of the world. But what might happen, if the US refuses to pay these higher amounts anymore? There are already changes either approved or heavily discussed like the pricing inflation act, the cap on out-of-pocket cost and the opportunity for Medicare negotiating prices starting in 2026. If the global price system changes, it will become even more important to get the price right from the beginning.

Those and other questions are discussed by the market access and pricing experts Dr. Stefan Walzer, Dr. Renato Dellamano and Jack Mycka. 

 

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: https://lnkd.in/dZtyKw8B

 

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

 

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #germany #US #Europe

]]>It seems to be a given, that prices in the US are higher than in the rest of the world. But what might happen, if the US refuses to pay these higher amounts anymore? There are already changes either approved or heavily discussed like the pricing inflation act, the cap on out-of-pocket cost and the opportunity for Medicare negotiating prices starting in 2026. If the global price system changes, it will become even more important to get the price right from the beginning.

Those and other questions are discussed by the market access and pricing experts Dr. Stefan Walzer, Dr. Renato Dellamano and Jack Mycka. 

 

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: https://lnkd.in/dZtyKw8B

 

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

 

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #germany #US #Europe

]]>80541aa5-77c7-452f-99de-69a119154e6eSun, 15 Jan 2023 09:00:00 +020036:42falsefull134341What are the main obstacles in oncology market access, Ed Schoonveld?What are the main obstacles in oncology market access, Ed Schoonveld?Companies launching oncology drugs sometimes struggle with existing reimbursement pathways and negotiations with payers, mainly in Europe, but also in other parts of the world. Evidence generation is the start of every drug development, but especially in oncology the design is important – not only that payers want to get a proof of a longer survival, but they also have further needs in their internal assessment. Enjoy the insights shared by the oncology market access veterans Dr. Stefan Walzer and Ed Schoonveld. 

 

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: https://lnkd.in/dZtyKw8B

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

 

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #germany #Europe #oncology 

]]>Companies launching oncology drugs sometimes struggle with existing reimbursement pathways and negotiations with payers, mainly in Europe, but also in other parts of the world. Evidence generation is the start of every drug development, but especially in oncology the design is important – not only that payers want to get a proof of a longer survival, but they also have further needs in their internal assessment. Enjoy the insights shared by the oncology market access veterans Dr. Stefan Walzer and Ed Schoonveld. 

 

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: https://lnkd.in/dZtyKw8B

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

 

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #germany #Europe #oncology 

]]>88cd2c5a-41ba-4a83-9e5f-a22dfc971902Sun, 01 Jan 2023 09:00:00 +020038:28falsefull133331Why should companies get early advice from payers, Esther Nzenza and Dr. Nick Leach?Why should companies get early advice from payers, Esther Nzenza and Dr. Nick Leach?In Europe there are many different options to get engaged with payers across different jurisdictions. Given the complexity, the benefit of these might be questioned by some. However, if the pathway is clear and the company knows how to approach payers and asks the right questions it provides valuable insights securing commercial success. Within the podcast the European, UK and German pathways are being discussed including how to approach payers and what to ask them. Get the right insights from a great discussion between these market access experts!

  

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: https://lnkd.in/dZtyKw8B

 

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

 

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #germany #Europe #UK #Germany 

]]>In Europe there are many different options to get engaged with payers across different jurisdictions. Given the complexity, the benefit of these might be questioned by some. However, if the pathway is clear and the company knows how to approach payers and asks the right questions it provides valuable insights securing commercial success. Within the podcast the European, UK and German pathways are being discussed including how to approach payers and what to ask them. Get the right insights from a great discussion between these market access experts!

  

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: https://lnkd.in/dZtyKw8B

 

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

 

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #germany #Europe #UK #Germany 

]]>09bad26c-a6af-49f9-9b64-5219a72688eeThu, 15 Dec 2022 09:00:00 +020038:39falsefull132321The AMNOG process - how does it work from a legal perspective, Alexander Meier?The AMNOG process - how does it work from a legal perspective, Alexander Meier?New, innovative drugs are assessed within the so-called AMNOG process in Germany. Given the legal nature of this process, lawyers also play an important role. At the end of the AMNOG process there is a legal contract – and also important, lawyers are experienced in negotiations by nature? If this is true and how lawyers can support market access teams is discussed between the AMNOG expert Dr. Stefan Walzer and the experienced market access lawyer Alexander Meier.

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: https://lnkd.in/dZtyKw8B

 MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

 

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #germany #AMNOG #law #lawyer

]]>New, innovative drugs are assessed within the so-called AMNOG process in Germany. Given the legal nature of this process, lawyers also play an important role. At the end of the AMNOG process there is a legal contract – and also important, lawyers are experienced in negotiations by nature? If this is true and how lawyers can support market access teams is discussed between the AMNOG expert Dr. Stefan Walzer and the experienced market access lawyer Alexander Meier.

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: https://lnkd.in/dZtyKw8B

 MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

 

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #germany #AMNOG #law #lawyer

]]>d7b5b973-c2e7-445f-8ec2-c9633ea8e7e4Thu, 01 Dec 2022 09:00:00 +020039:25falsefull131311What are the hot topics in market access based on ISPOR Europe 2022, Dr. Stefan Walzer?What are the hot topics in market access based on ISPOR Europe 2022, Dr. Stefan Walzer?In this special podcast episode Dr. Stefan Walzer jumps into the latest trends and researches around market access, reimbursement and pricing presented and discussed just beginning of November 2022 at ISPOR Europe. From 6th to 9th of November the leading European experts including Dr. Stefan Walzer have met and discussed in Vienna. Discussion topics ranged widely around market access and pricing including buckets being discussed within this episode:

1) ATMPs

2) EU joint  HTA

3) Digital Health

4) Germany / AMNOG

5) European reimbursement

 

Please enjoy this compressed summary and let us know your questions that we should cover in the following podcast episodes. 

 

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: https://lnkd.in/dZtyKw8B

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

 

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #germany #europe #ispor #isporeurope

]]>In this special podcast episode Dr. Stefan Walzer jumps into the latest trends and researches around market access, reimbursement and pricing presented and discussed just beginning of November 2022 at ISPOR Europe. From 6th to 9th of November the leading European experts including Dr. Stefan Walzer have met and discussed in Vienna. Discussion topics ranged widely around market access and pricing including buckets being discussed within this episode:

1) ATMPs

2) EU joint  HTA

3) Digital Health

4) Germany / AMNOG

5) European reimbursement

 

Please enjoy this compressed summary and let us know your questions that we should cover in the following podcast episodes. 

 

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: https://lnkd.in/dZtyKw8B

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

 

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #germany #europe #ispor #isporeurope

]]>835b1052-5605-4e8b-b283-902c688f048dTue, 15 Nov 2022 09:00:00 +020052:14falsefull130301AMNOG Reform - will Germany remain the most attractive market for orphan drugs?AMNOG Reform - will Germany remain the most attractive market for orphan drugs?Given the current reforms and adaptions in the German system, one can wonder if the German market might remain the most attractive to launch pharmaceutical products and especially orphan drugs. Are there still ways to get innovative products into the market and get paid well? What do we need to know in order to still gain from the strengths of the German market size and economic power? This might be an even more important question in a global climate of declining prices. 

This podcast was recorded as part of the „Let‘s talk rare“ podcast. In this discussion Dr. Stefan Walzer discusses with Owen Bryant, Georgie Rack and Fisentzos Stylianou, all working at Partners 4 Access, the specifics of orphan drugs in the AMNOG context. (https://partners4access.com/insights/podcasts/)

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: https://lnkd.in/dZtyKw8B

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

 

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #germany

]]>Given the current reforms and adaptions in the German system, one can wonder if the German market might remain the most attractive to launch pharmaceutical products and especially orphan drugs. Are there still ways to get innovative products into the market and get paid well? What do we need to know in order to still gain from the strengths of the German market size and economic power? This might be an even more important question in a global climate of declining prices. 

This podcast was recorded as part of the „Let‘s talk rare“ podcast. In this discussion Dr. Stefan Walzer discusses with Owen Bryant, Georgie Rack and Fisentzos Stylianou, all working at Partners 4 Access, the specifics of orphan drugs in the AMNOG context. (https://partners4access.com/insights/podcasts/)

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: https://lnkd.in/dZtyKw8B

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

 

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #germany

]]>4da0d181-f161-41e9-923f-4de2a3da6d67Tue, 01 Nov 2022 09:00:00 +020041:04falsefull129291Why should Market Access Managers care about statistics, Alexander Schacht?Why should Market Access Managers care about statistics, Alexander Schacht?Not everybody can be a statistician, but >The Effective Statistician< Alexander Schacht argues, that every Market Access Manager should work with statisticians and should learn how to communicate statistics effectively. Together with Dr. Stefan Walzer he is framing the needs and importance of statistics in the context of market access and reimbursement. 

Don’t miss this insightful conversation! 

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: https://lnkd.in/dZtyKw8B

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

 

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #germany #statistics

]]>Not everybody can be a statistician, but >The Effective Statistician< Alexander Schacht argues, that every Market Access Manager should work with statisticians and should learn how to communicate statistics effectively. Together with Dr. Stefan Walzer he is framing the needs and importance of statistics in the context of market access and reimbursement. 

Don’t miss this insightful conversation! 

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: https://lnkd.in/dZtyKw8B

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

 

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #germany #statistics

]]>c94509b4-7717-41b2-92df-a1cf6e5037b3Sat, 15 Oct 2022 09:00:00 +020035:43falsefull128281How might digitization change health care in Germany by 2035, Julian Molitor?How might digitization change health care in Germany by 2035, Julian Molitor?Digital health could improve the efficiency, care and way patients are treated in all health care systems in the next years. Germany has started by implementing digital health applications (“DIGAs”) and is currently on its way to improve the digital infrastructure in hospitals. Anyway, some core questions remain such as reimbursement for high risk medical devices, e.g. artificial intelligence (AI), interoperability.

Dr. Stefan Walzer and Julian Molitor are discussing the current state as well as future opportunities with digital tools across the health care system. If you need to know where the German adoption is with respect to digitization you should not miss this podcast episode. 

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: https://lnkd.in/dZtyKw8B

 

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

 

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #digitalisation #germany

]]>Digital health could improve the efficiency, care and way patients are treated in all health care systems in the next years. Germany has started by implementing digital health applications (“DIGAs”) and is currently on its way to improve the digital infrastructure in hospitals. Anyway, some core questions remain such as reimbursement for high risk medical devices, e.g. artificial intelligence (AI), interoperability.

Dr. Stefan Walzer and Julian Molitor are discussing the current state as well as future opportunities with digital tools across the health care system. If you need to know where the German adoption is with respect to digitization you should not miss this podcast episode. 

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: https://lnkd.in/dZtyKw8B

 

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

 

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #digitalisation #germany

]]>11f28f5b-fd29-4cb7-96b0-1de3e183f5bcSat, 01 Oct 2022 09:00:00 +020030:56falsefull127271Are selective contracts with German insurances a smarter reimbursement pathway, Tim Hering?Are selective contracts with German insurances a smarter reimbursement pathway, Tim Hering?Within the opportunity of contracting in the German health care market, prices, reimbursement and integrated care paths could be agreed on. However, for some medical devices, especially in the outpatient setting, selective contracts could be the most attractive pathway to enter into reimbursement agreements. Dr. But which health insurance companies should contacted and how? What makes a contarct attractive for a health insurance?

Stefan Walzer and Tim Hering, experienced in integrated care contracts, are discussing the unique possibilities with smart contracts. 

Don’t miss this insightful conversation!

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: https://lnkd.in/dZtyKw8B

 

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

 

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #germany

]]>Within the opportunity of contracting in the German health care market, prices, reimbursement and integrated care paths could be agreed on. However, for some medical devices, especially in the outpatient setting, selective contracts could be the most attractive pathway to enter into reimbursement agreements. Dr. But which health insurance companies should contacted and how? What makes a contarct attractive for a health insurance?

Stefan Walzer and Tim Hering, experienced in integrated care contracts, are discussing the unique possibilities with smart contracts. 

Don’t miss this insightful conversation!

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: https://lnkd.in/dZtyKw8B

 

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

 

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #germany

]]>14943677-004a-4160-82e1-4d1d46a2f26eThu, 15 Sep 2022 09:00:00 +020028:06falsefull126261Would AI substitute or (only) support market access managers, Dr. Andree Bates?Would AI substitute or (only) support market access managers, Dr. Andree Bates?Dr. Stefan Walzer, market access expert, and his guest Dr. Andree Battes, expert in artificial intelligence (AI), are discussing the future of market access within the health care industry. How could AI support market access planning, submissions and negotiations, especially with the ever-increasing data? How could AI be beneficial in defining an optimal price anchor? And finally, would AI substitute the market access manager roles within the industry?

Further reading is available on "How to Embed AI into the Market Access Process“:  https://eularis.com/resources 


Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: https://lnkd.in/dZtyKw8B

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de


#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #ai #artificialintelligence

]]>Dr. Stefan Walzer, market access expert, and his guest Dr. Andree Battes, expert in artificial intelligence (AI), are discussing the future of market access within the health care industry. How could AI support market access planning, submissions and negotiations, especially with the ever-increasing data? How could AI be beneficial in defining an optimal price anchor? And finally, would AI substitute the market access manager roles within the industry?

Further reading is available on "How to Embed AI into the Market Access Process“:  https://eularis.com/resources 


Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: https://lnkd.in/dZtyKw8B

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de


#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #ai #artificialintelligence

]]>86fd845d-53db-4c00-ad02-a527104d7b21Thu, 01 Sep 2022 09:00:00 +020031:31falsefull125251How successful is the DiGA fast track, Dr. Henrik Matthies ?How successful is the DiGA fast track, Dr. Henrik Matthies ?Dr. Matthies used to be at the epicenter of the DIGA launch in 2020. He was the managing director of the Health innovation hub: digital health think tank of the federal ministry of health in Germany. The first project of agile lawmaking in Germany. What are key takeaways and learnings from 2 years DiGAs? What are pitfalls with a focus on BfArM and the German payers (GKV-SV)? How to be successful in the German DiGA environment?

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: https://lnkd.in/dZtyKw8B

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #germany #diga

]]>Dr. Matthies used to be at the epicenter of the DIGA launch in 2020. He was the managing director of the Health innovation hub: digital health think tank of the federal ministry of health in Germany. The first project of agile lawmaking in Germany. What are key takeaways and learnings from 2 years DiGAs? What are pitfalls with a focus on BfArM and the German payers (GKV-SV)? How to be successful in the German DiGA environment?

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: https://lnkd.in/dZtyKw8B

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #germany #diga

]]>bb41914a-7f9f-4beb-849e-47002d9bf096Mon, 15 Aug 2022 09:00:00 +020033:40falsefull124241The UK market access has always been complex, now even more than before, Graham Foxon and Paul Craddy?The UK market access has always been complex, now even more than before, Graham Foxon and Paul Craddy?The UK has always been on the forefront of market access with its unique pathways within England, but especially also considering Wales, Ireland and Scotland as well. Furthermore, since the Brexit there were new innovation paths introduced. The core question remains, how one could identify the optimal path for their product (including digital health)…

Dr. Stefan Walzer and his guests Dr. Paul Craddy and Dr. Graham Foxon from Remap Consulting are discussing these and many other questions around market access in the UK. 

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: https://lnkd.in/dZtyKw8B

 

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

 

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #europe #uk #england #scotland #wales #nice

]]>The UK has always been on the forefront of market access with its unique pathways within England, but especially also considering Wales, Ireland and Scotland as well. Furthermore, since the Brexit there were new innovation paths introduced. The core question remains, how one could identify the optimal path for their product (including digital health)…

Dr. Stefan Walzer and his guests Dr. Paul Craddy and Dr. Graham Foxon from Remap Consulting are discussing these and many other questions around market access in the UK. 

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: https://lnkd.in/dZtyKw8B

 

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

 

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #europe #uk #england #scotland #wales #nice

]]>c5b46963-41a5-4184-b5ee-55f9f7a5d927Mon, 01 Aug 2022 09:00:00 +020033:54falsefull123231Switzerland is strong in many aspects, so also in its health care system, Dr. Peter Indra?Switzerland is strong in many aspects, so also in its health care system, Dr. Peter Indra?The Swiss healthcare system is rather complex but at the same time quite effective. High expenditures into health care corresponds with high life expectancy. However, what are the core processes in Switzerland with regards to health care delivery? What is the path towards innovation pricing and new price models? And what is the status quo on (health care) digitalization?

 

Dr. Stefan Walzer discusses with Dr. Peter Indra one of the core stakeholders in the Swiss system with a wide ranging experience in the board of the Swiss payer institution BAG, core insurance companies and federal political levels. 

 

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: https://lnkd.in/dZtyKw8B

 

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

 

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #europe #switzerland

]]>The Swiss healthcare system is rather complex but at the same time quite effective. High expenditures into health care corresponds with high life expectancy. However, what are the core processes in Switzerland with regards to health care delivery? What is the path towards innovation pricing and new price models? And what is the status quo on (health care) digitalization?

 

Dr. Stefan Walzer discusses with Dr. Peter Indra one of the core stakeholders in the Swiss system with a wide ranging experience in the board of the Swiss payer institution BAG, core insurance companies and federal political levels. 

 

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: https://lnkd.in/dZtyKw8B

 

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

 

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #europe #switzerland

]]>425e65c3-560d-4af2-ab9e-e6cbeea5ad1aFri, 15 Jul 2022 09:00:00 +020034:30falsefull122221AMNOG was the end of paradise for pharmaceutical companies, correct Prof. Hammerschmidt?AMNOG was the end of paradise for pharmaceutical companies, correct Prof. Hammerschmidt?What have been the main changes after 10 years of AMNOG for pharmaceutical companies? What have been the biggest successes within these years? For orphan drug the benefit evaluation process was eased in order to keep incentives high. Have price expectations been up met - by both sides? After 10 years of AMNOG first conclusions and recommendations for changes can be made.

 

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: https://lnkd.in/dZtyKw8B

 

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

 

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #europe #amnog

]]>What have been the main changes after 10 years of AMNOG for pharmaceutical companies? What have been the biggest successes within these years? For orphan drug the benefit evaluation process was eased in order to keep incentives high. Have price expectations been up met - by both sides? After 10 years of AMNOG first conclusions and recommendations for changes can be made.

 

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: https://lnkd.in/dZtyKw8B

 

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

 

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #europe #amnog

]]>5ddf57cf-847f-460e-a551-d622b923643cFri, 01 Jul 2022 09:00:00 +020037:54falsefull121211What is the secret of the cost-efficient healthcare system in Israel, Mirel Stelian?What is the secret of the cost-efficient healthcare system in Israel, Mirel Stelian?Israel spends only 7.6% of the GDP on healthcare – significantly less than most other Western OECD countries. At the same time Israel has a higher life expectancy and lower infant mortality. So, better results for less money?! How does Israel do this?

Dr. Stefan Walzer and Mirel Stelian are discussing in depth, how the application and reimbursement process works and what options are available for companies who want to enter the Israeli market. If you want to understand the Israeli health care market and specifically the reimbursement process in Israel, you should not miss this episode.

 

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: https://lnkd.in/dZtyKw8B

 

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

 

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #europe #israel

]]>Israel spends only 7.6% of the GDP on healthcare – significantly less than most other Western OECD countries. At the same time Israel has a higher life expectancy and lower infant mortality. So, better results for less money?! How does Israel do this?

Dr. Stefan Walzer and Mirel Stelian are discussing in depth, how the application and reimbursement process works and what options are available for companies who want to enter the Israeli market. If you want to understand the Israeli health care market and specifically the reimbursement process in Israel, you should not miss this episode.

 

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: https://lnkd.in/dZtyKw8B

 

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

 

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #europe #israel

]]>73c01be2-e314-475b-9320-2ac51f6cc2e9Wed, 15 Jun 2022 09:00:00 +020033:41falsefull120201Dutch payers are pragmatic, especially when discussing medical devices, isn’t it, Ron de Graaff?Dutch payers are pragmatic, especially when discussing medical devices, isn’t it, Ron de Graaff?The market access process in the Netherlands can be very special, especially for medical devices. Besides standard reimbursement processes with evidence-based medicine assessments, there are also more pragmatic pathways available. How do these work and what needs to be considered before moving into the Dutch health care market? Listen to the insightful discussion of Dr. Stefan Walzer and the Dutch market access expert Ron de Graaff.

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: https://lnkd.in/dZtyKw8B

 

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy, visit: marketaccess-pricingstrategy.de

 

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #europe #netherlands

]]>The market access process in the Netherlands can be very special, especially for medical devices. Besides standard reimbursement processes with evidence-based medicine assessments, there are also more pragmatic pathways available. How do these work and what needs to be considered before moving into the Dutch health care market? Listen to the insightful discussion of Dr. Stefan Walzer and the Dutch market access expert Ron de Graaff.

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: https://lnkd.in/dZtyKw8B

 

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy, visit: marketaccess-pricingstrategy.de

 

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #europe #netherlands

]]>ddc7092c-8e89-40ee-8e0b-8e011c44f86cWed, 01 Jun 2022 09:00:00 +020034:11falsefull119191The Belgium reimbursement pathway for digital health applications is similarly easy as in Germany, correct Katrien de Groote?The Belgium reimbursement pathway for digital health applications is similarly easy as in Germany, correct Katrien de Groote?Belgium has created a similar fast-track process as in Germany even though that some differences exist. Anyway, core question with new processes is always how the rules are being interpreted and applied. So, how important are clinical studies and when are those required? What are the price levels and negotiations components of the process? Can companies with a successful track record in Germany also be successful in Belgium?

Dr. Stefan Walzer and the Belgian market access expert Katrien de Groote are discussing these and other aspects around digital healthcare in Belgium. 

Don’t miss these insights on market access for digital products!

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: https://lnkd.in/dZtyKw8B

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

 

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #europe #belgium

]]>Belgium has created a similar fast-track process as in Germany even though that some differences exist. Anyway, core question with new processes is always how the rules are being interpreted and applied. So, how important are clinical studies and when are those required? What are the price levels and negotiations components of the process? Can companies with a successful track record in Germany also be successful in Belgium?

Dr. Stefan Walzer and the Belgian market access expert Katrien de Groote are discussing these and other aspects around digital healthcare in Belgium. 

Don’t miss these insights on market access for digital products!

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: https://lnkd.in/dZtyKw8B

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

 

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #europe #belgium

]]>63ce1be2-8d91-4a02-aaac-b3c4870cc138Sun, 15 May 2022 09:00:00 +020020:14falsefull118181Is European market access really so difficult? Tell us the truth being successful in Europe, Esther Nzenza!Is European market access really so difficult? Tell us the truth being successful in Europe, Esther Nzenza!Europe is one continent, with one Union (plus the UK)… Health policy is still the responsibility of each individual country and hence there are still (at least) as many reimbursement pathways as countries. Planning for business success in health care is hence difficult? Not necessarily according to Dr. Stefan Walzer and Esther Nzenza. Both show up important topics and to dos in order to plan and execute successfully. As a summary, local access leaders have a critical role and (obviously) R&D, Medical Affairs, Commercial, Regularity, Supply Chain all need to have a common touchpoint within market access. 

Don’t miss these insights on market access and European business strategy! 

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: https://lnkd.in/dZtyKw8B

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

 

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #europe #jointHTA

]]>Europe is one continent, with one Union (plus the UK)… Health policy is still the responsibility of each individual country and hence there are still (at least) as many reimbursement pathways as countries. Planning for business success in health care is hence difficult? Not necessarily according to Dr. Stefan Walzer and Esther Nzenza. Both show up important topics and to dos in order to plan and execute successfully. As a summary, local access leaders have a critical role and (obviously) R&D, Medical Affairs, Commercial, Regularity, Supply Chain all need to have a common touchpoint within market access. 

Don’t miss these insights on market access and European business strategy! 

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: https://lnkd.in/dZtyKw8B

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

 

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #europe #jointHTA

]]>3a9e00d5-dba7-47a5-8671-8a550dbbdc0bSun, 01 May 2022 09:00:00 +020027:20falsefull117171What can Europeans learn from Canada for the upcoming EU joint HTA, Gabriel Tremblay?What can Europeans learn from Canada for the upcoming EU joint HTA, Gabriel Tremblay?EU joint HTA will become reality in the next few years as communicated recently by the European Commission. However, applicability and implementation questions are still open such as timing, inclusion into national regulations and HTA processes in the EU member states. In Canada a similar process, including a single joint HTA process which is then being implemented in the respective provinces, has been introduced early 2000s. Core question remains what could be learned by European health care systems especially with respect to reimbursement and market access.

The dedicated debate is lead by Dr. Stefan Walzer who is discussing the potential learnings and take-aways with Gabriel Tremblay, a well-known Canadian Health Economic Expert. Don’t miss theses insights.

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: https://lnkd.in/dZtyKw8B 

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

 

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #Canada #jointHTA

]]>EU joint HTA will become reality in the next few years as communicated recently by the European Commission. However, applicability and implementation questions are still open such as timing, inclusion into national regulations and HTA processes in the EU member states. In Canada a similar process, including a single joint HTA process which is then being implemented in the respective provinces, has been introduced early 2000s. Core question remains what could be learned by European health care systems especially with respect to reimbursement and market access.

The dedicated debate is lead by Dr. Stefan Walzer who is discussing the potential learnings and take-aways with Gabriel Tremblay, a well-known Canadian Health Economic Expert. Don’t miss theses insights.

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: https://lnkd.in/dZtyKw8B 

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

 

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #Canada #jointHTA

]]>8c019101-ed49-43e0-b3e5-064a01585dafFri, 15 Apr 2022 09:00:00 +020043:50falsefull116161Digital Health Care is already fully utilized in the US, isn’t it?Digital Health Care is already fully utilized in the US, isn’t it?Dr. Stefan Walzer and Kate Claessens, the experienced consultant on healthcare in the US, are discussing the public acceptance as well as the various reimbursement pathways in the USA. What is the status of digital health care in the USA? How does reimbursement work for the different paths? What changes might we expect with the Biden administration? And what are the next steps to take?

In order to make it even more practical, Anna Forsythe the Managing Partner at Purple Squirrel Economics and expert in global product commercialization and strategic drug development, has joined the discussion in the second half of the discussion. Don't miss these insights as well.

The US market is for sure very interesting for digital healthcare products. This podcast episode will help you to get an idea of your next steps to enter this attractive market. 

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: 


MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: https://lnkd.in/dDCTND2 

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #usa #diga #digital 

]]>Dr. Stefan Walzer and Kate Claessens, the experienced consultant on healthcare in the US, are discussing the public acceptance as well as the various reimbursement pathways in the USA. What is the status of digital health care in the USA? How does reimbursement work for the different paths? What changes might we expect with the Biden administration? And what are the next steps to take?

In order to make it even more practical, Anna Forsythe the Managing Partner at Purple Squirrel Economics and expert in global product commercialization and strategic drug development, has joined the discussion in the second half of the discussion. Don't miss these insights as well.

The US market is for sure very interesting for digital healthcare products. This podcast episode will help you to get an idea of your next steps to enter this attractive market. 

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: 


MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: https://lnkd.in/dDCTND2 

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #usa #diga #digital 

]]>0481357a-31d6-4ec4-a1ac-85798b342aa8Fri, 01 Apr 2022 11:45:00 +020001:01:29falsefull115151Does the Italian reimbursement pathway allow for innovative drugs being highly priced, Dr. Stefano Capri and Dr. Entela Xoxi?Does the Italian reimbursement pathway allow for innovative drugs being highly priced, Dr. Stefano Capri and Dr. Entela Xoxi?The Italian reimbursement system is unique in terms of its structure, especially also for innovative drugs. However, what does the new innovation pathway means to the industry and health care availability? How easy is it really to negotiate a premium price? Listen to the discussions and explanations of Dr Stefan Walzer and his experts from Italy Prof. Dr. Stefano Capri and Dr. Entela Xoxi. 

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: 


MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: https://lnkd.in/dDCTND2 

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #italy

]]>The Italian reimbursement system is unique in terms of its structure, especially also for innovative drugs. However, what does the new innovation pathway means to the industry and health care availability? How easy is it really to negotiate a premium price? Listen to the discussions and explanations of Dr Stefan Walzer and his experts from Italy Prof. Dr. Stefano Capri and Dr. Entela Xoxi. 

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: 


MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: https://lnkd.in/dDCTND2 

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #italy

]]>96e55c7f-0154-4f60-814b-e0d07adc35f5Tue, 15 Mar 2022 09:00:00 +020028:30falsefull114141What are the specific elements about the Austrian market access pathway, Dr. Anna Bucsics?What are the specific elements about the Austrian market access pathway, Dr. Anna Bucsics?The Austrian market access pathway in the outpatient setting is unique in its pragmatic approach with their box system.

The two experts on the Austrian market, Dr. Stefan Walzer and Dr. Anna Bucsics, discuss about the pathways in Asutria but also the similarities between Germany and the Austrian system. On top, the joint EU HTA approach will also be included in a scenario analysis in terms of implementation. Listen into this breakthrough discussions with a span between Austria, Germany the EU.

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: 


MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: https://lnkd.in/dDCTND2 

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #austria

]]>The Austrian market access pathway in the outpatient setting is unique in its pragmatic approach with their box system.

The two experts on the Austrian market, Dr. Stefan Walzer and Dr. Anna Bucsics, discuss about the pathways in Asutria but also the similarities between Germany and the Austrian system. On top, the joint EU HTA approach will also be included in a scenario analysis in terms of implementation. Listen into this breakthrough discussions with a span between Austria, Germany the EU.

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: 


MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: https://lnkd.in/dDCTND2 

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #austria

]]>07dcb9c5-8498-489d-89bc-022deb64d73dTue, 01 Mar 2022 09:00:00 +020030:04falsefull113131The private health insurances as the entrance into German market access – is this true, Dr. Bastian Biermann?The private health insurances as the entrance into German market access – is this true, Dr. Bastian Biermann?The German health care system consists of the statutory and private health insurances, whereas the latter covers around 10% of the population. Anyhow, access and commercialization, especially of new and innovative therapies could firstly be introduced through the private system. What are the core differences to follow with such a strategy? What are the specifics of the private health insurances? And are there examples of such a market access pathway?

 

Dr. Stefan Walzer and Dr. Sebastian Biermann, representative of the Association of the private health insurance funds are discussing these questions and beyond.

 

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: https://lnkd.in/dZtyKw8B

 

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: https://lnkd.in/dDCTND2 

 

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations

]]>The German health care system consists of the statutory and private health insurances, whereas the latter covers around 10% of the population. Anyhow, access and commercialization, especially of new and innovative therapies could firstly be introduced through the private system. What are the core differences to follow with such a strategy? What are the specifics of the private health insurances? And are there examples of such a market access pathway?

 

Dr. Stefan Walzer and Dr. Sebastian Biermann, representative of the Association of the private health insurance funds are discussing these questions and beyond.

 

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: https://lnkd.in/dZtyKw8B

 

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: https://lnkd.in/dDCTND2 

 

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations

]]>c1c6dddb-3e34-4fec-9d64-f0f81a2ef805Tue, 15 Feb 2022 09:00:00 +020035:44falsefull112121How can a company derive the optimal price for their medical product, Dr. Renato Dellamano?How can a company derive the optimal price for their medical product, Dr. Renato Dellamano?What are drivers of pricing and ultimately negotiations? How can a global strategy best be implemented in individual countries? How do payers react to different prices? And finally the two pricing experts Dr. Stefan Walzer and Dr. Renato Dellamano discuss philosophically whether pricing is rather an art or science…

 Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: https://lnkd.in/dZtyKw8B

 

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

]]>What are drivers of pricing and ultimately negotiations? How can a global strategy best be implemented in individual countries? How do payers react to different prices? And finally the two pricing experts Dr. Stefan Walzer and Dr. Renato Dellamano discuss philosophically whether pricing is rather an art or science…

 Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: https://lnkd.in/dZtyKw8B

 

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

]]>8521cdd6-94cb-4efb-9f60-0ea23810f083Tue, 01 Feb 2022 09:00:00 +020032:14falsefull111111How do innovations reach patients in German hospitals, Dr. Sebastian Casu?How do innovations reach patients in German hospitals, Dr. Sebastian Casu?How important are the famous NUBs, OPS and DRG values? How can innovations reach patients beyond administrative barriers? What are the next steps in terms of digitalization of health care in Germany? Dr. Stefan Walzer and Dr. Sebastian Casu – medical doctor and medical influencer - are continuing the conversation about inpatient market access processes with a strong focus on bed-side innovation including digitalization of healthcare. This episode is linked to episode 9 with Willi Wöllner and the hospital business administration perspective (from January 1 2022). 

 

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: https://lnkd.in/dZtyKw8B

 

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

]]>How important are the famous NUBs, OPS and DRG values? How can innovations reach patients beyond administrative barriers? What are the next steps in terms of digitalization of health care in Germany? Dr. Stefan Walzer and Dr. Sebastian Casu – medical doctor and medical influencer - are continuing the conversation about inpatient market access processes with a strong focus on bed-side innovation including digitalization of healthcare. This episode is linked to episode 9 with Willi Wöllner and the hospital business administration perspective (from January 1 2022). 

 

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: https://lnkd.in/dZtyKw8B

 

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

]]>fd2e1d9b-b749-415b-918a-8f30879f4dedSat, 15 Jan 2022 09:00:00 +020032:44falsefull110101How does hospital funding work in Germany, Willi Wöllner?How does hospital funding work in Germany, Willi Wöllner?How does reimbursement work in the German hospital setting and how are hospitals organized doing such negotiations? What is a NUB and how does this relate to annual hospital budget discussions with the health insurance funds? Can industry really take part in this process?

Dr. Stefan Walzer and the experienced hospital adminstrator Willi Wöllner are going deep on inpatient settings from a business perspective. Part II from a medical perspective will follow in the next episode with Dr. Sebastian Casu.

Take the chance to stay connected and subscribe with your favorite podcasting platform.

For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

]]>How does reimbursement work in the German hospital setting and how are hospitals organized doing such negotiations? What is a NUB and how does this relate to annual hospital budget discussions with the health insurance funds? Can industry really take part in this process?

Dr. Stefan Walzer and the experienced hospital adminstrator Willi Wöllner are going deep on inpatient settings from a business perspective. Part II from a medical perspective will follow in the next episode with Dr. Sebastian Casu.

Take the chance to stay connected and subscribe with your favorite podcasting platform.

For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

]]>e7d995e2-709f-405a-97ee-492ab60c006fSat, 01 Jan 2022 09:00:00 +020036:08falsefull1991Prof. Dr. Jürgen Wasem - What happens, when negotiations fail?Prof. Dr. Jürgen Wasem - What happens, when negotiations fail?Who could be better to tell us the real insights, how the arbitration board works than Prof. Dr. Juergen Wasem, the former head of the AMNOG arbitration board and the current head of the DiGA arbitration board.

In this wide ranging conversation Dr. Stefan Walzer confronted Prof. Wasem with in-depth issues to take the arbitration board as well into strategic considerations.

Take the chance to stay connected and subscribe with your favorite podcasting platform.

For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

]]>Who could be better to tell us the real insights, how the arbitration board works than Prof. Dr. Juergen Wasem, the former head of the AMNOG arbitration board and the current head of the DiGA arbitration board.

In this wide ranging conversation Dr. Stefan Walzer confronted Prof. Wasem with in-depth issues to take the arbitration board as well into strategic considerations.

Take the chance to stay connected and subscribe with your favorite podcasting platform.

For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

]]>95354169-b9e6-41ec-8d16-8eb6300af329Wed, 15 Dec 2021 09:00:00 +020038:31falsefull1881Dr. Michael Zuercher - Commercial attractiveness of the Swiss health care market – success starts with market access.Dr. Michael Zuercher - Commercial attractiveness of the Swiss health care market – success starts with market access.In this Podcast episode Dr. Stefan Walzer confronts the Swiss expert Michael Zuercher with his perspective on Market Access to Switzerland. Furthermore they are discussing the right commercial planning in the context of a successful market access submission in Switzerland. Even though the Swiss market is low in volumes due to a limited number of patients in comparison to other European countries, it is a very attractive market with unique entrance options such as “early paid access”! 

Take the chance to stay connected and subscribe with your favorite podcasting platform.

For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

]]>In this Podcast episode Dr. Stefan Walzer confronts the Swiss expert Michael Zuercher with his perspective on Market Access to Switzerland. Furthermore they are discussing the right commercial planning in the context of a successful market access submission in Switzerland. Even though the Swiss market is low in volumes due to a limited number of patients in comparison to other European countries, it is a very attractive market with unique entrance options such as “early paid access”! 

Take the chance to stay connected and subscribe with your favorite podcasting platform.

For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

]]>7b07928d-5014-4b3c-857f-3fd766315047Wed, 01 Dec 2021 09:00:00 +020032:49falsefull1771Prof. Peter Zweifel & Door Vonk - Digital innovation - from theory into practice!Prof. Peter Zweifel & Door Vonk - Digital innovation - from theory into practice!In this Podcast episode, Dr. Stefan Walzer is discussing innovation theory from an economics perspective together with Prof. Peter Zweifel from the University of Zürich. Afterwards theory will be confronted with real life! Door Vonk talsk about founding the company „Tired of Cancer“ in the context of innovation theory.

Take the chance to stay connected and subscribe with your favorite podcasting platform.

For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

]]>In this Podcast episode, Dr. Stefan Walzer is discussing innovation theory from an economics perspective together with Prof. Peter Zweifel from the University of Zürich. Afterwards theory will be confronted with real life! Door Vonk talsk about founding the company „Tired of Cancer“ in the context of innovation theory.

Take the chance to stay connected and subscribe with your favorite podcasting platform.

For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

]]>bbb2ecfd-3e14-42a9-94a6-b8d6fedadab5Mon, 15 Nov 2021 09:00:00 +020001:01:02falsefull1661Bibiane Schulte-Bosse - How to fight well in AMNOG negotiations.Bibiane Schulte-Bosse - How to fight well in AMNOG negotiations.In this Podcast episode, Dr. Stefan Walzer is explaining the details of the price negotiations within the AMNOG process together with negotiating expert and lawyer  Bibiane Schulte-Bosse. 

Get into the hot areas of AMNOG – the negotiations and let us know in case you might have any questions.

Take the chance to stay connected and subscribe with your favorite podcasting platform.

For more information about MArS Market Access and Pricing Strategy visit: 

marketaccess-pricingstrategy.de

]]>In this Podcast episode, Dr. Stefan Walzer is explaining the details of the price negotiations within the AMNOG process together with negotiating expert and lawyer  Bibiane Schulte-Bosse. 

Get into the hot areas of AMNOG – the negotiations and let us know in case you might have any questions.

Take the chance to stay connected and subscribe with your favorite podcasting platform.

For more information about MArS Market Access and Pricing Strategy visit: 

marketaccess-pricingstrategy.de

]]>e64097f3-e89d-4ef2-82d4-8bf93c8a8e1aMon, 01 Nov 2021 09:00:00 +020034:38falsefull1551Prof. Dr. David Matusiewicz & Dr. Anne Sophie Geier - 1 year DIGAs. Is the "fast track process" for digital health applications successful?Prof. Dr. David Matusiewicz & Dr. Anne Sophie Geier - 1 year DIGAs. Is the "fast track process" for digital health applications successful?In this Podcast episode, Dr. Stefan Walzer is reflecting on 1 year DIGAs

with the leading question whether the "fast track process" for digital health applications is successful?

Additionally, the two digital health experts, Prof. Dr. David Matusiewicz from the FOM Universtity and Dr. Anne Sophie Geier from the head association of digital healthcare SVDGV, will also discuss the status of digitalization in the German health care system.

Get into the latest digital health care discussions and let us know in case you might have any questions.

Take the chance to stay connected and subscribe with your favorite podcasting platform.

For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

]]>In this Podcast episode, Dr. Stefan Walzer is reflecting on 1 year DIGAs

with the leading question whether the "fast track process" for digital health applications is successful?

Additionally, the two digital health experts, Prof. Dr. David Matusiewicz from the FOM Universtity and Dr. Anne Sophie Geier from the head association of digital healthcare SVDGV, will also discuss the status of digitalization in the German health care system.

Get into the latest digital health care discussions and let us know in case you might have any questions.

Take the chance to stay connected and subscribe with your favorite podcasting platform.

For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

]]>2fec0542-b772-4e77-8800-b10f5e6c9cf8Fri, 15 Oct 2021 09:00:00 +020028:10falsefull1441Remo Christen – Early paid access in Switzerland – Switzerland, wonderland??Remo Christen – Early paid access in Switzerland – Switzerland, wonderland??In this Podcast episode, Dr. Stefan Walzer is discussing the specifics of the Swiss market access & reimbursement specifics including the famous article 71, which allows an early paid access.

Who else could better speak about the Swiss system with him than Remo Christen? Remo is working since > 20 years in the Swiss market access environment in a leading role at Roche’s Swiss affiliate.

In this episode, listeners will learn the specifics of the Swiss culture, the reimbursement process also in comparison to the German AMNOG and why Switzerland is attractive for drug launches.

Subscribe with your favorite podcasting platform.

For more information about MArS Market Access and Pricing Strategy visit: 

marketaccess-pricingstrategy.de

]]>In this Podcast episode, Dr. Stefan Walzer is discussing the specifics of the Swiss market access & reimbursement specifics including the famous article 71, which allows an early paid access.

Who else could better speak about the Swiss system with him than Remo Christen? Remo is working since > 20 years in the Swiss market access environment in a leading role at Roche’s Swiss affiliate.

In this episode, listeners will learn the specifics of the Swiss culture, the reimbursement process also in comparison to the German AMNOG and why Switzerland is attractive for drug launches.

Subscribe with your favorite podcasting platform.

For more information about MArS Market Access and Pricing Strategy visit: 

marketaccess-pricingstrategy.de

]]>67dae8bb-6ae7-418e-9952-82041fad3dd6Fri, 01 Oct 2021 09:00:00 +020034:11falsefull1331Prof. Dr. Wagschal - What can we expect from the upcoming elections in Germany?Prof. Dr. Wagschal - What can we expect from the upcoming elections in Germany?In this Podcast episode, Dr. Stefan Walzer is speaking to Prof. Dr. Wagschal from the University of Freiburg about the upcoming elections in Germany.

They are discussing latest forecasts and potential policy implications.

Prof. Wagschal also explains limitations of forecasts and dynamics of recent elections.

Another important part is in the potential (new) coalitions and their likely impact on the health care market.

Subscribe at your favourite podcasting platform and for more information about MArS Market Access and Pricing Strategy visit:

marketaccess-pricingstrategy.de

]]>In this Podcast episode, Dr. Stefan Walzer is speaking to Prof. Dr. Wagschal from the University of Freiburg about the upcoming elections in Germany.

They are discussing latest forecasts and potential policy implications.

Prof. Wagschal also explains limitations of forecasts and dynamics of recent elections.

Another important part is in the potential (new) coalitions and their likely impact on the health care market.

Subscribe at your favourite podcasting platform and for more information about MArS Market Access and Pricing Strategy visit:

marketaccess-pricingstrategy.de

]]>46eaca6d-4d37-4a5b-8166-0e489b038c74Wed, 15 Sep 2021 09:00:00 +020035:43falsefull1221Dr. Mathias Flume - AMNOG will change in 2022, but how?Dr. Mathias Flume - AMNOG will change in 2022, but how?In this Podcast episode, Dr. Stefan Walzer is talking with Dr. Mathias Flume about the AMNOG process as well as interesting details about the market access process in Germany.

Mathias is a core stakeholder within the regional payer system in Germany at one of the most innovative Statutory Health Insurance Physician Associations (KV Westphalia-Lippe). Mathias brings the payer view into the discussion of 10 years AMNOG. Success or failure?

]]>In this Podcast episode, Dr. Stefan Walzer is talking with Dr. Mathias Flume about the AMNOG process as well as interesting details about the market access process in Germany.

Mathias is a core stakeholder within the regional payer system in Germany at one of the most innovative Statutory Health Insurance Physician Associations (KV Westphalia-Lippe). Mathias brings the payer view into the discussion of 10 years AMNOG. Success or failure?

]]>2c11a859-e2cc-4fb1-91cf-8ae122c675a5Thu, 02 Sep 2021 10:00:00 +020034:16falsefull1111